_unit_id,_created_at,_canary,_id,_started_at,_channel,_trust,_worker_id,_country,_region,_city,_ip,direction,b1,b2,direction_gold,e1,e2,relation,relex_relcos,sent_id,sentence,term1,term2,twrex
502912457,7/14/2014 12:54:36,,1322817966,7/14/2014 12:54:04,clixsense,0.8194,15189335,GBR,K3,Peterborough,81.156.166.189,DENTAL CARIES diagnosed by SODIUM FLUORIDE,181,69,,193,84,diagnosed by,0.707106781186547,907106-FS1-13,"A sample of 1,824 schoolchildren was randomly assigned to either the SODIUM FLUORIDE dentifrice or the stannous fluoride dentifrice and examined clinically and radiographically for DENTAL CARIES initially and after one, two, and three years of dentifrice usage.",DENTAL CARIES,SODIUM FLUORIDE,RO-may_prevent
502912457,7/14/2014 13:02:43,,1322823257,7/14/2014 13:02:13,rewardsspot,0.7153,24482174,GBR,H9,London,46.23.68.180,DENTAL CARIES diagnosed by SODIUM FLUORIDE,181,69,,193,84,diagnosed by,0.707106781186547,907106-FS1-13,"A sample of 1,824 schoolchildren was randomly assigned to either the SODIUM FLUORIDE dentifrice or the stannous fluoride dentifrice and examined clinically and radiographically for DENTAL CARIES initially and after one, two, and three years of dentifrice usage.",DENTAL CARIES,SODIUM FLUORIDE,RO-may_prevent
502912457,7/14/2014 13:51:40,,1322857657,7/14/2014 13:51:13,clixsense,0.4042,25402344,CAN,ON,Wawa,24.109.124.45,SODIUM FLUORIDE diagnosed by DENTAL CARIES,181,69,,193,84,diagnosed by,0.707106781186547,907106-FS1-13,"A sample of 1,824 schoolchildren was randomly assigned to either the SODIUM FLUORIDE dentifrice or the stannous fluoride dentifrice and examined clinically and radiographically for DENTAL CARIES initially and after one, two, and three years of dentifrice usage.",DENTAL CARIES,SODIUM FLUORIDE,RO-may_prevent
502912457,7/14/2014 14:45:45,,1322894857,7/14/2014 14:45:40,instagc,0.4611,27753923,GBR,"","",188.30.192.65,DENTAL CARIES diagnosed by SODIUM FLUORIDE,181,69,,193,84,diagnosed by,0.707106781186547,907106-FS1-13,"A sample of 1,824 schoolchildren was randomly assigned to either the SODIUM FLUORIDE dentifrice or the stannous fluoride dentifrice and examined clinically and radiographically for DENTAL CARIES initially and after one, two, and three years of dentifrice usage.",DENTAL CARIES,SODIUM FLUORIDE,RO-may_prevent
502912457,7/14/2014 15:00:27,,1322903753,7/14/2014 15:00:14,instagc,0.5536,18960682,GBR,"","",86.29.147.112,SODIUM FLUORIDE diagnosed by DENTAL CARIES,181,69,,193,84,diagnosed by,0.707106781186547,907106-FS1-13,"A sample of 1,824 schoolchildren was randomly assigned to either the SODIUM FLUORIDE dentifrice or the stannous fluoride dentifrice and examined clinically and radiographically for DENTAL CARIES initially and after one, two, and three years of dentifrice usage.",DENTAL CARIES,SODIUM FLUORIDE,RO-may_prevent
502912457,7/14/2014 15:00:29,,1322903777,7/14/2014 14:59:32,vivatic,0.5339,25451531,GBR,"","",83.67.28.193,SODIUM FLUORIDE diagnosed by DENTAL CARIES,181,69,,193,84,diagnosed by,0.707106781186547,907106-FS1-13,"A sample of 1,824 schoolchildren was randomly assigned to either the SODIUM FLUORIDE dentifrice or the stannous fluoride dentifrice and examined clinically and radiographically for DENTAL CARIES initially and after one, two, and three years of dentifrice usage.",DENTAL CARIES,SODIUM FLUORIDE,RO-may_prevent
502912457,7/14/2014 15:28:21,,1322919319,7/14/2014 15:27:40,gifthulk,0.6484,21916793,GBR,"","",87.113.87.199,no_relation,181,69,,193,84,diagnosed by,0.707106781186547,907106-FS1-13,"A sample of 1,824 schoolchildren was randomly assigned to either the SODIUM FLUORIDE dentifrice or the stannous fluoride dentifrice and examined clinically and radiographically for DENTAL CARIES initially and after one, two, and three years of dentifrice usage.",DENTAL CARIES,SODIUM FLUORIDE,RO-may_prevent
502912458,7/14/2014 12:34:13,,1322804074,7/14/2014 12:33:54,clixsense,0.9583,27871219,NLD,07,Amsterdam,87.210.207.223,GLIOBLASTOMA MULTIFORME diagnosed by MICROVASCULAR PROLIFERATION,16,83,,42,106,diagnosed by,0.6,901588-FS1-13,The presence of MICROVASCULAR PROLIFERATION leads to the histological diagnosis of GLIOBLASTOMA MULTIFORME.,MICROVASCULAR PROLIFERATION,GLIOBLASTOMA MULTIFORME,RO-disease_has_finding
502912458,7/14/2014 12:43:20,,1322810291,7/14/2014 12:43:13,clixsense,0.875,25419319,GBR,H8,Liverpool,94.4.192.228,MICROVASCULAR PROLIFERATION diagnosed by GLIOBLASTOMA MULTIFORME,16,83,,42,106,diagnosed by,0.6,901588-FS1-13,The presence of MICROVASCULAR PROLIFERATION leads to the histological diagnosis of GLIOBLASTOMA MULTIFORME.,MICROVASCULAR PROLIFERATION,GLIOBLASTOMA MULTIFORME,RO-disease_has_finding
502912458,7/14/2014 13:03:35,,1322823834,7/14/2014 13:02:49,rewardsspot,0.7153,24482174,GBR,H9,London,46.23.68.180,MICROVASCULAR PROLIFERATION diagnosed by GLIOBLASTOMA MULTIFORME,16,83,,42,106,diagnosed by,0.6,901588-FS1-13,The presence of MICROVASCULAR PROLIFERATION leads to the histological diagnosis of GLIOBLASTOMA MULTIFORME.,MICROVASCULAR PROLIFERATION,GLIOBLASTOMA MULTIFORME,RO-disease_has_finding
502912458,7/14/2014 14:45:28,,1322894667,7/14/2014 14:45:23,instagc,0.4611,27753923,GBR,"","",188.30.192.65,MICROVASCULAR PROLIFERATION diagnosed by GLIOBLASTOMA MULTIFORME,16,83,,42,106,diagnosed by,0.6,901588-FS1-13,The presence of MICROVASCULAR PROLIFERATION leads to the histological diagnosis of GLIOBLASTOMA MULTIFORME.,MICROVASCULAR PROLIFERATION,GLIOBLASTOMA MULTIFORME,RO-disease_has_finding
502912458,7/14/2014 15:27:42,,1322918910,7/14/2014 15:27:22,instagc,0.3552,19004168,GBR,H2,Accrington,80.47.185.52,GLIOBLASTOMA MULTIFORME diagnosed by MICROVASCULAR PROLIFERATION,16,83,,42,106,diagnosed by,0.6,901588-FS1-13,The presence of MICROVASCULAR PROLIFERATION leads to the histological diagnosis of GLIOBLASTOMA MULTIFORME.,MICROVASCULAR PROLIFERATION,GLIOBLASTOMA MULTIFORME,RO-disease_has_finding
502912458,7/14/2014 15:33:51,,1322922688,7/14/2014 15:33:30,neodev,0.5101,21405167,USA,MD,Glen Burnie,69.137.237.73,GLIOBLASTOMA MULTIFORME diagnosed by MICROVASCULAR PROLIFERATION,16,83,,42,106,diagnosed by,0.6,901588-FS1-13,The presence of MICROVASCULAR PROLIFERATION leads to the histological diagnosis of GLIOBLASTOMA MULTIFORME.,MICROVASCULAR PROLIFERATION,GLIOBLASTOMA MULTIFORME,RO-disease_has_finding
502912458,7/14/2014 15:54:58,,1322934479,7/14/2014 15:54:16,clixsense,0.573,22177255,USA,CA,San Francisco,73.32.39.90,GLIOBLASTOMA MULTIFORME diagnosed by MICROVASCULAR PROLIFERATION,16,83,,42,106,diagnosed by,0.6,901588-FS1-13,The presence of MICROVASCULAR PROLIFERATION leads to the histological diagnosis of GLIOBLASTOMA MULTIFORME.,MICROVASCULAR PROLIFERATION,GLIOBLASTOMA MULTIFORME,RO-disease_has_finding
502912459,7/14/2014 12:34:49,,1322804466,7/14/2014 12:34:43,neodev,0.9583,17610000,GBR,I2,Manchester,90.200.140.201,ESOPHAGUS is location of ESOPHAGEAL CANCER,122,32,,130,49,is location of,0.875113012593303,902460-FS1-9,"Since 1982, three patients with ESOPHAGEAL CANCER complicated with pulmonary bullae have been treated by operation on the ESOPHAGUS and lung in one performance: In all the patients, the bullae were on the same side of the operation.",ESOPHAGUS,ESOPHAGEAL CANCER,RO-disease_has_primary_anatomic_site
502912459,7/14/2014 12:43:20,,1322810290,7/14/2014 12:43:13,clixsense,0.875,25419319,GBR,H8,Liverpool,94.4.192.228,ESOPHAGUS is location of ESOPHAGEAL CANCER,122,32,,130,49,is location of,0.875113012593303,902460-FS1-9,"Since 1982, three patients with ESOPHAGEAL CANCER complicated with pulmonary bullae have been treated by operation on the ESOPHAGUS and lung in one performance: In all the patients, the bullae were on the same side of the operation.",ESOPHAGUS,ESOPHAGEAL CANCER,RO-disease_has_primary_anatomic_site
502912459,7/14/2014 12:51:41,,1322815922,7/14/2014 12:50:47,clixsense,0.8194,15189335,GBR,K3,Peterborough,81.156.166.189,ESOPHAGUS is location of ESOPHAGEAL CANCER,122,32,,130,49,is location of,0.875113012593303,902460-FS1-9,"Since 1982, three patients with ESOPHAGEAL CANCER complicated with pulmonary bullae have been treated by operation on the ESOPHAGUS and lung in one performance: In all the patients, the bullae were on the same side of the operation.",ESOPHAGUS,ESOPHAGEAL CANCER,RO-disease_has_primary_anatomic_site
502912459,7/14/2014 12:59:57,,1322821427,7/14/2014 12:59:34,prodege,0.7639,7664351,USA,NY,Cicero,74.111.0.21,ESOPHAGUS is location of ESOPHAGEAL CANCER,122,32,,130,49,is location of,0.875113012593303,902460-FS1-9,"Since 1982, three patients with ESOPHAGEAL CANCER complicated with pulmonary bullae have been treated by operation on the ESOPHAGUS and lung in one performance: In all the patients, the bullae were on the same side of the operation.",ESOPHAGUS,ESOPHAGEAL CANCER,RO-disease_has_primary_anatomic_site
502912459,7/14/2014 13:21:16,,1322835773,7/14/2014 13:20:17,clixsense,0.7,24896327,GBR,V2,Glasgow,94.2.231.4,ESOPHAGUS is location of ESOPHAGEAL CANCER,122,32,,130,49,is location of,0.875113012593303,902460-FS1-9,"Since 1982, three patients with ESOPHAGEAL CANCER complicated with pulmonary bullae have been treated by operation on the ESOPHAGUS and lung in one performance: In all the patients, the bullae were on the same side of the operation.",ESOPHAGUS,ESOPHAGEAL CANCER,RO-disease_has_primary_anatomic_site
502912459,7/14/2014 14:26:51,,1322881732,7/14/2014 14:26:23,neodev,0.4306,21515166,NLD,11,Nootdorp,83.86.58.179,ESOPHAGEAL CANCER is location of ESOPHAGUS,122,32,,130,49,is location of,0.875113012593303,902460-FS1-9,"Since 1982, three patients with ESOPHAGEAL CANCER complicated with pulmonary bullae have been treated by operation on the ESOPHAGUS and lung in one performance: In all the patients, the bullae were on the same side of the operation.",ESOPHAGUS,ESOPHAGEAL CANCER,RO-disease_has_primary_anatomic_site
502912459,7/14/2014 14:49:01,,1322896781,7/14/2014 14:48:50,clixsense,0.5125,7415230,GBR,A7,Birmingham,147.188.47.242,no_relation,122,32,,130,49,is location of,0.875113012593303,902460-FS1-9,"Since 1982, three patients with ESOPHAGEAL CANCER complicated with pulmonary bullae have been treated by operation on the ESOPHAGUS and lung in one performance: In all the patients, the bullae were on the same side of the operation.",ESOPHAGUS,ESOPHAGEAL CANCER,RO-disease_has_primary_anatomic_site
502912460,7/14/2014 12:34:28,,1322804272,7/14/2014 12:34:23,neodev,0.9583,17610000,GBR,I2,Manchester,90.200.140.201,BONE causes PSEUDARTHROSIS,15,90,,18,104,causes,0.928587879040964,905494-FS1-4,Instability of BONE fragments is regarded as the most important factor in pathogenesis of PSEUDARTHROSIS,BONE,PSEUDARTHROSIS,RO-has_finding_site
502912460,7/14/2014 12:36:18,,1322805375,7/14/2014 12:35:56,prodege,0.8889,27934334,GBR,Q2,Wokingham,86.166.73.21,no_relation,15,90,,18,104,causes,0.928587879040964,905494-FS1-4,Instability of BONE fragments is regarded as the most important factor in pathogenesis of PSEUDARTHROSIS,BONE,PSEUDARTHROSIS,RO-has_finding_site
502912460,7/14/2014 15:04:46,,1322906337,7/14/2014 15:04:29,neodev,0.719,18755947,GBR,H2,Accrington,80.47.185.52,no_relation,15,90,,18,104,causes,0.928587879040964,905494-FS1-4,Instability of BONE fragments is regarded as the most important factor in pathogenesis of PSEUDARTHROSIS,BONE,PSEUDARTHROSIS,RO-has_finding_site
502912460,7/14/2014 15:11:07,,1322909632,7/14/2014 15:10:38,clixsense,0.5718,19803139,NLD,06,Veldhoven,212.61.84.196,no_relation,15,90,,18,104,causes,0.928587879040964,905494-FS1-4,Instability of BONE fragments is regarded as the most important factor in pathogenesis of PSEUDARTHROSIS,BONE,PSEUDARTHROSIS,RO-has_finding_site
502912460,7/14/2014 15:30:36,,1322920619,7/14/2014 15:30:28,prodege,0.5494,2143114,CAN,BC,Vancouver,24.84.160.12,BONE causes PSEUDARTHROSIS,15,90,,18,104,causes,0.928587879040964,905494-FS1-4,Instability of BONE fragments is regarded as the most important factor in pathogenesis of PSEUDARTHROSIS,BONE,PSEUDARTHROSIS,RO-has_finding_site
502912460,7/14/2014 15:53:42,,1322933698,7/14/2014 15:53:19,clixsense,0.573,22177255,USA,CA,San Francisco,73.32.39.90,no_relation,15,90,,18,104,causes,0.928587879040964,905494-FS1-4,Instability of BONE fragments is regarded as the most important factor in pathogenesis of PSEUDARTHROSIS,BONE,PSEUDARTHROSIS,RO-has_finding_site
502912460,7/14/2014 15:58:55,,1322936657,7/14/2014 15:58:25,prodege,0.5,28039757,GBR,L8,Southport,109.155.158.54,no_relation,15,90,,18,104,causes,0.928587879040964,905494-FS1-4,Instability of BONE fragments is regarded as the most important factor in pathogenesis of PSEUDARTHROSIS,BONE,PSEUDARTHROSIS,RO-has_finding_site
502912461,7/14/2014 12:48:17,,1322813506,7/14/2014 12:47:16,elite,0.75,27433978,AUS,05,Plympton,110.174.120.88,no_relation,75,128,,81,136,treats,0.306186217847897,904836-FS1-2,Serial addition to 3 or more antiepileptic drugs is less likely to lead to SEIZURE freedom for patients with difficult to treat EPILEPSY,SEIZURE,EPILEPSY,RO-has_definitional_manifestation
502912461,7/14/2014 12:59:57,,1322821439,7/14/2014 12:59:34,prodege,0.7639,7664351,USA,NY,Cicero,74.111.0.21,no_relation,75,128,,81,136,treats,0.306186217847897,904836-FS1-2,Serial addition to 3 or more antiepileptic drugs is less likely to lead to SEIZURE freedom for patients with difficult to treat EPILEPSY,SEIZURE,EPILEPSY,RO-has_definitional_manifestation
502912461,7/14/2014 14:09:43,,1322869769,7/14/2014 14:09:28,clixsense,0.7708,27793793,GBR,C5,Chester,151.230.27.155,no_relation,75,128,,81,136,treats,0.306186217847897,904836-FS1-2,Serial addition to 3 or more antiepileptic drugs is less likely to lead to SEIZURE freedom for patients with difficult to treat EPILEPSY,SEIZURE,EPILEPSY,RO-has_definitional_manifestation
502912461,7/14/2014 14:23:30,,1322879227,7/14/2014 14:23:24,neodev,0.3792,25224036,CAN,ON,Sudbury,67.204.218.187,SEIZURE treats EPILEPSY,75,128,,81,136,treats,0.306186217847897,904836-FS1-2,Serial addition to 3 or more antiepileptic drugs is less likely to lead to SEIZURE freedom for patients with difficult to treat EPILEPSY,SEIZURE,EPILEPSY,RO-has_definitional_manifestation
502912461,7/14/2014 14:36:32,,1322888629,7/14/2014 14:36:03,rewardsspot,0.57,17763704,USA,IL,Chicago,67.212.175.123,SEIZURE treats EPILEPSY,75,128,,81,136,treats,0.306186217847897,904836-FS1-2,Serial addition to 3 or more antiepileptic drugs is less likely to lead to SEIZURE freedom for patients with difficult to treat EPILEPSY,SEIZURE,EPILEPSY,RO-has_definitional_manifestation
502912461,7/14/2014 15:25:00,,1322917258,7/14/2014 15:23:41,clixsense,0.4244,26889820,GBR,C3,Shelford,92.18.120.203,no_relation,75,128,,81,136,treats,0.306186217847897,904836-FS1-2,Serial addition to 3 or more antiepileptic drugs is less likely to lead to SEIZURE freedom for patients with difficult to treat EPILEPSY,SEIZURE,EPILEPSY,RO-has_definitional_manifestation
502912461,7/14/2014 15:57:14,,1322935760,7/14/2014 15:56:45,prodege,0.5,28039757,GBR,L8,Southport,109.155.158.54,no_relation,75,128,,81,136,treats,0.306186217847897,904836-FS1-2,Serial addition to 3 or more antiepileptic drugs is less likely to lead to SEIZURE freedom for patients with difficult to treat EPILEPSY,SEIZURE,EPILEPSY,RO-has_definitional_manifestation
502912462,7/14/2014 12:43:32,,1322810461,7/14/2014 12:43:28,clixsense,0.875,25419319,GBR,H8,Liverpool,94.4.192.228,CHRONIC HEPATITIS causes LIVER BIOPSY SPECIMEN,100,142,,120,159,causes,0.307793505625546,902294-FS1-4,"In addition to the characterization of the degree of inflammation and fibrosis, the evaluation of a LIVER BIOPSY SPECIMEN from a patient with CHRONIC HEPATITIS includes a description of all of the findings present (e.g., steatosis, bile duct changes, granulomas, type of inflammatory cells, presence of iron, and Mallory hyaline) or a notation of their absence.",LIVER BIOPSY SPECIMEN,CHRONIC HEPATITIS,RO-disease_has_primary_anatomic_site
502912462,7/14/2014 13:07:39,,1322826518,7/14/2014 13:07:25,prodege,0.6278,11616695,GBR,P7,Wigan,92.29.199.166,no_relation,100,142,,120,159,causes,0.307793505625546,902294-FS1-4,"In addition to the characterization of the degree of inflammation and fibrosis, the evaluation of a LIVER BIOPSY SPECIMEN from a patient with CHRONIC HEPATITIS includes a description of all of the findings present (e.g., steatosis, bile duct changes, granulomas, type of inflammatory cells, presence of iron, and Mallory hyaline) or a notation of their absence.",LIVER BIOPSY SPECIMEN,CHRONIC HEPATITIS,RO-disease_has_primary_anatomic_site
502912462,7/14/2014 13:39:49,,1322848950,7/14/2014 13:39:00,prodege,0.6181,17982533,GBR,H3,Leeds,90.193.39.185,no_relation,100,142,,120,159,causes,0.307793505625546,902294-FS1-4,"In addition to the characterization of the degree of inflammation and fibrosis, the evaluation of a LIVER BIOPSY SPECIMEN from a patient with CHRONIC HEPATITIS includes a description of all of the findings present (e.g., steatosis, bile duct changes, granulomas, type of inflammatory cells, presence of iron, and Mallory hyaline) or a notation of their absence.",LIVER BIOPSY SPECIMEN,CHRONIC HEPATITIS,RO-disease_has_primary_anatomic_site
502912462,7/14/2014 13:51:11,,1322857346,7/14/2014 13:50:46,clixsense,0.4042,25402344,CAN,ON,Wawa,24.109.124.45,CHRONIC HEPATITIS causes LIVER BIOPSY SPECIMEN,100,142,,120,159,causes,0.307793505625546,902294-FS1-4,"In addition to the characterization of the degree of inflammation and fibrosis, the evaluation of a LIVER BIOPSY SPECIMEN from a patient with CHRONIC HEPATITIS includes a description of all of the findings present (e.g., steatosis, bile duct changes, granulomas, type of inflammatory cells, presence of iron, and Mallory hyaline) or a notation of their absence.",LIVER BIOPSY SPECIMEN,CHRONIC HEPATITIS,RO-disease_has_primary_anatomic_site
502912462,7/14/2014 13:54:46,,1322859810,7/14/2014 13:54:29,zoombucks,0.7764,5919735,USA,PA,Doylestown,173.49.91.231,no_relation,100,142,,120,159,causes,0.307793505625546,902294-FS1-4,"In addition to the characterization of the degree of inflammation and fibrosis, the evaluation of a LIVER BIOPSY SPECIMEN from a patient with CHRONIC HEPATITIS includes a description of all of the findings present (e.g., steatosis, bile duct changes, granulomas, type of inflammatory cells, presence of iron, and Mallory hyaline) or a notation of their absence.",LIVER BIOPSY SPECIMEN,CHRONIC HEPATITIS,RO-disease_has_primary_anatomic_site
502912462,7/14/2014 14:23:09,,1322878961,7/14/2014 14:23:01,neodev,0.3792,25224036,CAN,ON,Sudbury,67.204.218.187,CHRONIC HEPATITIS causes LIVER BIOPSY SPECIMEN,100,142,,120,159,causes,0.307793505625546,902294-FS1-4,"In addition to the characterization of the degree of inflammation and fibrosis, the evaluation of a LIVER BIOPSY SPECIMEN from a patient with CHRONIC HEPATITIS includes a description of all of the findings present (e.g., steatosis, bile duct changes, granulomas, type of inflammatory cells, presence of iron, and Mallory hyaline) or a notation of their absence.",LIVER BIOPSY SPECIMEN,CHRONIC HEPATITIS,RO-disease_has_primary_anatomic_site
502912462,7/14/2014 14:57:16,,1322901865,7/14/2014 14:57:00,instagc,0.6593,13763729,USA,"","",75.182.89.225,no_relation,100,142,,120,159,causes,0.307793505625546,902294-FS1-4,"In addition to the characterization of the degree of inflammation and fibrosis, the evaluation of a LIVER BIOPSY SPECIMEN from a patient with CHRONIC HEPATITIS includes a description of all of the findings present (e.g., steatosis, bile duct changes, granulomas, type of inflammatory cells, presence of iron, and Mallory hyaline) or a notation of their absence.",LIVER BIOPSY SPECIMEN,CHRONIC HEPATITIS,RO-disease_has_primary_anatomic_site
502912463,7/14/2014 12:34:13,,1322804068,7/14/2014 12:33:54,clixsense,0.9583,27871219,NLD,07,Amsterdam,87.210.207.223,PRIMAQUINE treats BENIGN TERTIAN MALARIA,70,118,,91,128,treats,0.98058067569092,907114-FS1-2,"The inadequacy of the 4 aminoquinolines for protection against latent BENIGN TERTIAN MALARIA is noted, and the use of PRIMAQUINE is recommended.",BENIGN TERTIAN MALARIA,PRIMAQUINE,RO-may_prevent
502912463,7/14/2014 12:35:19,,1322804784,7/14/2014 12:34:50,prodege,0.8889,27934334,GBR,Q2,Wokingham,86.166.73.21,PRIMAQUINE treats BENIGN TERTIAN MALARIA,70,118,,91,128,treats,0.98058067569092,907114-FS1-2,"The inadequacy of the 4 aminoquinolines for protection against latent BENIGN TERTIAN MALARIA is noted, and the use of PRIMAQUINE is recommended.",BENIGN TERTIAN MALARIA,PRIMAQUINE,RO-may_prevent
502912463,7/14/2014 14:56:09,,1322901063,7/14/2014 14:55:52,elite,0.4302,28276268,USA,MI,Taylor,67.149.247.166,BENIGN TERTIAN MALARIA treats PRIMAQUINE,70,118,,91,128,treats,0.98058067569092,907114-FS1-2,"The inadequacy of the 4 aminoquinolines for protection against latent BENIGN TERTIAN MALARIA is noted, and the use of PRIMAQUINE is recommended.",BENIGN TERTIAN MALARIA,PRIMAQUINE,RO-may_prevent
502912463,7/14/2014 15:00:12,,1322903643,7/14/2014 15:00:02,instagc,0.5536,18960682,GBR,"","",86.29.147.112,PRIMAQUINE treats BENIGN TERTIAN MALARIA,70,118,,91,128,treats,0.98058067569092,907114-FS1-2,"The inadequacy of the 4 aminoquinolines for protection against latent BENIGN TERTIAN MALARIA is noted, and the use of PRIMAQUINE is recommended.",BENIGN TERTIAN MALARIA,PRIMAQUINE,RO-may_prevent
502912463,7/14/2014 15:08:06,,1322908173,7/14/2014 15:07:37,instagc,0.7125,28519532,USA,IA,Honey Creek,12.73.110.26,PRIMAQUINE treats BENIGN TERTIAN MALARIA,70,118,,91,128,treats,0.98058067569092,907114-FS1-2,"The inadequacy of the 4 aminoquinolines for protection against latent BENIGN TERTIAN MALARIA is noted, and the use of PRIMAQUINE is recommended.",BENIGN TERTIAN MALARIA,PRIMAQUINE,RO-may_prevent
502912463,7/14/2014 15:10:37,,1322909430,7/14/2014 15:10:11,clixsense,0.5718,19803139,NLD,06,Veldhoven,212.61.84.196,PRIMAQUINE treats BENIGN TERTIAN MALARIA,70,118,,91,128,treats,0.98058067569092,907114-FS1-2,"The inadequacy of the 4 aminoquinolines for protection against latent BENIGN TERTIAN MALARIA is noted, and the use of PRIMAQUINE is recommended.",BENIGN TERTIAN MALARIA,PRIMAQUINE,RO-may_prevent
502912463,7/14/2014 15:30:09,,1322920428,7/14/2014 15:29:58,prodege,0.5494,2143114,CAN,BC,Vancouver,24.84.160.12,PRIMAQUINE treats BENIGN TERTIAN MALARIA,70,118,,91,128,treats,0.98058067569092,907114-FS1-2,"The inadequacy of the 4 aminoquinolines for protection against latent BENIGN TERTIAN MALARIA is noted, and the use of PRIMAQUINE is recommended.",BENIGN TERTIAN MALARIA,PRIMAQUINE,RO-may_prevent
502912464,7/14/2014 12:49:46,,1322814557,7/14/2014 12:49:11,elite,0.75,27433978,AUS,05,Plympton,110.174.120.88,no_relation,75,128,,81,136,causes,0.918558653543692,904836-FS1-4,Serial addition to 3 or more antiepileptic drugs is less likely to lead to SEIZURE freedom for patients with difficult to treat EPILEPSY,SEIZURE,EPILEPSY,RO-has_definitional_manifestation
502912464,7/14/2014 12:55:37,,1322818564,7/14/2014 12:54:58,clixsense,0.8194,15189335,GBR,K3,Peterborough,81.156.166.189,EPILEPSY causes SEIZURE,75,128,,81,136,causes,0.918558653543692,904836-FS1-4,Serial addition to 3 or more antiepileptic drugs is less likely to lead to SEIZURE freedom for patients with difficult to treat EPILEPSY,SEIZURE,EPILEPSY,RO-has_definitional_manifestation
502912464,7/14/2014 13:42:47,,1322851012,7/14/2014 13:42:12,prodege,0.6181,17982533,GBR,H3,Leeds,90.193.39.185,no_relation,75,128,,81,136,causes,0.918558653543692,904836-FS1-4,Serial addition to 3 or more antiepileptic drugs is less likely to lead to SEIZURE freedom for patients with difficult to treat EPILEPSY,SEIZURE,EPILEPSY,RO-has_definitional_manifestation
502912464,7/14/2014 14:26:22,,1322881374,7/14/2014 14:25:55,neodev,0.4306,21515166,NLD,11,Nootdorp,83.86.58.179,EPILEPSY causes SEIZURE,75,128,,81,136,causes,0.918558653543692,904836-FS1-4,Serial addition to 3 or more antiepileptic drugs is less likely to lead to SEIZURE freedom for patients with difficult to treat EPILEPSY,SEIZURE,EPILEPSY,RO-has_definitional_manifestation
502912464,7/14/2014 14:45:28,,1322894662,7/14/2014 14:45:23,instagc,0.4611,27753923,GBR,"","",188.30.192.65,EPILEPSY causes SEIZURE,75,128,,81,136,causes,0.918558653543692,904836-FS1-4,Serial addition to 3 or more antiepileptic drugs is less likely to lead to SEIZURE freedom for patients with difficult to treat EPILEPSY,SEIZURE,EPILEPSY,RO-has_definitional_manifestation
502912464,7/14/2014 15:18:23,,1322913336,7/14/2014 15:18:15,clixsense,0.4823,19162475,GBR,M3,Frome,82.33.126.30,SEIZURE causes EPILEPSY,75,128,,81,136,causes,0.918558653543692,904836-FS1-4,Serial addition to 3 or more antiepileptic drugs is less likely to lead to SEIZURE freedom for patients with difficult to treat EPILEPSY,SEIZURE,EPILEPSY,RO-has_definitional_manifestation
502912464,7/14/2014 15:26:51,,1322918352,7/14/2014 15:26:17,clixsense,0.4244,26889820,GBR,C3,Shelford,92.18.120.203,no_relation,75,128,,81,136,causes,0.918558653543692,904836-FS1-4,Serial addition to 3 or more antiepileptic drugs is less likely to lead to SEIZURE freedom for patients with difficult to treat EPILEPSY,SEIZURE,EPILEPSY,RO-has_definitional_manifestation
502912465,7/14/2014 12:46:36,,1322812399,7/14/2014 12:45:53,elite,0.75,27433978,AUS,05,Plympton,110.174.120.88,no_relation,66,112,,72,126,causes,0.485071250072666,902028-FS1-4,"However, the patients with extensive intestinal metaplasia of the STOMACH belong to the high risk group for the GASTRIC CANCER",STOMACH,GASTRIC CANCER,RO-disease_has_primary_anatomic_site
502912465,7/14/2014 14:26:51,,1322881728,7/14/2014 14:26:23,neodev,0.4306,21515166,NLD,11,Nootdorp,83.86.58.179,STOMACH causes GASTRIC CANCER,66,112,,72,126,causes,0.485071250072666,902028-FS1-4,"However, the patients with extensive intestinal metaplasia of the STOMACH belong to the high risk group for the GASTRIC CANCER",STOMACH,GASTRIC CANCER,RO-disease_has_primary_anatomic_site
502912465,7/14/2014 14:45:39,,1322894817,7/14/2014 14:45:34,instagc,0.4611,27753923,GBR,"","",188.30.192.65,GASTRIC CANCER causes STOMACH,66,112,,72,126,causes,0.485071250072666,902028-FS1-4,"However, the patients with extensive intestinal metaplasia of the STOMACH belong to the high risk group for the GASTRIC CANCER",STOMACH,GASTRIC CANCER,RO-disease_has_primary_anatomic_site
502912465,7/14/2014 15:19:29,,1322914007,7/14/2014 15:18:33,prodege,0.639,27996604,CAN,QC,Boucherville,24.201.21.27,no_relation,66,112,,72,126,causes,0.485071250072666,902028-FS1-4,"However, the patients with extensive intestinal metaplasia of the STOMACH belong to the high risk group for the GASTRIC CANCER",STOMACH,GASTRIC CANCER,RO-disease_has_primary_anatomic_site
502912465,7/14/2014 15:36:53,,1322924409,7/14/2014 15:36:34,clixsense,0.6484,19638651,USA,"","",173.23.121.63,no_relation,66,112,,72,126,causes,0.485071250072666,902028-FS1-4,"However, the patients with extensive intestinal metaplasia of the STOMACH belong to the high risk group for the GASTRIC CANCER",STOMACH,GASTRIC CANCER,RO-disease_has_primary_anatomic_site
502912465,7/14/2014 15:52:44,,1322933192,7/14/2014 15:51:56,clixsense,0.573,22177255,USA,CA,San Francisco,73.32.39.90,no_relation,66,112,,72,126,causes,0.485071250072666,902028-FS1-4,"However, the patients with extensive intestinal metaplasia of the STOMACH belong to the high risk group for the GASTRIC CANCER",STOMACH,GASTRIC CANCER,RO-disease_has_primary_anatomic_site
502912465,7/14/2014 15:57:14,,1322935759,7/14/2014 15:56:45,prodege,0.5,28039757,GBR,L8,Southport,109.155.158.54,no_relation,66,112,,72,126,causes,0.485071250072666,902028-FS1-4,"However, the patients with extensive intestinal metaplasia of the STOMACH belong to the high risk group for the GASTRIC CANCER",STOMACH,GASTRIC CANCER,RO-disease_has_primary_anatomic_site
502912466,7/14/2014 12:43:32,,1322810445,7/14/2014 12:43:28,clixsense,0.875,25419319,GBR,H8,Liverpool,94.4.192.228,THROMBOCYTOPENIA diagnosed by IDIOPATHIC THROMBOCYTOPENIC PURPURA,215,118,,230,153,diagnosed by,0.458831467741123,904858-FS1-13,"Acute idiopathic thrombocytopenic purpura is the most common cause of thrombocytopenia in childhood, and diagnosis of IDIOPATHIC THROMBOCYTOPENIC PURPURA is made clinically based on the exclusion of other causes of THROMBOCYTOPENIA.",THROMBOCYTOPENIA,IDIOPATHIC THROMBOCYTOPENIC PURPURA,RO-has_definitional_manifestation
502912466,7/14/2014 12:48:17,,1322813505,7/14/2014 12:47:16,elite,0.75,27433978,AUS,05,Plympton,110.174.120.88,IDIOPATHIC THROMBOCYTOPENIC PURPURA diagnosed by THROMBOCYTOPENIA,215,118,,230,153,diagnosed by,0.458831467741123,904858-FS1-13,"Acute idiopathic thrombocytopenic purpura is the most common cause of thrombocytopenia in childhood, and diagnosis of IDIOPATHIC THROMBOCYTOPENIC PURPURA is made clinically based on the exclusion of other causes of THROMBOCYTOPENIA.",THROMBOCYTOPENIA,IDIOPATHIC THROMBOCYTOPENIC PURPURA,RO-has_definitional_manifestation
502912466,7/14/2014 13:42:11,,1322850607,7/14/2014 13:41:40,prodege,0.6181,17982533,GBR,H3,Leeds,90.193.39.185,IDIOPATHIC THROMBOCYTOPENIC PURPURA diagnosed by THROMBOCYTOPENIA,215,118,,230,153,diagnosed by,0.458831467741123,904858-FS1-13,"Acute idiopathic thrombocytopenic purpura is the most common cause of thrombocytopenia in childhood, and diagnosis of IDIOPATHIC THROMBOCYTOPENIC PURPURA is made clinically based on the exclusion of other causes of THROMBOCYTOPENIA.",THROMBOCYTOPENIA,IDIOPATHIC THROMBOCYTOPENIC PURPURA,RO-has_definitional_manifestation
502912466,7/14/2014 13:52:15,,1322858113,7/14/2014 13:51:40,clixsense,0.4042,25402344,CAN,ON,Wawa,24.109.124.45,THROMBOCYTOPENIA diagnosed by IDIOPATHIC THROMBOCYTOPENIC PURPURA,215,118,,230,153,diagnosed by,0.458831467741123,904858-FS1-13,"Acute idiopathic thrombocytopenic purpura is the most common cause of thrombocytopenia in childhood, and diagnosis of IDIOPATHIC THROMBOCYTOPENIC PURPURA is made clinically based on the exclusion of other causes of THROMBOCYTOPENIA.",THROMBOCYTOPENIA,IDIOPATHIC THROMBOCYTOPENIC PURPURA,RO-has_definitional_manifestation
502912466,7/14/2014 13:53:00,,1322858543,7/14/2014 13:52:03,zoombucks,0.7764,5919735,USA,PA,Doylestown,173.49.91.231,no_relation,215,118,,230,153,diagnosed by,0.458831467741123,904858-FS1-13,"Acute idiopathic thrombocytopenic purpura is the most common cause of thrombocytopenia in childhood, and diagnosis of IDIOPATHIC THROMBOCYTOPENIC PURPURA is made clinically based on the exclusion of other causes of THROMBOCYTOPENIA.",THROMBOCYTOPENIA,IDIOPATHIC THROMBOCYTOPENIC PURPURA,RO-has_definitional_manifestation
502912466,7/14/2014 14:23:37,,1322879290,7/14/2014 14:23:31,neodev,0.3792,25224036,CAN,ON,Sudbury,67.204.218.187,THROMBOCYTOPENIA diagnosed by IDIOPATHIC THROMBOCYTOPENIC PURPURA,215,118,,230,153,diagnosed by,0.458831467741123,904858-FS1-13,"Acute idiopathic thrombocytopenic purpura is the most common cause of thrombocytopenia in childhood, and diagnosis of IDIOPATHIC THROMBOCYTOPENIC PURPURA is made clinically based on the exclusion of other causes of THROMBOCYTOPENIA.",THROMBOCYTOPENIA,IDIOPATHIC THROMBOCYTOPENIC PURPURA,RO-has_definitional_manifestation
502912466,7/14/2014 14:57:08,,1322901784,7/14/2014 14:56:52,elite,0.4302,28276268,USA,MI,Taylor,67.149.247.166,IDIOPATHIC THROMBOCYTOPENIC PURPURA diagnosed by THROMBOCYTOPENIA,215,118,,230,153,diagnosed by,0.458831467741123,904858-FS1-13,"Acute idiopathic thrombocytopenic purpura is the most common cause of thrombocytopenia in childhood, and diagnosis of IDIOPATHIC THROMBOCYTOPENIC PURPURA is made clinically based on the exclusion of other causes of THROMBOCYTOPENIA.",THROMBOCYTOPENIA,IDIOPATHIC THROMBOCYTOPENIC PURPURA,RO-has_definitional_manifestation
502912467,7/14/2014 12:34:14,,1322804067,7/14/2014 12:34:08,neodev,0.9583,17610000,GBR,I2,Manchester,90.200.140.201,HIGH GRADE DYSPLASIA is location of TUBULOVILLOUS ADENOMA,81,54,,100,75,is location of,0.583459965991578,901552-FS1-9,"A right hemicolectomy was performed, which revealed a TUBULOVILLOUS ADENOMA with HIGH GRADE DYSPLASIA located in the ascending colon, and a diffuse ischemic colitis.",HIGH GRADE DYSPLASIA,TUBULOVILLOUS ADENOMA,RO-disease_has_finding
502912467,7/14/2014 12:43:39,,1322810491,7/14/2014 12:43:34,clixsense,0.875,25419319,GBR,H8,Liverpool,94.4.192.228,TUBULOVILLOUS ADENOMA is location of HIGH GRADE DYSPLASIA,81,54,,100,75,is location of,0.583459965991578,901552-FS1-9,"A right hemicolectomy was performed, which revealed a TUBULOVILLOUS ADENOMA with HIGH GRADE DYSPLASIA located in the ascending colon, and a diffuse ischemic colitis.",HIGH GRADE DYSPLASIA,TUBULOVILLOUS ADENOMA,RO-disease_has_finding
502912467,7/14/2014 13:00:03,,1322821493,7/14/2014 12:59:23,rewardsspot,0.7153,24482174,GBR,H9,London,46.23.68.180,HIGH GRADE DYSPLASIA is location of TUBULOVILLOUS ADENOMA,81,54,,100,75,is location of,0.583459965991578,901552-FS1-9,"A right hemicolectomy was performed, which revealed a TUBULOVILLOUS ADENOMA with HIGH GRADE DYSPLASIA located in the ascending colon, and a diffuse ischemic colitis.",HIGH GRADE DYSPLASIA,TUBULOVILLOUS ADENOMA,RO-disease_has_finding
502912467,7/14/2014 13:19:11,,1322834334,7/14/2014 13:18:21,clixsense,0.7,24896327,GBR,V2,Glasgow,94.2.231.4,no_relation,81,54,,100,75,is location of,0.583459965991578,901552-FS1-9,"A right hemicolectomy was performed, which revealed a TUBULOVILLOUS ADENOMA with HIGH GRADE DYSPLASIA located in the ascending colon, and a diffuse ischemic colitis.",HIGH GRADE DYSPLASIA,TUBULOVILLOUS ADENOMA,RO-disease_has_finding
502912467,7/14/2014 14:24:40,,1322880128,7/14/2014 14:24:06,neodev,0.4306,21515166,NLD,11,Nootdorp,83.86.58.179,TUBULOVILLOUS ADENOMA is location of HIGH GRADE DYSPLASIA,81,54,,100,75,is location of,0.583459965991578,901552-FS1-9,"A right hemicolectomy was performed, which revealed a TUBULOVILLOUS ADENOMA with HIGH GRADE DYSPLASIA located in the ascending colon, and a diffuse ischemic colitis.",HIGH GRADE DYSPLASIA,TUBULOVILLOUS ADENOMA,RO-disease_has_finding
502912467,7/14/2014 15:04:27,,1322906163,7/14/2014 15:03:58,neodev,0.719,18755947,GBR,H2,Accrington,80.47.185.52,TUBULOVILLOUS ADENOMA is location of HIGH GRADE DYSPLASIA,81,54,,100,75,is location of,0.583459965991578,901552-FS1-9,"A right hemicolectomy was performed, which revealed a TUBULOVILLOUS ADENOMA with HIGH GRADE DYSPLASIA located in the ascending colon, and a diffuse ischemic colitis.",HIGH GRADE DYSPLASIA,TUBULOVILLOUS ADENOMA,RO-disease_has_finding
502912467,7/14/2014 15:11:07,,1322909622,7/14/2014 15:10:38,clixsense,0.5718,19803139,NLD,06,Veldhoven,212.61.84.196,no_relation,81,54,,100,75,is location of,0.583459965991578,901552-FS1-9,"A right hemicolectomy was performed, which revealed a TUBULOVILLOUS ADENOMA with HIGH GRADE DYSPLASIA located in the ascending colon, and a diffuse ischemic colitis.",HIGH GRADE DYSPLASIA,TUBULOVILLOUS ADENOMA,RO-disease_has_finding
502912468,7/14/2014 13:54:28,,1322859645,7/14/2014 13:54:08,zoombucks,0.7764,5919735,USA,PA,Doylestown,173.49.91.231,no_relation,191,133,,197,141,causes,0.904194430179465,905412-FS1-4,Lacunes consist of small vascular lesions with a volume of between 2 and about 30 mm. These lacunar infarctions are determined by an ISCHEMIA caused by obstructive diseases of small terminal VESSELS in the deep areas of the brain.,VESSELS,ISCHEMIA,RO-has_finding_site
502912468,7/14/2014 15:10:37,,1322909429,7/14/2014 15:10:11,clixsense,0.5718,19803139,NLD,06,Veldhoven,212.61.84.196,no_relation,191,133,,197,141,causes,0.904194430179465,905412-FS1-4,Lacunes consist of small vascular lesions with a volume of between 2 and about 30 mm. These lacunar infarctions are determined by an ISCHEMIA caused by obstructive diseases of small terminal VESSELS in the deep areas of the brain.,VESSELS,ISCHEMIA,RO-has_finding_site
502912468,7/14/2014 15:18:13,,1322913246,7/14/2014 15:18:05,clixsense,0.4823,19162475,GBR,M3,Frome,82.33.126.30,ISCHEMIA causes VESSELS,191,133,,197,141,causes,0.904194430179465,905412-FS1-4,Lacunes consist of small vascular lesions with a volume of between 2 and about 30 mm. These lacunar infarctions are determined by an ISCHEMIA caused by obstructive diseases of small terminal VESSELS in the deep areas of the brain.,VESSELS,ISCHEMIA,RO-has_finding_site
502912468,7/14/2014 15:29:57,,1322920350,7/14/2014 15:29:46,prodege,0.5494,2143114,CAN,BC,Vancouver,24.84.160.12,ISCHEMIA causes VESSELS,191,133,,197,141,causes,0.904194430179465,905412-FS1-4,Lacunes consist of small vascular lesions with a volume of between 2 and about 30 mm. These lacunar infarctions are determined by an ISCHEMIA caused by obstructive diseases of small terminal VESSELS in the deep areas of the brain.,VESSELS,ISCHEMIA,RO-has_finding_site
502912468,7/14/2014 15:31:08,,1322920897,7/14/2014 15:30:54,gifthulk,0.6484,21916793,GBR,"","",87.113.87.199,no_relation,191,133,,197,141,causes,0.904194430179465,905412-FS1-4,Lacunes consist of small vascular lesions with a volume of between 2 and about 30 mm. These lacunar infarctions are determined by an ISCHEMIA caused by obstructive diseases of small terminal VESSELS in the deep areas of the brain.,VESSELS,ISCHEMIA,RO-has_finding_site
502912468,7/14/2014 15:54:15,,1322934028,7/14/2014 15:53:43,clixsense,0.573,22177255,USA,CA,San Francisco,73.32.39.90,no_relation,191,133,,197,141,causes,0.904194430179465,905412-FS1-4,Lacunes consist of small vascular lesions with a volume of between 2 and about 30 mm. These lacunar infarctions are determined by an ISCHEMIA caused by obstructive diseases of small terminal VESSELS in the deep areas of the brain.,VESSELS,ISCHEMIA,RO-has_finding_site
502912468,7/14/2014 15:58:24,,1322936379,7/14/2014 15:57:53,prodege,0.5,28039757,GBR,L8,Southport,109.155.158.54,no_relation,191,133,,197,141,causes,0.904194430179465,905412-FS1-4,Lacunes consist of small vascular lesions with a volume of between 2 and about 30 mm. These lacunar infarctions are determined by an ISCHEMIA caused by obstructive diseases of small terminal VESSELS in the deep areas of the brain.,VESSELS,ISCHEMIA,RO-has_finding_site
502912469,7/14/2014 12:47:15,,1322812848,7/14/2014 12:46:37,elite,0.75,27433978,AUS,05,Plympton,110.174.120.88,ACUTE PROMYELOCYTIC LEUKEMIA causes DISSEMINATED INTRAVASCULAR COAGULATION,61,103,,98,131,causes,0.911684611677103,902751-FS1-4,"Higuchi T, Shimizu T, Mori H, et al: Coagulation patterns of DISSEMINATED INTRAVASCULAR COAGULATION in ACUTE PROMYELOCYTIC LEUKEMIA",DISSEMINATED INTRAVASCULAR COAGULATION,ACUTE PROMYELOCYTIC LEUKEMIA,RO-disease_may_have_finding
502912469,7/14/2014 14:17:14,,1322874894,7/14/2014 14:16:59,clixsense,0.5125,7415230,GBR,A7,Birmingham,147.188.47.242,no_relation,61,103,,98,131,causes,0.911684611677103,902751-FS1-4,"Higuchi T, Shimizu T, Mori H, et al: Coagulation patterns of DISSEMINATED INTRAVASCULAR COAGULATION in ACUTE PROMYELOCYTIC LEUKEMIA",DISSEMINATED INTRAVASCULAR COAGULATION,ACUTE PROMYELOCYTIC LEUKEMIA,RO-disease_may_have_finding
502912469,7/14/2014 14:55:30,,1322900623,7/14/2014 14:55:09,instagc,0.6593,13763729,USA,"","",75.182.89.225,no_relation,61,103,,98,131,causes,0.911684611677103,902751-FS1-4,"Higuchi T, Shimizu T, Mori H, et al: Coagulation patterns of DISSEMINATED INTRAVASCULAR COAGULATION in ACUTE PROMYELOCYTIC LEUKEMIA",DISSEMINATED INTRAVASCULAR COAGULATION,ACUTE PROMYELOCYTIC LEUKEMIA,RO-disease_may_have_finding
502912469,7/14/2014 15:28:21,,1322919324,7/14/2014 15:27:40,gifthulk,0.6484,21916793,GBR,"","",87.113.87.199,ACUTE PROMYELOCYTIC LEUKEMIA causes DISSEMINATED INTRAVASCULAR COAGULATION,61,103,,98,131,causes,0.911684611677103,902751-FS1-4,"Higuchi T, Shimizu T, Mori H, et al: Coagulation patterns of DISSEMINATED INTRAVASCULAR COAGULATION in ACUTE PROMYELOCYTIC LEUKEMIA",DISSEMINATED INTRAVASCULAR COAGULATION,ACUTE PROMYELOCYTIC LEUKEMIA,RO-disease_may_have_finding
502912469,7/14/2014 15:30:36,,1322920648,7/14/2014 15:30:28,prodege,0.5494,2143114,CAN,BC,Vancouver,24.84.160.12,DISSEMINATED INTRAVASCULAR COAGULATION causes ACUTE PROMYELOCYTIC LEUKEMIA,61,103,,98,131,causes,0.911684611677103,902751-FS1-4,"Higuchi T, Shimizu T, Mori H, et al: Coagulation patterns of DISSEMINATED INTRAVASCULAR COAGULATION in ACUTE PROMYELOCYTIC LEUKEMIA",DISSEMINATED INTRAVASCULAR COAGULATION,ACUTE PROMYELOCYTIC LEUKEMIA,RO-disease_may_have_finding
502912469,7/14/2014 15:51:55,,1322932712,7/14/2014 15:50:53,clixsense,0.573,22177255,USA,CA,San Francisco,73.32.39.90,ACUTE PROMYELOCYTIC LEUKEMIA causes DISSEMINATED INTRAVASCULAR COAGULATION,61,103,,98,131,causes,0.911684611677103,902751-FS1-4,"Higuchi T, Shimizu T, Mori H, et al: Coagulation patterns of DISSEMINATED INTRAVASCULAR COAGULATION in ACUTE PROMYELOCYTIC LEUKEMIA",DISSEMINATED INTRAVASCULAR COAGULATION,ACUTE PROMYELOCYTIC LEUKEMIA,RO-disease_may_have_finding
502912469,7/14/2014 15:58:55,,1322936658,7/14/2014 15:58:25,prodege,0.5,28039757,GBR,L8,Southport,109.155.158.54,no_relation,61,103,,98,131,causes,0.911684611677103,902751-FS1-4,"Higuchi T, Shimizu T, Mori H, et al: Coagulation patterns of DISSEMINATED INTRAVASCULAR COAGULATION in ACUTE PROMYELOCYTIC LEUKEMIA",DISSEMINATED INTRAVASCULAR COAGULATION,ACUTE PROMYELOCYTIC LEUKEMIA,RO-disease_may_have_finding
502912470,7/14/2014 15:05:02,,1322906497,7/14/2014 15:04:47,neodev,0.719,18755947,GBR,H2,Accrington,80.47.185.52,BONE is location of BONE LOSS,67,67,,70,76,is location of,0.609994281330419,905117-FS1-9,"In contrast, all ITAM adapter deficient mice responded to OVX with BONE LOSS in both femur and tibia of approximately 40%, relative to basal BONE volumes.",BONE,BONE LOSS,RO-has_finding_site
502912470,7/14/2014 15:05:58,,1322906901,7/14/2014 15:05:07,instagc,0.7125,28519532,USA,IA,Honey Creek,12.73.110.26,no_relation,67,67,,70,76,is location of,0.609994281330419,905117-FS1-9,"In contrast, all ITAM adapter deficient mice responded to OVX with BONE LOSS in both femur and tibia of approximately 40%, relative to basal BONE volumes.",BONE,BONE LOSS,RO-has_finding_site
502912470,7/14/2014 15:10:10,,1322909243,7/14/2014 15:09:45,clixsense,0.5718,19803139,NLD,06,Veldhoven,212.61.84.196,BONE is location of BONE LOSS,67,67,,70,76,is location of,0.609994281330419,905117-FS1-9,"In contrast, all ITAM adapter deficient mice responded to OVX with BONE LOSS in both femur and tibia of approximately 40%, relative to basal BONE volumes.",BONE,BONE LOSS,RO-has_finding_site
502912470,7/14/2014 15:18:49,,1322913590,7/14/2014 15:18:43,clixsense,0.4823,19162475,GBR,M3,Frome,82.33.126.30,BONE is location of BONE LOSS,67,67,,70,76,is location of,0.609994281330419,905117-FS1-9,"In contrast, all ITAM adapter deficient mice responded to OVX with BONE LOSS in both femur and tibia of approximately 40%, relative to basal BONE volumes.",BONE,BONE LOSS,RO-has_finding_site
502912470,7/14/2014 15:22:33,,1322915885,7/14/2014 15:21:32,clixsense,0.4244,26889820,GBR,C3,Shelford,92.18.120.203,no_relation,67,67,,70,76,is location of,0.609994281330419,905117-FS1-9,"In contrast, all ITAM adapter deficient mice responded to OVX with BONE LOSS in both femur and tibia of approximately 40%, relative to basal BONE volumes.",BONE,BONE LOSS,RO-has_finding_site
502912470,7/14/2014 15:28:34,,1322919429,7/14/2014 15:28:23,gifthulk,0.6484,21916793,GBR,"","",87.113.87.199,BONE is location of BONE LOSS,67,67,,70,76,is location of,0.609994281330419,905117-FS1-9,"In contrast, all ITAM adapter deficient mice responded to OVX with BONE LOSS in both femur and tibia of approximately 40%, relative to basal BONE volumes.",BONE,BONE LOSS,RO-has_finding_site
502912470,7/14/2014 15:33:29,,1322922447,7/14/2014 15:33:12,neodev,0.5101,21405167,USA,MD,Glen Burnie,69.137.237.73,BONE is location of BONE LOSS,67,67,,70,76,is location of,0.609994281330419,905117-FS1-9,"In contrast, all ITAM adapter deficient mice responded to OVX with BONE LOSS in both femur and tibia of approximately 40%, relative to basal BONE volumes.",BONE,BONE LOSS,RO-has_finding_site
502912471,7/14/2014 13:22:18,,1322836566,7/14/2014 13:21:50,neodev,0.6667,19004420,GBR,M3,Bridgwater,86.160.70.204,CHRONIC HEPATITIS diagnosed by LIVER BIOPSY SPECIMEN,100,142,,120,159,diagnosed by,0.923380516876639,902294-FS1-13,"In addition to the characterization of the degree of inflammation and fibrosis, the evaluation of a LIVER BIOPSY SPECIMEN from a patient with CHRONIC HEPATITIS includes a description of all of the findings present (e.g., steatosis, bile duct changes, granulomas, type of inflammatory cells, presence of iron, and Mallory hyaline) or a notation of their absence.",LIVER BIOPSY SPECIMEN,CHRONIC HEPATITIS,RO-disease_has_primary_anatomic_site
502912471,7/14/2014 13:54:07,,1322859337,7/14/2014 13:53:46,zoombucks,0.7764,5919735,USA,PA,Doylestown,173.49.91.231,CHRONIC HEPATITIS diagnosed by LIVER BIOPSY SPECIMEN,100,142,,120,159,diagnosed by,0.923380516876639,902294-FS1-13,"In addition to the characterization of the degree of inflammation and fibrosis, the evaluation of a LIVER BIOPSY SPECIMEN from a patient with CHRONIC HEPATITIS includes a description of all of the findings present (e.g., steatosis, bile duct changes, granulomas, type of inflammatory cells, presence of iron, and Mallory hyaline) or a notation of their absence.",LIVER BIOPSY SPECIMEN,CHRONIC HEPATITIS,RO-disease_has_primary_anatomic_site
502912471,7/14/2014 14:11:18,,1322870781,7/14/2014 14:10:55,clixsense,0.5125,7415230,GBR,A7,Birmingham,147.188.47.242,no_relation,100,142,,120,159,diagnosed by,0.923380516876639,902294-FS1-13,"In addition to the characterization of the degree of inflammation and fibrosis, the evaluation of a LIVER BIOPSY SPECIMEN from a patient with CHRONIC HEPATITIS includes a description of all of the findings present (e.g., steatosis, bile duct changes, granulomas, type of inflammatory cells, presence of iron, and Mallory hyaline) or a notation of their absence.",LIVER BIOPSY SPECIMEN,CHRONIC HEPATITIS,RO-disease_has_primary_anatomic_site
502912471,7/14/2014 15:05:02,,1322906506,7/14/2014 15:04:33,instagc,0.7125,28519532,USA,IA,Honey Creek,12.73.110.26,CHRONIC HEPATITIS diagnosed by LIVER BIOPSY SPECIMEN,100,142,,120,159,diagnosed by,0.923380516876639,902294-FS1-13,"In addition to the characterization of the degree of inflammation and fibrosis, the evaluation of a LIVER BIOPSY SPECIMEN from a patient with CHRONIC HEPATITIS includes a description of all of the findings present (e.g., steatosis, bile duct changes, granulomas, type of inflammatory cells, presence of iron, and Mallory hyaline) or a notation of their absence.",LIVER BIOPSY SPECIMEN,CHRONIC HEPATITIS,RO-disease_has_primary_anatomic_site
502912471,7/14/2014 15:18:13,,1322913252,7/14/2014 15:18:05,clixsense,0.4823,19162475,GBR,M3,Frome,82.33.126.30,LIVER BIOPSY SPECIMEN diagnosed by CHRONIC HEPATITIS,100,142,,120,159,diagnosed by,0.923380516876639,902294-FS1-13,"In addition to the characterization of the degree of inflammation and fibrosis, the evaluation of a LIVER BIOPSY SPECIMEN from a patient with CHRONIC HEPATITIS includes a description of all of the findings present (e.g., steatosis, bile duct changes, granulomas, type of inflammatory cells, presence of iron, and Mallory hyaline) or a notation of their absence.",LIVER BIOPSY SPECIMEN,CHRONIC HEPATITIS,RO-disease_has_primary_anatomic_site
502912471,7/14/2014 15:31:08,,1322920896,7/14/2014 15:30:54,gifthulk,0.6484,21916793,GBR,"","",87.113.87.199,CHRONIC HEPATITIS diagnosed by LIVER BIOPSY SPECIMEN,100,142,,120,159,diagnosed by,0.923380516876639,902294-FS1-13,"In addition to the characterization of the degree of inflammation and fibrosis, the evaluation of a LIVER BIOPSY SPECIMEN from a patient with CHRONIC HEPATITIS includes a description of all of the findings present (e.g., steatosis, bile duct changes, granulomas, type of inflammatory cells, presence of iron, and Mallory hyaline) or a notation of their absence.",LIVER BIOPSY SPECIMEN,CHRONIC HEPATITIS,RO-disease_has_primary_anatomic_site
502912471,7/14/2014 15:33:29,,1322922448,7/14/2014 15:33:12,neodev,0.5101,21405167,USA,MD,Glen Burnie,69.137.237.73,CHRONIC HEPATITIS diagnosed by LIVER BIOPSY SPECIMEN,100,142,,120,159,diagnosed by,0.923380516876639,902294-FS1-13,"In addition to the characterization of the degree of inflammation and fibrosis, the evaluation of a LIVER BIOPSY SPECIMEN from a patient with CHRONIC HEPATITIS includes a description of all of the findings present (e.g., steatosis, bile duct changes, granulomas, type of inflammatory cells, presence of iron, and Mallory hyaline) or a notation of their absence.",LIVER BIOPSY SPECIMEN,CHRONIC HEPATITIS,RO-disease_has_primary_anatomic_site
502912472,7/14/2014 12:35:19,,1322804783,7/14/2014 12:34:50,prodege,0.8889,27934334,GBR,Q2,Wokingham,86.166.73.21,no_relation,215,118,,230,153,causes,0.802955068546966,904858-FS1-4,"Acute idiopathic thrombocytopenic purpura is the most common cause of thrombocytopenia in childhood, and diagnosis of IDIOPATHIC THROMBOCYTOPENIC PURPURA is made clinically based on the exclusion of other causes of THROMBOCYTOPENIA.",THROMBOCYTOPENIA,IDIOPATHIC THROMBOCYTOPENIC PURPURA,RO-has_definitional_manifestation
502912472,7/14/2014 14:23:23,,1322879150,7/14/2014 14:23:18,neodev,0.3792,25224036,CAN,ON,Sudbury,67.204.218.187,IDIOPATHIC THROMBOCYTOPENIC PURPURA causes THROMBOCYTOPENIA,215,118,,230,153,causes,0.802955068546966,904858-FS1-4,"Acute idiopathic thrombocytopenic purpura is the most common cause of thrombocytopenia in childhood, and diagnosis of IDIOPATHIC THROMBOCYTOPENIC PURPURA is made clinically based on the exclusion of other causes of THROMBOCYTOPENIA.",THROMBOCYTOPENIA,IDIOPATHIC THROMBOCYTOPENIC PURPURA,RO-has_definitional_manifestation
502912472,7/14/2014 14:25:52,,1322881032,7/14/2014 14:25:18,neodev,0.4306,21515166,NLD,11,Nootdorp,83.86.58.179,IDIOPATHIC THROMBOCYTOPENIC PURPURA causes THROMBOCYTOPENIA,215,118,,230,153,causes,0.802955068546966,904858-FS1-4,"Acute idiopathic thrombocytopenic purpura is the most common cause of thrombocytopenia in childhood, and diagnosis of IDIOPATHIC THROMBOCYTOPENIC PURPURA is made clinically based on the exclusion of other causes of THROMBOCYTOPENIA.",THROMBOCYTOPENIA,IDIOPATHIC THROMBOCYTOPENIC PURPURA,RO-has_definitional_manifestation
502912472,7/14/2014 14:31:12,,1322884974,7/14/2014 14:31:00,instagc,0.644,15445601,USA,FL,Jacksonville,24.129.68.254,IDIOPATHIC THROMBOCYTOPENIC PURPURA causes THROMBOCYTOPENIA,215,118,,230,153,causes,0.802955068546966,904858-FS1-4,"Acute idiopathic thrombocytopenic purpura is the most common cause of thrombocytopenia in childhood, and diagnosis of IDIOPATHIC THROMBOCYTOPENIC PURPURA is made clinically based on the exclusion of other causes of THROMBOCYTOPENIA.",THROMBOCYTOPENIA,IDIOPATHIC THROMBOCYTOPENIC PURPURA,RO-has_definitional_manifestation
502912472,7/14/2014 14:45:33,,1322894785,7/14/2014 14:45:29,instagc,0.4611,27753923,GBR,"","",188.30.192.65,THROMBOCYTOPENIA causes IDIOPATHIC THROMBOCYTOPENIC PURPURA,215,118,,230,153,causes,0.802955068546966,904858-FS1-4,"Acute idiopathic thrombocytopenic purpura is the most common cause of thrombocytopenia in childhood, and diagnosis of IDIOPATHIC THROMBOCYTOPENIC PURPURA is made clinically based on the exclusion of other causes of THROMBOCYTOPENIA.",THROMBOCYTOPENIA,IDIOPATHIC THROMBOCYTOPENIC PURPURA,RO-has_definitional_manifestation
502912472,7/14/2014 15:00:49,,1322904039,7/14/2014 15:00:28,instagc,0.5536,18960682,GBR,"","",86.29.147.112,THROMBOCYTOPENIA causes IDIOPATHIC THROMBOCYTOPENIC PURPURA,215,118,,230,153,causes,0.802955068546966,904858-FS1-4,"Acute idiopathic thrombocytopenic purpura is the most common cause of thrombocytopenia in childhood, and diagnosis of IDIOPATHIC THROMBOCYTOPENIC PURPURA is made clinically based on the exclusion of other causes of THROMBOCYTOPENIA.",THROMBOCYTOPENIA,IDIOPATHIC THROMBOCYTOPENIC PURPURA,RO-has_definitional_manifestation
502912472,7/14/2014 15:04:04,,1322905948,7/14/2014 15:03:13,vivatic,0.5339,25451531,GBR,"","",83.67.28.193,IDIOPATHIC THROMBOCYTOPENIC PURPURA causes THROMBOCYTOPENIA,215,118,,230,153,causes,0.802955068546966,904858-FS1-4,"Acute idiopathic thrombocytopenic purpura is the most common cause of thrombocytopenia in childhood, and diagnosis of IDIOPATHIC THROMBOCYTOPENIC PURPURA is made clinically based on the exclusion of other causes of THROMBOCYTOPENIA.",THROMBOCYTOPENIA,IDIOPATHIC THROMBOCYTOPENIC PURPURA,RO-has_definitional_manifestation
502912473,7/14/2014 12:34:14,,1322804071,7/14/2014 12:34:08,neodev,0.9583,17610000,GBR,I2,Manchester,90.200.140.201,HYPERTENSION causes NEPHROBLASTOMA,65,0,,76,14,causes,0.683763458757828,902706-FS1-4,"NEPHROBLASTOMA must be included in the differential diagnosis of HYPERTENSION associated with increased renin concentrations, even in the absence of an abdominal mass..",HYPERTENSION,NEPHROBLASTOMA,RO-disease_may_have_finding
502912473,7/14/2014 12:54:56,,1322818150,7/14/2014 12:54:37,clixsense,0.8194,15189335,GBR,K3,Peterborough,81.156.166.189,HYPERTENSION causes NEPHROBLASTOMA,65,0,,76,14,causes,0.683763458757828,902706-FS1-4,"NEPHROBLASTOMA must be included in the differential diagnosis of HYPERTENSION associated with increased renin concentrations, even in the absence of an abdominal mass..",HYPERTENSION,NEPHROBLASTOMA,RO-disease_may_have_finding
502912473,7/14/2014 13:18:19,,1322833772,7/14/2014 13:17:21,clixsense,0.7,24896327,GBR,V2,Glasgow,94.2.231.4,no_relation,65,0,,76,14,causes,0.683763458757828,902706-FS1-4,"NEPHROBLASTOMA must be included in the differential diagnosis of HYPERTENSION associated with increased renin concentrations, even in the absence of an abdominal mass..",HYPERTENSION,NEPHROBLASTOMA,RO-disease_may_have_finding
502912473,7/14/2014 13:41:39,,1322850190,7/14/2014 13:41:12,prodege,0.6181,17982533,GBR,H3,Leeds,90.193.39.185,no_relation,65,0,,76,14,causes,0.683763458757828,902706-FS1-4,"NEPHROBLASTOMA must be included in the differential diagnosis of HYPERTENSION associated with increased renin concentrations, even in the absence of an abdominal mass..",HYPERTENSION,NEPHROBLASTOMA,RO-disease_may_have_finding
502912473,7/14/2014 14:23:37,,1322879299,7/14/2014 14:23:31,neodev,0.3792,25224036,CAN,ON,Sudbury,67.204.218.187,NEPHROBLASTOMA causes HYPERTENSION,65,0,,76,14,causes,0.683763458757828,902706-FS1-4,"NEPHROBLASTOMA must be included in the differential diagnosis of HYPERTENSION associated with increased renin concentrations, even in the absence of an abdominal mass..",HYPERTENSION,NEPHROBLASTOMA,RO-disease_may_have_finding
502912473,7/14/2014 14:57:55,,1322902292,7/14/2014 14:57:28,elite,0.4302,28276268,USA,MI,Taylor,67.149.247.166,NEPHROBLASTOMA causes HYPERTENSION,65,0,,76,14,causes,0.683763458757828,902706-FS1-4,"NEPHROBLASTOMA must be included in the differential diagnosis of HYPERTENSION associated with increased renin concentrations, even in the absence of an abdominal mass..",HYPERTENSION,NEPHROBLASTOMA,RO-disease_may_have_finding
502912473,7/14/2014 15:27:02,,1322918423,7/14/2014 15:26:47,instagc,0.3552,19004168,GBR,H2,Accrington,80.47.185.52,no_relation,65,0,,76,14,causes,0.683763458757828,902706-FS1-4,"NEPHROBLASTOMA must be included in the differential diagnosis of HYPERTENSION associated with increased renin concentrations, even in the absence of an abdominal mass..",HYPERTENSION,NEPHROBLASTOMA,RO-disease_may_have_finding
502912474,7/14/2014 13:02:01,,1322822818,7/14/2014 13:01:34,prodege,0.7639,7664351,USA,NY,Cicero,74.111.0.21,no_relation,222,167,,227,191,diagnosed by,0.301511344577764,906234-FS1-13,"PDGFRA, PDGFRB, and EGFR were immunohistochemically, biochemically, cytogenetically, and mutationally analyzed along with the detection of their cognate ligands in 16 NEUROFIBROMATOSIS TYPE 1 (NF1) related and 11 sporadic MPNSTS",MPNSTS,NEUROFIBROMATOSIS TYPE 1,RO-has_manifestation
502912474,7/14/2014 13:50:16,,1322856574,7/14/2014 13:49:47,clixsense,0.4042,25402344,CAN,ON,Wawa,24.109.124.45,NEUROFIBROMATOSIS TYPE 1 diagnosed by MPNSTS,222,167,,227,191,diagnosed by,0.301511344577764,906234-FS1-13,"PDGFRA, PDGFRB, and EGFR were immunohistochemically, biochemically, cytogenetically, and mutationally analyzed along with the detection of their cognate ligands in 16 NEUROFIBROMATOSIS TYPE 1 (NF1) related and 11 sporadic MPNSTS",MPNSTS,NEUROFIBROMATOSIS TYPE 1,RO-has_manifestation
502912474,7/14/2014 14:31:32,,1322885300,7/14/2014 14:31:18,clixsense,0.5125,7415230,GBR,A7,Birmingham,147.188.47.242,no_relation,222,167,,227,191,diagnosed by,0.301511344577764,906234-FS1-13,"PDGFRA, PDGFRB, and EGFR were immunohistochemically, biochemically, cytogenetically, and mutationally analyzed along with the detection of their cognate ligands in 16 NEUROFIBROMATOSIS TYPE 1 (NF1) related and 11 sporadic MPNSTS",MPNSTS,NEUROFIBROMATOSIS TYPE 1,RO-has_manifestation
502912474,7/14/2014 15:22:33,,1322915886,7/14/2014 15:21:32,clixsense,0.4244,26889820,GBR,C3,Shelford,92.18.120.203,no_relation,222,167,,227,191,diagnosed by,0.301511344577764,906234-FS1-13,"PDGFRA, PDGFRB, and EGFR were immunohistochemically, biochemically, cytogenetically, and mutationally analyzed along with the detection of their cognate ligands in 16 NEUROFIBROMATOSIS TYPE 1 (NF1) related and 11 sporadic MPNSTS",MPNSTS,NEUROFIBROMATOSIS TYPE 1,RO-has_manifestation
502912474,7/14/2014 15:32:14,,1322921598,7/14/2014 15:31:46,gifthulk,0.6484,21916793,GBR,"","",87.113.87.199,no_relation,222,167,,227,191,diagnosed by,0.301511344577764,906234-FS1-13,"PDGFRA, PDGFRB, and EGFR were immunohistochemically, biochemically, cytogenetically, and mutationally analyzed along with the detection of their cognate ligands in 16 NEUROFIBROMATOSIS TYPE 1 (NF1) related and 11 sporadic MPNSTS",MPNSTS,NEUROFIBROMATOSIS TYPE 1,RO-has_manifestation
502912474,7/14/2014 15:51:55,,1322932713,7/14/2014 15:50:53,clixsense,0.573,22177255,USA,CA,San Francisco,73.32.39.90,NEUROFIBROMATOSIS TYPE 1 diagnosed by MPNSTS,222,167,,227,191,diagnosed by,0.301511344577764,906234-FS1-13,"PDGFRA, PDGFRB, and EGFR were immunohistochemically, biochemically, cytogenetically, and mutationally analyzed along with the detection of their cognate ligands in 16 NEUROFIBROMATOSIS TYPE 1 (NF1) related and 11 sporadic MPNSTS",MPNSTS,NEUROFIBROMATOSIS TYPE 1,RO-has_manifestation
502912474,7/14/2014 15:59:31,,1322937011,7/14/2014 15:58:56,prodege,0.5,28039757,GBR,L8,Southport,109.155.158.54,NEUROFIBROMATOSIS TYPE 1 diagnosed by MPNSTS,222,167,,227,191,diagnosed by,0.301511344577764,906234-FS1-13,"PDGFRA, PDGFRB, and EGFR were immunohistochemically, biochemically, cytogenetically, and mutationally analyzed along with the detection of their cognate ligands in 16 NEUROFIBROMATOSIS TYPE 1 (NF1) related and 11 sporadic MPNSTS",MPNSTS,NEUROFIBROMATOSIS TYPE 1,RO-has_manifestation
502912475,7/14/2014 13:08:06,,1322826854,7/14/2014 13:07:40,prodege,0.6278,11616695,GBR,P7,Wigan,92.29.199.166,no_relation,63,13,,67,24,causes,0.643267520902677,905480-FS1-4,Infants with ANENCEPHALY are born without all or most of their BRAIN and die within a few days of life.,BRAIN,ANENCEPHALY,RO-has_finding_site
502912475,7/14/2014 13:19:11,,1322834332,7/14/2014 13:18:21,clixsense,0.7,24896327,GBR,V2,Glasgow,94.2.231.4,no_relation,63,13,,67,24,causes,0.643267520902677,905480-FS1-4,Infants with ANENCEPHALY are born without all or most of their BRAIN and die within a few days of life.,BRAIN,ANENCEPHALY,RO-has_finding_site
502912475,7/14/2014 13:54:28,,1322859644,7/14/2014 13:54:08,zoombucks,0.7764,5919735,USA,PA,Doylestown,173.49.91.231,no_relation,63,13,,67,24,causes,0.643267520902677,905480-FS1-4,Infants with ANENCEPHALY are born without all or most of their BRAIN and die within a few days of life.,BRAIN,ANENCEPHALY,RO-has_finding_site
502912475,7/14/2014 14:31:46,,1322885440,7/14/2014 14:31:33,clixsense,0.5125,7415230,GBR,A7,Birmingham,147.188.47.242,no_relation,63,13,,67,24,causes,0.643267520902677,905480-FS1-4,Infants with ANENCEPHALY are born without all or most of their BRAIN and die within a few days of life.,BRAIN,ANENCEPHALY,RO-has_finding_site
502912475,7/14/2014 14:55:08,,1322900440,7/14/2014 14:54:45,instagc,0.6593,13763729,USA,"","",75.182.89.225,no_relation,63,13,,67,24,causes,0.643267520902677,905480-FS1-4,Infants with ANENCEPHALY are born without all or most of their BRAIN and die within a few days of life.,BRAIN,ANENCEPHALY,RO-has_finding_site
502912475,7/14/2014 14:57:27,,1322901971,7/14/2014 14:57:10,elite,0.4302,28276268,USA,MI,Taylor,67.149.247.166,ANENCEPHALY causes BRAIN,63,13,,67,24,causes,0.643267520902677,905480-FS1-4,Infants with ANENCEPHALY are born without all or most of their BRAIN and die within a few days of life.,BRAIN,ANENCEPHALY,RO-has_finding_site
502912475,7/14/2014 15:00:49,,1322904043,7/14/2014 15:00:28,instagc,0.5536,18960682,GBR,"","",86.29.147.112,no_relation,63,13,,67,24,causes,0.643267520902677,905480-FS1-4,Infants with ANENCEPHALY are born without all or most of their BRAIN and die within a few days of life.,BRAIN,ANENCEPHALY,RO-has_finding_site
502912476,7/14/2014 12:35:00,,1322804555,7/14/2014 12:34:41,clixsense,0.9583,27871219,NLD,07,Amsterdam,87.210.207.223,DUCTAL CARCINOMA IN SITU causes MICROCALCIFICATION,53,0,,70,24,causes,1,902812-FS1-4,"DUCTAL CARCINOMA IN SITU (DCIS) usually manifests as MICROCALCIFICATION on mammography, but several other unusual forms of presentation on mammography are also described.",MICROCALCIFICATION,DUCTAL CARCINOMA IN SITU,RO-disease_may_have_finding
502912476,7/14/2014 12:36:46,,1322805653,7/14/2014 12:36:19,prodege,0.8889,27934334,GBR,Q2,Wokingham,86.166.73.21,DUCTAL CARCINOMA IN SITU causes MICROCALCIFICATION,53,0,,70,24,causes,1,902812-FS1-4,"DUCTAL CARCINOMA IN SITU (DCIS) usually manifests as MICROCALCIFICATION on mammography, but several other unusual forms of presentation on mammography are also described.",MICROCALCIFICATION,DUCTAL CARCINOMA IN SITU,RO-disease_may_have_finding
502912476,7/14/2014 14:10:31,,1322870256,7/14/2014 14:10:22,clixsense,0.7708,27793793,GBR,C5,Chester,151.230.27.155,DUCTAL CARCINOMA IN SITU causes MICROCALCIFICATION,53,0,,70,24,causes,1,902812-FS1-4,"DUCTAL CARCINOMA IN SITU (DCIS) usually manifests as MICROCALCIFICATION on mammography, but several other unusual forms of presentation on mammography are also described.",MICROCALCIFICATION,DUCTAL CARCINOMA IN SITU,RO-disease_may_have_finding
502912476,7/14/2014 14:55:08,,1322900448,7/14/2014 14:54:45,instagc,0.6593,13763729,USA,"","",75.182.89.225,DUCTAL CARCINOMA IN SITU causes MICROCALCIFICATION,53,0,,70,24,causes,1,902812-FS1-4,"DUCTAL CARCINOMA IN SITU (DCIS) usually manifests as MICROCALCIFICATION on mammography, but several other unusual forms of presentation on mammography are also described.",MICROCALCIFICATION,DUCTAL CARCINOMA IN SITU,RO-disease_may_have_finding
502912476,7/14/2014 15:01:21,,1322904335,7/14/2014 15:01:11,instagc,0.5536,18960682,GBR,"","",86.29.147.112,MICROCALCIFICATION causes DUCTAL CARCINOMA IN SITU,53,0,,70,24,causes,1,902812-FS1-4,"DUCTAL CARCINOMA IN SITU (DCIS) usually manifests as MICROCALCIFICATION on mammography, but several other unusual forms of presentation on mammography are also described.",MICROCALCIFICATION,DUCTAL CARCINOMA IN SITU,RO-disease_may_have_finding
502912476,7/14/2014 15:07:32,,1322907768,7/14/2014 15:06:52,instagc,0.7125,28519532,USA,IA,Honey Creek,12.73.110.26,DUCTAL CARCINOMA IN SITU causes MICROCALCIFICATION,53,0,,70,24,causes,1,902812-FS1-4,"DUCTAL CARCINOMA IN SITU (DCIS) usually manifests as MICROCALCIFICATION on mammography, but several other unusual forms of presentation on mammography are also described.",MICROCALCIFICATION,DUCTAL CARCINOMA IN SITU,RO-disease_may_have_finding
502912476,7/14/2014 15:09:16,,1322908728,7/14/2014 15:08:49,clixsense,0.5718,19803139,NLD,06,Veldhoven,212.61.84.196,no_relation,53,0,,70,24,causes,1,902812-FS1-4,"DUCTAL CARCINOMA IN SITU (DCIS) usually manifests as MICROCALCIFICATION on mammography, but several other unusual forms of presentation on mammography are also described.",MICROCALCIFICATION,DUCTAL CARCINOMA IN SITU,RO-disease_may_have_finding
502912477,7/14/2014 12:56:13,,1322819024,7/14/2014 12:55:40,clixsense,0.8194,15189335,GBR,K3,Peterborough,81.156.166.189,FIBROMYALGIA SYNDROME causes PAIN,63,4,,66,25,causes,0.986393923832143,904620-FS1-4,The FIBROMYALGIA SYNDROME (FMS) is characterized by widespread PAIN and diffuse tenderness in specified locations.,PAIN,FIBROMYALGIA SYNDROME,RO-has_definitional_manifestation
502912477,7/14/2014 13:17:20,,1322833176,7/14/2014 13:16:47,clixsense,0.7,24896327,GBR,V2,Glasgow,94.2.231.4,FIBROMYALGIA SYNDROME causes PAIN,63,4,,66,25,causes,0.986393923832143,904620-FS1-4,The FIBROMYALGIA SYNDROME (FMS) is characterized by widespread PAIN and diffuse tenderness in specified locations.,PAIN,FIBROMYALGIA SYNDROME,RO-has_definitional_manifestation
502912477,7/14/2014 14:31:32,,1322885301,7/14/2014 14:31:18,clixsense,0.5125,7415230,GBR,A7,Birmingham,147.188.47.242,FIBROMYALGIA SYNDROME causes PAIN,63,4,,66,25,causes,0.986393923832143,904620-FS1-4,The FIBROMYALGIA SYNDROME (FMS) is characterized by widespread PAIN and diffuse tenderness in specified locations.,PAIN,FIBROMYALGIA SYNDROME,RO-has_definitional_manifestation
502912477,7/14/2014 14:34:41,,1322887342,7/14/2014 14:33:56,rewardsspot,0.57,17763704,USA,IL,Chicago,67.212.175.123,FIBROMYALGIA SYNDROME causes PAIN,63,4,,66,25,causes,0.986393923832143,904620-FS1-4,The FIBROMYALGIA SYNDROME (FMS) is characterized by widespread PAIN and diffuse tenderness in specified locations.,PAIN,FIBROMYALGIA SYNDROME,RO-has_definitional_manifestation
502912477,7/14/2014 15:00:12,,1322903642,7/14/2014 15:00:02,instagc,0.5536,18960682,GBR,"","",86.29.147.112,FIBROMYALGIA SYNDROME causes PAIN,63,4,,66,25,causes,0.986393923832143,904620-FS1-4,The FIBROMYALGIA SYNDROME (FMS) is characterized by widespread PAIN and diffuse tenderness in specified locations.,PAIN,FIBROMYALGIA SYNDROME,RO-has_definitional_manifestation
502912477,7/14/2014 15:01:07,,1322904196,7/14/2014 15:00:30,vivatic,0.5339,25451531,GBR,"","",83.67.28.193,FIBROMYALGIA SYNDROME causes PAIN,63,4,,66,25,causes,0.986393923832143,904620-FS1-4,The FIBROMYALGIA SYNDROME (FMS) is characterized by widespread PAIN and diffuse tenderness in specified locations.,PAIN,FIBROMYALGIA SYNDROME,RO-has_definitional_manifestation
502912477,7/14/2014 15:06:46,,1322907282,7/14/2014 15:06:03,instagc,0.7125,28519532,USA,IA,Honey Creek,12.73.110.26,FIBROMYALGIA SYNDROME causes PAIN,63,4,,66,25,causes,0.986393923832143,904620-FS1-4,The FIBROMYALGIA SYNDROME (FMS) is characterized by widespread PAIN and diffuse tenderness in specified locations.,PAIN,FIBROMYALGIA SYNDROME,RO-has_definitional_manifestation
502912478,7/14/2014 13:01:21,,1322822375,7/14/2014 13:00:47,rewardsspot,0.7153,24482174,GBR,H9,London,46.23.68.180,WART treats HUMAN PAPILLOMA VIRUS,110,147,,130,151,treats,0.328797974610715,903914-FS1-2,These results support the hypothesis that stimulation of local cytokines by imiquimod leads to a reduction in HUMAN PAPILLOMA VIRUS (HPV) load; to WART regression and to the normalisation of keratinocyte proliferation without evidence of scarring.,HUMAN PAPILLOMA VIRUS,WART,RO-has_causative_agent
502912478,7/14/2014 13:08:23,,1322827097,7/14/2014 13:08:07,prodege,0.6278,11616695,GBR,P7,Wigan,92.29.199.166,no_relation,110,147,,130,151,treats,0.328797974610715,903914-FS1-2,These results support the hypothesis that stimulation of local cytokines by imiquimod leads to a reduction in HUMAN PAPILLOMA VIRUS (HPV) load; to WART regression and to the normalisation of keratinocyte proliferation without evidence of scarring.,HUMAN PAPILLOMA VIRUS,WART,RO-has_causative_agent
502912478,7/14/2014 14:35:40,,1322888026,7/14/2014 14:35:22,rewardsspot,0.57,17763704,USA,IL,Chicago,67.212.175.123,WART treats HUMAN PAPILLOMA VIRUS,110,147,,130,151,treats,0.328797974610715,903914-FS1-2,These results support the hypothesis that stimulation of local cytokines by imiquimod leads to a reduction in HUMAN PAPILLOMA VIRUS (HPV) load; to WART regression and to the normalisation of keratinocyte proliferation without evidence of scarring.,HUMAN PAPILLOMA VIRUS,WART,RO-has_causative_agent
502912478,7/14/2014 15:30:44,,1322920708,7/14/2014 15:30:38,prodege,0.5494,2143114,CAN,BC,Vancouver,24.84.160.12,WART treats HUMAN PAPILLOMA VIRUS,110,147,,130,151,treats,0.328797974610715,903914-FS1-2,These results support the hypothesis that stimulation of local cytokines by imiquimod leads to a reduction in HUMAN PAPILLOMA VIRUS (HPV) load; to WART regression and to the normalisation of keratinocyte proliferation without evidence of scarring.,HUMAN PAPILLOMA VIRUS,WART,RO-has_causative_agent
502912478,7/14/2014 15:30:52,,1322920760,7/14/2014 15:30:20,gifthulk,0.6484,21916793,GBR,"","",87.113.87.199,no_relation,110,147,,130,151,treats,0.328797974610715,903914-FS1-2,These results support the hypothesis that stimulation of local cytokines by imiquimod leads to a reduction in HUMAN PAPILLOMA VIRUS (HPV) load; to WART regression and to the normalisation of keratinocyte proliferation without evidence of scarring.,HUMAN PAPILLOMA VIRUS,WART,RO-has_causative_agent
502912478,7/14/2014 15:36:53,,1322924408,7/14/2014 15:36:34,clixsense,0.6484,19638651,USA,"","",173.23.121.63,no_relation,110,147,,130,151,treats,0.328797974610715,903914-FS1-2,These results support the hypothesis that stimulation of local cytokines by imiquimod leads to a reduction in HUMAN PAPILLOMA VIRUS (HPV) load; to WART regression and to the normalisation of keratinocyte proliferation without evidence of scarring.,HUMAN PAPILLOMA VIRUS,WART,RO-has_causative_agent
502912478,7/14/2014 15:55:52,,1322934949,7/14/2014 15:55:16,instagc,0.3429,18985376,GBR,D2,Derby,86.5.192.8,no_relation,110,147,,130,151,treats,0.328797974610715,903914-FS1-2,These results support the hypothesis that stimulation of local cytokines by imiquimod leads to a reduction in HUMAN PAPILLOMA VIRUS (HPV) load; to WART regression and to the normalisation of keratinocyte proliferation without evidence of scarring.,HUMAN PAPILLOMA VIRUS,WART,RO-has_causative_agent
502912479,7/14/2014 12:35:00,,1322804553,7/14/2014 12:34:41,clixsense,0.9583,27871219,NLD,07,Amsterdam,87.210.207.223,MICROVASCULAR PROLIFERATION causes GLIOBLASTOMA MULTIFORME,16,83,,42,106,causes,0.8,901588-FS1-4,The presence of MICROVASCULAR PROLIFERATION leads to the histological diagnosis of GLIOBLASTOMA MULTIFORME.,MICROVASCULAR PROLIFERATION,GLIOBLASTOMA MULTIFORME,RO-disease_has_finding
502912479,7/14/2014 13:53:45,,1322859108,7/14/2014 13:53:25,zoombucks,0.7764,5919735,USA,PA,Doylestown,173.49.91.231,MICROVASCULAR PROLIFERATION causes GLIOBLASTOMA MULTIFORME,16,83,,42,106,causes,0.8,901588-FS1-4,The presence of MICROVASCULAR PROLIFERATION leads to the histological diagnosis of GLIOBLASTOMA MULTIFORME.,MICROVASCULAR PROLIFERATION,GLIOBLASTOMA MULTIFORME,RO-disease_has_finding
502912479,7/14/2014 14:57:08,,1322901787,7/14/2014 14:56:52,elite,0.4302,28276268,USA,MI,Taylor,67.149.247.166,MICROVASCULAR PROLIFERATION causes GLIOBLASTOMA MULTIFORME,16,83,,42,106,causes,0.8,901588-FS1-4,The presence of MICROVASCULAR PROLIFERATION leads to the histological diagnosis of GLIOBLASTOMA MULTIFORME.,MICROVASCULAR PROLIFERATION,GLIOBLASTOMA MULTIFORME,RO-disease_has_finding
502912479,7/14/2014 15:00:27,,1322903752,7/14/2014 15:00:14,instagc,0.5536,18960682,GBR,"","",86.29.147.112,GLIOBLASTOMA MULTIFORME causes MICROVASCULAR PROLIFERATION,16,83,,42,106,causes,0.8,901588-FS1-4,The presence of MICROVASCULAR PROLIFERATION leads to the histological diagnosis of GLIOBLASTOMA MULTIFORME.,MICROVASCULAR PROLIFERATION,GLIOBLASTOMA MULTIFORME,RO-disease_has_finding
502912479,7/14/2014 15:20:04,,1322914316,7/14/2014 15:19:31,prodege,0.639,27996604,CAN,QC,Boucherville,24.201.21.27,MICROVASCULAR PROLIFERATION causes GLIOBLASTOMA MULTIFORME,16,83,,42,106,causes,0.8,901588-FS1-4,The presence of MICROVASCULAR PROLIFERATION leads to the histological diagnosis of GLIOBLASTOMA MULTIFORME.,MICROVASCULAR PROLIFERATION,GLIOBLASTOMA MULTIFORME,RO-disease_has_finding
502912479,7/14/2014 15:33:51,,1322922691,7/14/2014 15:33:30,neodev,0.5101,21405167,USA,MD,Glen Burnie,69.137.237.73,GLIOBLASTOMA MULTIFORME causes MICROVASCULAR PROLIFERATION,16,83,,42,106,causes,0.8,901588-FS1-4,The presence of MICROVASCULAR PROLIFERATION leads to the histological diagnosis of GLIOBLASTOMA MULTIFORME.,MICROVASCULAR PROLIFERATION,GLIOBLASTOMA MULTIFORME,RO-disease_has_finding
502912479,7/14/2014 15:56:36,,1322935369,7/14/2014 15:55:53,instagc,0.3429,18985376,GBR,D2,Derby,86.5.192.8,no_relation,16,83,,42,106,causes,0.8,901588-FS1-4,The presence of MICROVASCULAR PROLIFERATION leads to the histological diagnosis of GLIOBLASTOMA MULTIFORME.,MICROVASCULAR PROLIFERATION,GLIOBLASTOMA MULTIFORME,RO-disease_has_finding
502912480,7/14/2014 12:34:49,,1322804472,7/14/2014 12:34:43,neodev,0.9583,17610000,GBR,I2,Manchester,90.200.140.201,BRAIN is location of ANENCEPHALY,63,13,,67,24,is location of,0.750478774386456,905480-FS1-9,Infants with ANENCEPHALY are born without all or most of their BRAIN and die within a few days of life.,BRAIN,ANENCEPHALY,RO-has_finding_site
502912480,7/14/2014 12:43:39,,1322810484,7/14/2014 12:43:34,clixsense,0.875,25419319,GBR,H8,Liverpool,94.4.192.228,ANENCEPHALY is location of BRAIN,63,13,,67,24,is location of,0.750478774386456,905480-FS1-9,Infants with ANENCEPHALY are born without all or most of their BRAIN and die within a few days of life.,BRAIN,ANENCEPHALY,RO-has_finding_site
502912480,7/14/2014 12:55:37,,1322818631,7/14/2014 12:54:58,clixsense,0.8194,15189335,GBR,K3,Peterborough,81.156.166.189,BRAIN is location of ANENCEPHALY,63,13,,67,24,is location of,0.750478774386456,905480-FS1-9,Infants with ANENCEPHALY are born without all or most of their BRAIN and die within a few days of life.,BRAIN,ANENCEPHALY,RO-has_finding_site
502912480,7/14/2014 13:00:42,,1322821948,7/14/2014 13:00:09,rewardsspot,0.7153,24482174,GBR,H9,London,46.23.68.180,BRAIN is location of ANENCEPHALY,63,13,,67,24,is location of,0.750478774386456,905480-FS1-9,Infants with ANENCEPHALY are born without all or most of their BRAIN and die within a few days of life.,BRAIN,ANENCEPHALY,RO-has_finding_site
502912480,7/14/2014 13:07:23,,1322826308,7/14/2014 13:06:58,prodege,0.6278,11616695,GBR,P7,Wigan,92.29.199.166,no_relation,63,13,,67,24,is location of,0.750478774386456,905480-FS1-9,Infants with ANENCEPHALY are born without all or most of their BRAIN and die within a few days of life.,BRAIN,ANENCEPHALY,RO-has_finding_site
502912480,7/14/2014 13:41:39,,1322850189,7/14/2014 13:41:12,prodege,0.6181,17982533,GBR,H3,Leeds,90.193.39.185,no_relation,63,13,,67,24,is location of,0.750478774386456,905480-FS1-9,Infants with ANENCEPHALY are born without all or most of their BRAIN and die within a few days of life.,BRAIN,ANENCEPHALY,RO-has_finding_site
502912480,7/14/2014 14:31:31,,1322885291,7/14/2014 14:31:26,instagc,0.644,15445601,USA,FL,Jacksonville,24.129.68.254,no_relation,63,13,,67,24,is location of,0.750478774386456,905480-FS1-9,Infants with ANENCEPHALY are born without all or most of their BRAIN and die within a few days of life.,BRAIN,ANENCEPHALY,RO-has_finding_site
502912481,7/14/2014 12:33:53,,1322803833,7/14/2014 12:33:17,clixsense,0.9583,27871219,NLD,07,Amsterdam,87.210.207.223,HYPERTENSION causes INCREASED BLOOD PRESSURE,120,44,,143,56,causes,0.610847221781526,904726-FS1-4,The number of patients with well controlled HYPERTENSION is alarmingly low worldwide and new approaches to treatment of INCREASED BLOOD PRESSURE (BP) are being sought.,INCREASED BLOOD PRESSURE,HYPERTENSION,RO-has_definitional_manifestation
502912481,7/14/2014 12:56:13,,1322819025,7/14/2014 12:55:40,clixsense,0.8194,15189335,GBR,K3,Peterborough,81.156.166.189,INCREASED BLOOD PRESSURE causes HYPERTENSION,120,44,,143,56,causes,0.610847221781526,904726-FS1-4,The number of patients with well controlled HYPERTENSION is alarmingly low worldwide and new approaches to treatment of INCREASED BLOOD PRESSURE (BP) are being sought.,INCREASED BLOOD PRESSURE,HYPERTENSION,RO-has_definitional_manifestation
502912481,7/14/2014 13:00:28,,1322821827,7/14/2014 12:59:57,prodege,0.7639,7664351,USA,NY,Cicero,74.111.0.21,INCREASED BLOOD PRESSURE causes HYPERTENSION,120,44,,143,56,causes,0.610847221781526,904726-FS1-4,The number of patients with well controlled HYPERTENSION is alarmingly low worldwide and new approaches to treatment of INCREASED BLOOD PRESSURE (BP) are being sought.,INCREASED BLOOD PRESSURE,HYPERTENSION,RO-has_definitional_manifestation
502912481,7/14/2014 14:23:48,,1322879453,7/14/2014 14:23:41,neodev,0.3792,25224036,CAN,ON,Sudbury,67.204.218.187,HYPERTENSION causes INCREASED BLOOD PRESSURE,120,44,,143,56,causes,0.610847221781526,904726-FS1-4,The number of patients with well controlled HYPERTENSION is alarmingly low worldwide and new approaches to treatment of INCREASED BLOOD PRESSURE (BP) are being sought.,INCREASED BLOOD PRESSURE,HYPERTENSION,RO-has_definitional_manifestation
502912481,7/14/2014 14:31:51,,1322885507,7/14/2014 14:31:46,instagc,0.644,15445601,USA,FL,Jacksonville,24.129.68.254,no_relation,120,44,,143,56,causes,0.610847221781526,904726-FS1-4,The number of patients with well controlled HYPERTENSION is alarmingly low worldwide and new approaches to treatment of INCREASED BLOOD PRESSURE (BP) are being sought.,INCREASED BLOOD PRESSURE,HYPERTENSION,RO-has_definitional_manifestation
502912481,7/14/2014 14:45:59,,1322895011,7/14/2014 14:45:52,instagc,0.4611,27753923,GBR,"","",188.30.192.65,INCREASED BLOOD PRESSURE causes HYPERTENSION,120,44,,143,56,causes,0.610847221781526,904726-FS1-4,The number of patients with well controlled HYPERTENSION is alarmingly low worldwide and new approaches to treatment of INCREASED BLOOD PRESSURE (BP) are being sought.,INCREASED BLOOD PRESSURE,HYPERTENSION,RO-has_definitional_manifestation
502912481,7/14/2014 14:56:59,,1322901702,7/14/2014 14:56:26,instagc,0.6593,13763729,USA,"","",75.182.89.225,HYPERTENSION causes INCREASED BLOOD PRESSURE,120,44,,143,56,causes,0.610847221781526,904726-FS1-4,The number of patients with well controlled HYPERTENSION is alarmingly low worldwide and new approaches to treatment of INCREASED BLOOD PRESSURE (BP) are being sought.,INCREASED BLOOD PRESSURE,HYPERTENSION,RO-has_definitional_manifestation
502912482,7/14/2014 12:34:36,,1322804335,7/14/2014 12:34:29,neodev,0.9583,17610000,GBR,I2,Manchester,90.200.140.201,MULTIPLE SCLEROSIS treats ORAL CLADRIBINE,99,69,,116,84,treats,0.959403223600247,907766-FS1-2,New Reference of Interest  2010 02 04  A placebo controlled trial of ORAL CLADRIBINE for relapsing MULTIPLE SCLEROSIS,MULTIPLE SCLEROSIS,ORAL CLADRIBINE,RO-may_treat
502912482,7/14/2014 12:44:23,,1322810930,7/14/2014 12:43:21,elite,0.75,27433978,AUS,05,Plympton,110.174.120.88,ORAL CLADRIBINE treats MULTIPLE SCLEROSIS,99,69,,116,84,treats,0.959403223600247,907766-FS1-2,New Reference of Interest  2010 02 04  A placebo controlled trial of ORAL CLADRIBINE for relapsing MULTIPLE SCLEROSIS,MULTIPLE SCLEROSIS,ORAL CLADRIBINE,RO-may_treat
502912482,7/14/2014 13:53:24,,1322858898,7/14/2014 13:53:01,zoombucks,0.7764,5919735,USA,PA,Doylestown,173.49.91.231,ORAL CLADRIBINE treats MULTIPLE SCLEROSIS,99,69,,116,84,treats,0.959403223600247,907766-FS1-2,New Reference of Interest  2010 02 04  A placebo controlled trial of ORAL CLADRIBINE for relapsing MULTIPLE SCLEROSIS,MULTIPLE SCLEROSIS,ORAL CLADRIBINE,RO-may_treat
502912482,7/14/2014 14:45:39,,1322894831,7/14/2014 14:45:34,instagc,0.4611,27753923,GBR,"","",188.30.192.65,MULTIPLE SCLEROSIS treats ORAL CLADRIBINE,99,69,,116,84,treats,0.959403223600247,907766-FS1-2,New Reference of Interest  2010 02 04  A placebo controlled trial of ORAL CLADRIBINE for relapsing MULTIPLE SCLEROSIS,MULTIPLE SCLEROSIS,ORAL CLADRIBINE,RO-may_treat
502912482,7/14/2014 15:04:29,,1322906179,7/14/2014 15:03:54,instagc,0.7125,28519532,USA,IA,Honey Creek,12.73.110.26,ORAL CLADRIBINE treats MULTIPLE SCLEROSIS,99,69,,116,84,treats,0.959403223600247,907766-FS1-2,New Reference of Interest  2010 02 04  A placebo controlled trial of ORAL CLADRIBINE for relapsing MULTIPLE SCLEROSIS,MULTIPLE SCLEROSIS,ORAL CLADRIBINE,RO-may_treat
502912482,7/14/2014 15:10:10,,1322909242,7/14/2014 15:09:45,clixsense,0.5718,19803139,NLD,06,Veldhoven,212.61.84.196,ORAL CLADRIBINE treats MULTIPLE SCLEROSIS,99,69,,116,84,treats,0.959403223600247,907766-FS1-2,New Reference of Interest  2010 02 04  A placebo controlled trial of ORAL CLADRIBINE for relapsing MULTIPLE SCLEROSIS,MULTIPLE SCLEROSIS,ORAL CLADRIBINE,RO-may_treat
502912482,7/14/2014 15:34:10,,1322922913,7/14/2014 15:33:52,neodev,0.5101,21405167,USA,MD,Glen Burnie,69.137.237.73,ORAL CLADRIBINE treats MULTIPLE SCLEROSIS,99,69,,116,84,treats,0.959403223600247,907766-FS1-2,New Reference of Interest  2010 02 04  A placebo controlled trial of ORAL CLADRIBINE for relapsing MULTIPLE SCLEROSIS,MULTIPLE SCLEROSIS,ORAL CLADRIBINE,RO-may_treat
502912483,7/14/2014 12:34:42,,1322804393,7/14/2014 12:34:37,neodev,0.9583,17610000,GBR,I2,Manchester,90.200.140.201,STOMACH is location of GASTRIC CANCER,66,112,,72,126,is location of,0.606339062590832,902028-FS1-9,"However, the patients with extensive intestinal metaplasia of the STOMACH belong to the high risk group for the GASTRIC CANCER",STOMACH,GASTRIC CANCER,RO-disease_has_primary_anatomic_site
502912483,7/14/2014 12:37:18,,1322806017,7/14/2014 12:36:47,prodege,0.8889,27934334,GBR,Q2,Wokingham,86.166.73.21,STOMACH is location of GASTRIC CANCER,66,112,,72,126,is location of,0.606339062590832,902028-FS1-9,"However, the patients with extensive intestinal metaplasia of the STOMACH belong to the high risk group for the GASTRIC CANCER",STOMACH,GASTRIC CANCER,RO-disease_has_primary_anatomic_site
502912483,7/14/2014 14:10:21,,1322870121,7/14/2014 14:10:07,clixsense,0.7708,27793793,GBR,C5,Chester,151.230.27.155,STOMACH is location of GASTRIC CANCER,66,112,,72,126,is location of,0.606339062590832,902028-FS1-9,"However, the patients with extensive intestinal metaplasia of the STOMACH belong to the high risk group for the GASTRIC CANCER",STOMACH,GASTRIC CANCER,RO-disease_has_primary_anatomic_site
502912483,7/14/2014 14:45:50,,1322894904,7/14/2014 14:45:46,instagc,0.4611,27753923,GBR,"","",188.30.192.65,GASTRIC CANCER is location of STOMACH,66,112,,72,126,is location of,0.606339062590832,902028-FS1-9,"However, the patients with extensive intestinal metaplasia of the STOMACH belong to the high risk group for the GASTRIC CANCER",STOMACH,GASTRIC CANCER,RO-disease_has_primary_anatomic_site
502912483,7/14/2014 15:01:41,,1322904537,7/14/2014 15:01:08,vivatic,0.5339,25451531,GBR,"","",83.67.28.193,STOMACH is location of GASTRIC CANCER,66,112,,72,126,is location of,0.606339062590832,902028-FS1-9,"However, the patients with extensive intestinal metaplasia of the STOMACH belong to the high risk group for the GASTRIC CANCER",STOMACH,GASTRIC CANCER,RO-disease_has_primary_anatomic_site
502912483,7/14/2014 15:04:46,,1322906336,7/14/2014 15:04:29,neodev,0.719,18755947,GBR,H2,Accrington,80.47.185.52,STOMACH is location of GASTRIC CANCER,66,112,,72,126,is location of,0.606339062590832,902028-FS1-9,"However, the patients with extensive intestinal metaplasia of the STOMACH belong to the high risk group for the GASTRIC CANCER",STOMACH,GASTRIC CANCER,RO-disease_has_primary_anatomic_site
502912483,7/14/2014 15:28:34,,1322919425,7/14/2014 15:28:23,gifthulk,0.6484,21916793,GBR,"","",87.113.87.199,STOMACH is location of GASTRIC CANCER,66,112,,72,126,is location of,0.606339062590832,902028-FS1-9,"However, the patients with extensive intestinal metaplasia of the STOMACH belong to the high risk group for the GASTRIC CANCER",STOMACH,GASTRIC CANCER,RO-disease_has_primary_anatomic_site
502912484,7/14/2014 12:54:56,,1322818151,7/14/2014 12:54:37,clixsense,0.8194,15189335,GBR,K3,Peterborough,81.156.166.189,NEPHROBLASTOMA diagnosed by HYPERTENSION,65,0,,76,14,diagnosed by,0.683763458757828,902706-FS1-13,"NEPHROBLASTOMA must be included in the differential diagnosis of HYPERTENSION associated with increased renin concentrations, even in the absence of an abdominal mass..",HYPERTENSION,NEPHROBLASTOMA,RO-disease_may_have_finding
502912484,7/14/2014 14:09:43,,1322869768,7/14/2014 14:09:28,clixsense,0.7708,27793793,GBR,C5,Chester,151.230.27.155,HYPERTENSION diagnosed by NEPHROBLASTOMA,65,0,,76,14,diagnosed by,0.683763458757828,902706-FS1-13,"NEPHROBLASTOMA must be included in the differential diagnosis of HYPERTENSION associated with increased renin concentrations, even in the absence of an abdominal mass..",HYPERTENSION,NEPHROBLASTOMA,RO-disease_may_have_finding
502912484,7/14/2014 15:01:10,,1322904216,7/14/2014 15:00:50,instagc,0.5536,18960682,GBR,"","",86.29.147.112,NEPHROBLASTOMA diagnosed by HYPERTENSION,65,0,,76,14,diagnosed by,0.683763458757828,902706-FS1-13,"NEPHROBLASTOMA must be included in the differential diagnosis of HYPERTENSION associated with increased renin concentrations, even in the absence of an abdominal mass..",HYPERTENSION,NEPHROBLASTOMA,RO-disease_may_have_finding
502912484,7/14/2014 15:13:45,,1322910800,7/14/2014 15:12:55,elite,0.4429,28322695,GBR,A3,Barnsley,217.44.205.195,no_relation,65,0,,76,14,diagnosed by,0.683763458757828,902706-FS1-13,"NEPHROBLASTOMA must be included in the differential diagnosis of HYPERTENSION associated with increased renin concentrations, even in the absence of an abdominal mass..",HYPERTENSION,NEPHROBLASTOMA,RO-disease_may_have_finding
502912484,7/14/2014 15:18:23,,1322913335,7/14/2014 15:18:15,clixsense,0.4823,19162475,GBR,M3,Frome,82.33.126.30,HYPERTENSION diagnosed by NEPHROBLASTOMA,65,0,,76,14,diagnosed by,0.683763458757828,902706-FS1-13,"NEPHROBLASTOMA must be included in the differential diagnosis of HYPERTENSION associated with increased renin concentrations, even in the absence of an abdominal mass..",HYPERTENSION,NEPHROBLASTOMA,RO-disease_may_have_finding
502912484,7/14/2014 15:18:32,,1322913422,7/14/2014 15:17:59,prodege,0.639,27996604,CAN,QC,Boucherville,24.201.21.27,NEPHROBLASTOMA diagnosed by HYPERTENSION,65,0,,76,14,diagnosed by,0.683763458757828,902706-FS1-13,"NEPHROBLASTOMA must be included in the differential diagnosis of HYPERTENSION associated with increased renin concentrations, even in the absence of an abdominal mass..",HYPERTENSION,NEPHROBLASTOMA,RO-disease_may_have_finding
502912484,7/14/2014 15:27:42,,1322918915,7/14/2014 15:27:22,instagc,0.3552,19004168,GBR,H2,Accrington,80.47.185.52,no_relation,65,0,,76,14,diagnosed by,0.683763458757828,902706-FS1-13,"NEPHROBLASTOMA must be included in the differential diagnosis of HYPERTENSION associated with increased renin concentrations, even in the absence of an abdominal mass..",HYPERTENSION,NEPHROBLASTOMA,RO-disease_may_have_finding
502912485,7/14/2014 12:36:19,,1322805379,7/14/2014 12:35:56,clixsense,0.9583,27871219,NLD,07,Amsterdam,87.210.207.223,HYPERTENSION causes HYPERTENSIVE CRISIS,90,141,,101,160,causes,0.959403223600247,901968-FS1-4,The case is presented of a 49 year old female who had had chronic renal insufficiency and HYPERTENSION for several years and who developed a HYPERTENSIVE CRISIS after cessation of therapy with clonidine and nadolol.,HYPERTENSION,HYPERTENSIVE CRISIS,RO-disease_has_finding
502912485,7/14/2014 13:02:01,,1322822797,7/14/2014 13:01:34,prodege,0.7639,7664351,USA,NY,Cicero,74.111.0.21,HYPERTENSION causes HYPERTENSIVE CRISIS,90,141,,101,160,causes,0.959403223600247,901968-FS1-4,The case is presented of a 49 year old female who had had chronic renal insufficiency and HYPERTENSION for several years and who developed a HYPERTENSIVE CRISIS after cessation of therapy with clonidine and nadolol.,HYPERTENSION,HYPERTENSIVE CRISIS,RO-disease_has_finding
502912485,7/14/2014 13:50:45,,1322856906,7/14/2014 13:50:16,clixsense,0.4042,25402344,CAN,ON,Wawa,24.109.124.45,HYPERTENSION causes HYPERTENSIVE CRISIS,90,141,,101,160,causes,0.959403223600247,901968-FS1-4,The case is presented of a 49 year old female who had had chronic renal insufficiency and HYPERTENSION for several years and who developed a HYPERTENSIVE CRISIS after cessation of therapy with clonidine and nadolol.,HYPERTENSION,HYPERTENSIVE CRISIS,RO-disease_has_finding
502912485,7/14/2014 14:09:54,,1322869877,7/14/2014 14:09:45,clixsense,0.7708,27793793,GBR,C5,Chester,151.230.27.155,HYPERTENSION causes HYPERTENSIVE CRISIS,90,141,,101,160,causes,0.959403223600247,901968-FS1-4,The case is presented of a 49 year old female who had had chronic renal insufficiency and HYPERTENSION for several years and who developed a HYPERTENSIVE CRISIS after cessation of therapy with clonidine and nadolol.,HYPERTENSION,HYPERTENSIVE CRISIS,RO-disease_has_finding
502912485,7/14/2014 15:00:01,,1322903519,7/14/2014 14:59:43,instagc,0.5536,18960682,GBR,"","",86.29.147.112,HYPERTENSION causes HYPERTENSIVE CRISIS,90,141,,101,160,causes,0.959403223600247,901968-FS1-4,The case is presented of a 49 year old female who had had chronic renal insufficiency and HYPERTENSION for several years and who developed a HYPERTENSIVE CRISIS after cessation of therapy with clonidine and nadolol.,HYPERTENSION,HYPERTENSIVE CRISIS,RO-disease_has_finding
502912485,7/14/2014 15:23:40,,1322916530,7/14/2014 15:23:09,clixsense,0.4244,26889820,GBR,C3,Shelford,92.18.120.203,no_relation,90,141,,101,160,causes,0.959403223600247,901968-FS1-4,The case is presented of a 49 year old female who had had chronic renal insufficiency and HYPERTENSION for several years and who developed a HYPERTENSIVE CRISIS after cessation of therapy with clonidine and nadolol.,HYPERTENSION,HYPERTENSIVE CRISIS,RO-disease_has_finding
502912485,7/14/2014 15:33:11,,1322922298,7/14/2014 15:32:48,neodev,0.5101,21405167,USA,MD,Glen Burnie,69.137.237.73,no_relation,90,141,,101,160,causes,0.959403223600247,901968-FS1-4,The case is presented of a 49 year old female who had had chronic renal insufficiency and HYPERTENSION for several years and who developed a HYPERTENSIVE CRISIS after cessation of therapy with clonidine and nadolol.,HYPERTENSION,HYPERTENSIVE CRISIS,RO-disease_has_finding
502912486,7/14/2014 14:10:05,,1322869975,7/14/2014 14:09:56,clixsense,0.7708,27793793,GBR,C5,Chester,151.230.27.155,GLIOBLASTOMA diagnosed by DEDIFFERENTIATION,158,72,,174,84,diagnosed by,0.301511344577764,901970-FS1-13,The results of modern neuro oncology support the pathogenetic view that GLIOBLASTOMA results from neoplastic transformation of glial elements with continuing DEDIFFERENTIATION,DEDIFFERENTIATION,GLIOBLASTOMA,RO-disease_has_finding
502912486,7/14/2014 14:16:57,,1322874737,7/14/2014 14:16:48,clixsense,0.5125,7415230,GBR,A7,Birmingham,147.188.47.242,no_relation,158,72,,174,84,diagnosed by,0.301511344577764,901970-FS1-13,The results of modern neuro oncology support the pathogenetic view that GLIOBLASTOMA results from neoplastic transformation of glial elements with continuing DEDIFFERENTIATION,DEDIFFERENTIATION,GLIOBLASTOMA,RO-disease_has_finding
502912486,7/14/2014 14:30:59,,1322884848,7/14/2014 14:30:34,instagc,0.644,15445601,USA,FL,Jacksonville,24.129.68.254,GLIOBLASTOMA diagnosed by DEDIFFERENTIATION,158,72,,174,84,diagnosed by,0.301511344577764,901970-FS1-13,The results of modern neuro oncology support the pathogenetic view that GLIOBLASTOMA results from neoplastic transformation of glial elements with continuing DEDIFFERENTIATION,DEDIFFERENTIATION,GLIOBLASTOMA,RO-disease_has_finding
502912486,7/14/2014 15:02:22,,1322904880,7/14/2014 15:01:42,vivatic,0.5339,25451531,GBR,"","",83.67.28.193,DEDIFFERENTIATION diagnosed by GLIOBLASTOMA,158,72,,174,84,diagnosed by,0.301511344577764,901970-FS1-13,The results of modern neuro oncology support the pathogenetic view that GLIOBLASTOMA results from neoplastic transformation of glial elements with continuing DEDIFFERENTIATION,DEDIFFERENTIATION,GLIOBLASTOMA,RO-disease_has_finding
502912486,7/14/2014 15:09:44,,1322909026,7/14/2014 15:09:17,clixsense,0.5718,19803139,NLD,06,Veldhoven,212.61.84.196,GLIOBLASTOMA diagnosed by DEDIFFERENTIATION,158,72,,174,84,diagnosed by,0.301511344577764,901970-FS1-13,The results of modern neuro oncology support the pathogenetic view that GLIOBLASTOMA results from neoplastic transformation of glial elements with continuing DEDIFFERENTIATION,DEDIFFERENTIATION,GLIOBLASTOMA,RO-disease_has_finding
502912486,7/14/2014 15:18:42,,1322913530,7/14/2014 15:18:32,clixsense,0.4823,19162475,GBR,M3,Frome,82.33.126.30,GLIOBLASTOMA diagnosed by DEDIFFERENTIATION,158,72,,174,84,diagnosed by,0.301511344577764,901970-FS1-13,The results of modern neuro oncology support the pathogenetic view that GLIOBLASTOMA results from neoplastic transformation of glial elements with continuing DEDIFFERENTIATION,DEDIFFERENTIATION,GLIOBLASTOMA,RO-disease_has_finding
502912486,7/14/2014 15:27:21,,1322918664,7/14/2014 15:27:02,instagc,0.3552,19004168,GBR,H2,Accrington,80.47.185.52,no_relation,158,72,,174,84,diagnosed by,0.301511344577764,901970-FS1-13,The results of modern neuro oncology support the pathogenetic view that GLIOBLASTOMA results from neoplastic transformation of glial elements with continuing DEDIFFERENTIATION,DEDIFFERENTIATION,GLIOBLASTOMA,RO-disease_has_finding
502912487,7/14/2014 12:35:54,,1322805143,7/14/2014 12:35:01,clixsense,0.9583,27871219,NLD,07,Amsterdam,87.210.207.223,no_relation,104,159,,121,175,treats,0.412081691846067,903970-FS1-2,"The results suggest that cadmium thionein may play a paradoxical role, providing protection against the CADMIUM ION IN THE intracellular milieu, but promoting CADMIUM TOXICITY when it is present in sufficient amounts in the lumen of the intestine.",CADMIUM ION IN THE,CADMIUM TOXICITY,RO-has_causative_agent
502912487,7/14/2014 13:40:39,,1322849538,7/14/2014 13:39:51,prodege,0.6181,17982533,GBR,H3,Leeds,90.193.39.185,no_relation,104,159,,121,175,treats,0.412081691846067,903970-FS1-2,"The results suggest that cadmium thionein may play a paradoxical role, providing protection against the CADMIUM ION IN THE intracellular milieu, but promoting CADMIUM TOXICITY when it is present in sufficient amounts in the lumen of the intestine.",CADMIUM ION IN THE,CADMIUM TOXICITY,RO-has_causative_agent
502912487,7/14/2014 13:53:00,,1322858544,7/14/2014 13:52:03,zoombucks,0.7764,5919735,USA,PA,Doylestown,173.49.91.231,no_relation,104,159,,121,175,treats,0.412081691846067,903970-FS1-2,"The results suggest that cadmium thionein may play a paradoxical role, providing protection against the CADMIUM ION IN THE intracellular milieu, but promoting CADMIUM TOXICITY when it is present in sufficient amounts in the lumen of the intestine.",CADMIUM ION IN THE,CADMIUM TOXICITY,RO-has_causative_agent
502912487,7/14/2014 14:45:59,,1322895012,7/14/2014 14:45:52,instagc,0.4611,27753923,GBR,"","",188.30.192.65,CADMIUM TOXICITY treats CADMIUM ION IN THE,104,159,,121,175,treats,0.412081691846067,903970-FS1-2,"The results suggest that cadmium thionein may play a paradoxical role, providing protection against the CADMIUM ION IN THE intracellular milieu, but promoting CADMIUM TOXICITY when it is present in sufficient amounts in the lumen of the intestine.",CADMIUM ION IN THE,CADMIUM TOXICITY,RO-has_causative_agent
502912487,7/14/2014 14:56:59,,1322901729,7/14/2014 14:56:26,instagc,0.6593,13763729,USA,"","",75.182.89.225,no_relation,104,159,,121,175,treats,0.412081691846067,903970-FS1-2,"The results suggest that cadmium thionein may play a paradoxical role, providing protection against the CADMIUM ION IN THE intracellular milieu, but promoting CADMIUM TOXICITY when it is present in sufficient amounts in the lumen of the intestine.",CADMIUM ION IN THE,CADMIUM TOXICITY,RO-has_causative_agent
502912487,7/14/2014 15:29:57,,1322920351,7/14/2014 15:29:46,prodege,0.5494,2143114,CAN,BC,Vancouver,24.84.160.12,CADMIUM ION IN THE treats CADMIUM TOXICITY,104,159,,121,175,treats,0.412081691846067,903970-FS1-2,"The results suggest that cadmium thionein may play a paradoxical role, providing protection against the CADMIUM ION IN THE intracellular milieu, but promoting CADMIUM TOXICITY when it is present in sufficient amounts in the lumen of the intestine.",CADMIUM ION IN THE,CADMIUM TOXICITY,RO-has_causative_agent
502912487,7/14/2014 15:54:15,,1322934029,7/14/2014 15:53:43,clixsense,0.573,22177255,USA,CA,San Francisco,73.32.39.90,no_relation,104,159,,121,175,treats,0.412081691846067,903970-FS1-2,"The results suggest that cadmium thionein may play a paradoxical role, providing protection against the CADMIUM ION IN THE intracellular milieu, but promoting CADMIUM TOXICITY when it is present in sufficient amounts in the lumen of the intestine.",CADMIUM ION IN THE,CADMIUM TOXICITY,RO-has_causative_agent
502912488,7/14/2014 12:34:48,,1322804467,7/14/2014 12:34:12,prodege,0.8889,27934334,GBR,Q2,Wokingham,86.166.73.21,no_relation,55,127,,69,141,causes,0.753778361444409,900400-FS1-4,"The classic features of a patient with fully developed GRAVES' DISEASE are difficult to overlook, but the clinical features of THYROTOXICOSIS vary with the etiology of the disease and the sensitivity of the patient's peripheral tissues.",GRAVES' DISEASE,THYROTOXICOSIS,RO-cause_of
502912488,7/14/2014 12:49:09,,1322814100,7/14/2014 12:48:19,elite,0.75,27433978,AUS,05,Plympton,110.174.120.88,GRAVES' DISEASE causes THYROTOXICOSIS,55,127,,69,141,causes,0.753778361444409,900400-FS1-4,"The classic features of a patient with fully developed GRAVES' DISEASE are difficult to overlook, but the clinical features of THYROTOXICOSIS vary with the etiology of the disease and the sensitivity of the patient's peripheral tissues.",GRAVES' DISEASE,THYROTOXICOSIS,RO-cause_of
502912488,7/14/2014 13:02:27,,1322823037,7/14/2014 13:02:02,prodege,0.7639,7664351,USA,NY,Cicero,74.111.0.21,GRAVES' DISEASE causes THYROTOXICOSIS,55,127,,69,141,causes,0.753778361444409,900400-FS1-4,"The classic features of a patient with fully developed GRAVES' DISEASE are difficult to overlook, but the clinical features of THYROTOXICOSIS vary with the etiology of the disease and the sensitivity of the patient's peripheral tissues.",GRAVES' DISEASE,THYROTOXICOSIS,RO-cause_of
502912488,7/14/2014 13:40:39,,1322849535,7/14/2014 13:39:51,prodege,0.6181,17982533,GBR,H3,Leeds,90.193.39.185,no_relation,55,127,,69,141,causes,0.753778361444409,900400-FS1-4,"The classic features of a patient with fully developed GRAVES' DISEASE are difficult to overlook, but the clinical features of THYROTOXICOSIS vary with the etiology of the disease and the sensitivity of the patient's peripheral tissues.",GRAVES' DISEASE,THYROTOXICOSIS,RO-cause_of
502912488,7/14/2014 13:52:15,,1322858114,7/14/2014 13:51:40,clixsense,0.4042,25402344,CAN,ON,Wawa,24.109.124.45,GRAVES' DISEASE causes THYROTOXICOSIS,55,127,,69,141,causes,0.753778361444409,900400-FS1-4,"The classic features of a patient with fully developed GRAVES' DISEASE are difficult to overlook, but the clinical features of THYROTOXICOSIS vary with the etiology of the disease and the sensitivity of the patient's peripheral tissues.",GRAVES' DISEASE,THYROTOXICOSIS,RO-cause_of
502912488,7/14/2014 14:31:31,,1322885290,7/14/2014 14:31:26,instagc,0.644,15445601,USA,FL,Jacksonville,24.129.68.254,no_relation,55,127,,69,141,causes,0.753778361444409,900400-FS1-4,"The classic features of a patient with fully developed GRAVES' DISEASE are difficult to overlook, but the clinical features of THYROTOXICOSIS vary with the etiology of the disease and the sensitivity of the patient's peripheral tissues.",GRAVES' DISEASE,THYROTOXICOSIS,RO-cause_of
502912488,7/14/2014 14:36:01,,1322888244,7/14/2014 14:35:43,rewardsspot,0.57,17763704,USA,IL,Chicago,67.212.175.123,THYROTOXICOSIS causes GRAVES' DISEASE,55,127,,69,141,causes,0.753778361444409,900400-FS1-4,"The classic features of a patient with fully developed GRAVES' DISEASE are difficult to overlook, but the clinical features of THYROTOXICOSIS vary with the etiology of the disease and the sensitivity of the patient's peripheral tissues.",GRAVES' DISEASE,THYROTOXICOSIS,RO-cause_of
502912489,7/14/2014 13:00:42,,1322821947,7/14/2014 13:00:09,rewardsspot,0.7153,24482174,GBR,H9,London,46.23.68.180,INTRAEPITHELIAL LESION (HSIL) causes DYSPLASIA,169,96,,177,125,causes,0.794719414239026,901923-FS1-4,Pap smears were reliable in screening for CIN; 75% of patients with CIN had high grade squamous INTRAEPITHELIAL LESION (HSIL) or LSIL in Pap smears taken at the time of DYSPLASIA,DYSPLASIA,INTRAEPITHELIAL LESION (HSIL),RO-disease_has_finding
502912489,7/14/2014 13:00:59,,1322822145,7/14/2014 13:00:28,prodege,0.7639,7664351,USA,NY,Cicero,74.111.0.21,no_relation,169,96,,177,125,causes,0.794719414239026,901923-FS1-4,Pap smears were reliable in screening for CIN; 75% of patients with CIN had high grade squamous INTRAEPITHELIAL LESION (HSIL) or LSIL in Pap smears taken at the time of DYSPLASIA,DYSPLASIA,INTRAEPITHELIAL LESION (HSIL),RO-disease_has_finding
502912489,7/14/2014 13:23:13,,1322837395,7/14/2014 13:22:19,neodev,0.6667,19004420,GBR,M3,Bridgwater,86.160.70.204,INTRAEPITHELIAL LESION (HSIL) causes DYSPLASIA,169,96,,177,125,causes,0.794719414239026,901923-FS1-4,Pap smears were reliable in screening for CIN; 75% of patients with CIN had high grade squamous INTRAEPITHELIAL LESION (HSIL) or LSIL in Pap smears taken at the time of DYSPLASIA,DYSPLASIA,INTRAEPITHELIAL LESION (HSIL),RO-disease_has_finding
502912489,7/14/2014 13:49:47,,1322856257,7/14/2014 13:49:22,clixsense,0.4042,25402344,CAN,ON,Wawa,24.109.124.45,DYSPLASIA causes INTRAEPITHELIAL LESION (HSIL),169,96,,177,125,causes,0.794719414239026,901923-FS1-4,Pap smears were reliable in screening for CIN; 75% of patients with CIN had high grade squamous INTRAEPITHELIAL LESION (HSIL) or LSIL in Pap smears taken at the time of DYSPLASIA,DYSPLASIA,INTRAEPITHELIAL LESION (HSIL),RO-disease_has_finding
502912489,7/14/2014 14:31:46,,1322885441,7/14/2014 14:31:33,clixsense,0.5125,7415230,GBR,A7,Birmingham,147.188.47.242,no_relation,169,96,,177,125,causes,0.794719414239026,901923-FS1-4,Pap smears were reliable in screening for CIN; 75% of patients with CIN had high grade squamous INTRAEPITHELIAL LESION (HSIL) or LSIL in Pap smears taken at the time of DYSPLASIA,DYSPLASIA,INTRAEPITHELIAL LESION (HSIL),RO-disease_has_finding
502912489,7/14/2014 14:56:09,,1322901093,7/14/2014 14:55:52,elite,0.4302,28276268,USA,MI,Taylor,67.149.247.166,INTRAEPITHELIAL LESION (HSIL) causes DYSPLASIA,169,96,,177,125,causes,0.794719414239026,901923-FS1-4,Pap smears were reliable in screening for CIN; 75% of patients with CIN had high grade squamous INTRAEPITHELIAL LESION (HSIL) or LSIL in Pap smears taken at the time of DYSPLASIA,DYSPLASIA,INTRAEPITHELIAL LESION (HSIL),RO-disease_has_finding
502912489,7/14/2014 15:00:01,,1322903522,7/14/2014 14:59:43,instagc,0.5536,18960682,GBR,"","",86.29.147.112,DYSPLASIA causes INTRAEPITHELIAL LESION (HSIL),169,96,,177,125,causes,0.794719414239026,901923-FS1-4,Pap smears were reliable in screening for CIN; 75% of patients with CIN had high grade squamous INTRAEPITHELIAL LESION (HSIL) or LSIL in Pap smears taken at the time of DYSPLASIA,DYSPLASIA,INTRAEPITHELIAL LESION (HSIL),RO-disease_has_finding
502912490,7/14/2014 13:20:15,,1322835049,7/14/2014 13:19:14,clixsense,0.7,24896327,GBR,V2,Glasgow,94.2.231.4,no_relation,189,228,,200,244,causes,0.872871560943969,902695-FS1-4,"? Screen all patients with MEN2 for pheochromocytoma before parathyroidectomy, and consider screening for pheochromocytoma in patients with primary hyperparathyroidism who have significant HYPERTENSION or symptoms suggestive of PHEOCHROMOCYTOMA",HYPERTENSION,PHEOCHROMOCYTOMA,RO-disease_may_have_finding
502912490,7/14/2014 15:08:06,,1322908170,7/14/2014 15:07:37,instagc,0.7125,28519532,USA,IA,Honey Creek,12.73.110.26,no_relation,189,228,,200,244,causes,0.872871560943969,902695-FS1-4,"? Screen all patients with MEN2 for pheochromocytoma before parathyroidectomy, and consider screening for pheochromocytoma in patients with primary hyperparathyroidism who have significant HYPERTENSION or symptoms suggestive of PHEOCHROMOCYTOMA",HYPERTENSION,PHEOCHROMOCYTOMA,RO-disease_may_have_finding
502912490,7/14/2014 15:30:53,,1322920774,7/14/2014 15:30:45,prodege,0.5494,2143114,CAN,BC,Vancouver,24.84.160.12,HYPERTENSION causes PHEOCHROMOCYTOMA,189,228,,200,244,causes,0.872871560943969,902695-FS1-4,"? Screen all patients with MEN2 for pheochromocytoma before parathyroidectomy, and consider screening for pheochromocytoma in patients with primary hyperparathyroidism who have significant HYPERTENSION or symptoms suggestive of PHEOCHROMOCYTOMA",HYPERTENSION,PHEOCHROMOCYTOMA,RO-disease_may_have_finding
502912490,7/14/2014 15:32:14,,1322921600,7/14/2014 15:31:46,gifthulk,0.6484,21916793,GBR,"","",87.113.87.199,no_relation,189,228,,200,244,causes,0.872871560943969,902695-FS1-4,"? Screen all patients with MEN2 for pheochromocytoma before parathyroidectomy, and consider screening for pheochromocytoma in patients with primary hyperparathyroidism who have significant HYPERTENSION or symptoms suggestive of PHEOCHROMOCYTOMA",HYPERTENSION,PHEOCHROMOCYTOMA,RO-disease_may_have_finding
502912490,7/14/2014 15:34:10,,1322922884,7/14/2014 15:33:52,neodev,0.5101,21405167,USA,MD,Glen Burnie,69.137.237.73,PHEOCHROMOCYTOMA causes HYPERTENSION,189,228,,200,244,causes,0.872871560943969,902695-FS1-4,"? Screen all patients with MEN2 for pheochromocytoma before parathyroidectomy, and consider screening for pheochromocytoma in patients with primary hyperparathyroidism who have significant HYPERTENSION or symptoms suggestive of PHEOCHROMOCYTOMA",HYPERTENSION,PHEOCHROMOCYTOMA,RO-disease_may_have_finding
502912490,7/14/2014 15:37:31,,1322924787,7/14/2014 15:36:54,clixsense,0.6484,19638651,USA,"","",173.23.121.63,HYPERTENSION causes PHEOCHROMOCYTOMA,189,228,,200,244,causes,0.872871560943969,902695-FS1-4,"? Screen all patients with MEN2 for pheochromocytoma before parathyroidectomy, and consider screening for pheochromocytoma in patients with primary hyperparathyroidism who have significant HYPERTENSION or symptoms suggestive of PHEOCHROMOCYTOMA",HYPERTENSION,PHEOCHROMOCYTOMA,RO-disease_may_have_finding
502912490,7/14/2014 15:53:18,,1322933557,7/14/2014 15:52:45,clixsense,0.573,22177255,USA,CA,San Francisco,73.32.39.90,no_relation,189,228,,200,244,causes,0.872871560943969,902695-FS1-4,"? Screen all patients with MEN2 for pheochromocytoma before parathyroidectomy, and consider screening for pheochromocytoma in patients with primary hyperparathyroidism who have significant HYPERTENSION or symptoms suggestive of PHEOCHROMOCYTOMA",HYPERTENSION,PHEOCHROMOCYTOMA,RO-disease_may_have_finding
502912491,7/14/2014 12:51:41,,1322815921,7/14/2014 12:50:47,clixsense,0.8194,15189335,GBR,K3,Peterborough,81.156.166.189,GLIOBLASTOMA causes DEDIFFERENTIATION,158,72,,174,84,causes,0.904534033733291,901970-FS1-4,The results of modern neuro oncology support the pathogenetic view that GLIOBLASTOMA results from neoplastic transformation of glial elements with continuing DEDIFFERENTIATION,DEDIFFERENTIATION,GLIOBLASTOMA,RO-disease_has_finding
502912491,7/14/2014 13:01:21,,1322822377,7/14/2014 13:00:47,rewardsspot,0.7153,24482174,GBR,H9,London,46.23.68.180,DEDIFFERENTIATION causes GLIOBLASTOMA,158,72,,174,84,causes,0.904534033733291,901970-FS1-4,The results of modern neuro oncology support the pathogenetic view that GLIOBLASTOMA results from neoplastic transformation of glial elements with continuing DEDIFFERENTIATION,DEDIFFERENTIATION,GLIOBLASTOMA,RO-disease_has_finding
502912491,7/14/2014 14:55:53,,1322900871,7/14/2014 14:55:31,instagc,0.6593,13763729,USA,"","",75.182.89.225,DEDIFFERENTIATION causes GLIOBLASTOMA,158,72,,174,84,causes,0.904534033733291,901970-FS1-4,The results of modern neuro oncology support the pathogenetic view that GLIOBLASTOMA results from neoplastic transformation of glial elements with continuing DEDIFFERENTIATION,DEDIFFERENTIATION,GLIOBLASTOMA,RO-disease_has_finding
502912491,7/14/2014 15:01:07,,1322904200,7/14/2014 15:00:30,vivatic,0.5339,25451531,GBR,"","",83.67.28.193,GLIOBLASTOMA causes DEDIFFERENTIATION,158,72,,174,84,causes,0.904534033733291,901970-FS1-4,The results of modern neuro oncology support the pathogenetic view that GLIOBLASTOMA results from neoplastic transformation of glial elements with continuing DEDIFFERENTIATION,DEDIFFERENTIATION,GLIOBLASTOMA,RO-disease_has_finding
502912491,7/14/2014 15:06:46,,1322907291,7/14/2014 15:06:03,instagc,0.7125,28519532,USA,IA,Honey Creek,12.73.110.26,DEDIFFERENTIATION causes GLIOBLASTOMA,158,72,,174,84,causes,0.904534033733291,901970-FS1-4,The results of modern neuro oncology support the pathogenetic view that GLIOBLASTOMA results from neoplastic transformation of glial elements with continuing DEDIFFERENTIATION,DEDIFFERENTIATION,GLIOBLASTOMA,RO-disease_has_finding
502912491,7/14/2014 15:09:16,,1322908730,7/14/2014 15:08:49,clixsense,0.5718,19803139,NLD,06,Veldhoven,212.61.84.196,GLIOBLASTOMA causes DEDIFFERENTIATION,158,72,,174,84,causes,0.904534033733291,901970-FS1-4,The results of modern neuro oncology support the pathogenetic view that GLIOBLASTOMA results from neoplastic transformation of glial elements with continuing DEDIFFERENTIATION,DEDIFFERENTIATION,GLIOBLASTOMA,RO-disease_has_finding
502912491,7/14/2014 15:18:04,,1322913147,7/14/2014 15:17:54,clixsense,0.4823,19162475,GBR,M3,Frome,82.33.126.30,DEDIFFERENTIATION causes GLIOBLASTOMA,158,72,,174,84,causes,0.904534033733291,901970-FS1-4,The results of modern neuro oncology support the pathogenetic view that GLIOBLASTOMA results from neoplastic transformation of glial elements with continuing DEDIFFERENTIATION,DEDIFFERENTIATION,GLIOBLASTOMA,RO-disease_has_finding
502912492,7/14/2014 12:34:28,,1322804271,7/14/2014 12:34:23,neodev,0.9583,17610000,GBR,I2,Manchester,90.200.140.201,RHEUMATOID ARTHRITIS treats INJECTABLE GOLD FOR RHEUMATOID ARTHRITIS,327,307,,346,347,treats,0.993127066322841,907956-FS1-2,"Sulfasalazine for rheumatoid arthritis  Penicillamine for treating rheumatoid arthritis  Moderate term, low dose corticosteroids for rheumatoid arthritis  Biologics for rheumatoid arthritis: an overview of Cochrane reviews  Low level laser therapy (Classes I, II and III) for treating rheumatoid arthritis  INJECTABLE GOLD FOR RHEUMATOID ARTHRITIS  Herbal therapy for treating rheumatoid arthritis  Folic acid and folinic acid for reducing side effects in patients receiving methotrexate for RHEUMATOID ARTHRITIS  WITHDRAWN: Dynamic exercise therapy for rheumatoid arthritis  Cyclosporine for treating rheumatoid arthritis  Cyclophosphamide for treating rheumatoid arthritis  Balneotherapy for rheumatoid arthritis  Azathioprine for treating rheumatoid arthritis.",RHEUMATOID ARTHRITIS,INJECTABLE GOLD FOR RHEUMATOID ARTHRITIS,RO-may_treat
502912492,7/14/2014 12:35:54,,1322805144,7/14/2014 12:35:20,prodege,0.8889,27934334,GBR,Q2,Wokingham,86.166.73.21,INJECTABLE GOLD FOR RHEUMATOID ARTHRITIS treats RHEUMATOID ARTHRITIS,327,307,,346,347,treats,0.993127066322841,907956-FS1-2,"Sulfasalazine for rheumatoid arthritis  Penicillamine for treating rheumatoid arthritis  Moderate term, low dose corticosteroids for rheumatoid arthritis  Biologics for rheumatoid arthritis: an overview of Cochrane reviews  Low level laser therapy (Classes I, II and III) for treating rheumatoid arthritis  INJECTABLE GOLD FOR RHEUMATOID ARTHRITIS  Herbal therapy for treating rheumatoid arthritis  Folic acid and folinic acid for reducing side effects in patients receiving methotrexate for RHEUMATOID ARTHRITIS  WITHDRAWN: Dynamic exercise therapy for rheumatoid arthritis  Cyclosporine for treating rheumatoid arthritis  Cyclophosphamide for treating rheumatoid arthritis  Balneotherapy for rheumatoid arthritis  Azathioprine for treating rheumatoid arthritis.",RHEUMATOID ARTHRITIS,INJECTABLE GOLD FOR RHEUMATOID ARTHRITIS,RO-may_treat
502912492,7/14/2014 12:54:36,,1322817961,7/14/2014 12:54:04,clixsense,0.8194,15189335,GBR,K3,Peterborough,81.156.166.189,INJECTABLE GOLD FOR RHEUMATOID ARTHRITIS treats RHEUMATOID ARTHRITIS,327,307,,346,347,treats,0.993127066322841,907956-FS1-2,"Sulfasalazine for rheumatoid arthritis  Penicillamine for treating rheumatoid arthritis  Moderate term, low dose corticosteroids for rheumatoid arthritis  Biologics for rheumatoid arthritis: an overview of Cochrane reviews  Low level laser therapy (Classes I, II and III) for treating rheumatoid arthritis  INJECTABLE GOLD FOR RHEUMATOID ARTHRITIS  Herbal therapy for treating rheumatoid arthritis  Folic acid and folinic acid for reducing side effects in patients receiving methotrexate for RHEUMATOID ARTHRITIS  WITHDRAWN: Dynamic exercise therapy for rheumatoid arthritis  Cyclosporine for treating rheumatoid arthritis  Cyclophosphamide for treating rheumatoid arthritis  Balneotherapy for rheumatoid arthritis  Azathioprine for treating rheumatoid arthritis.",RHEUMATOID ARTHRITIS,INJECTABLE GOLD FOR RHEUMATOID ARTHRITIS,RO-may_treat
502912492,7/14/2014 13:01:34,,1322822534,7/14/2014 13:00:59,prodege,0.7639,7664351,USA,NY,Cicero,74.111.0.21,INJECTABLE GOLD FOR RHEUMATOID ARTHRITIS treats RHEUMATOID ARTHRITIS,327,307,,346,347,treats,0.993127066322841,907956-FS1-2,"Sulfasalazine for rheumatoid arthritis  Penicillamine for treating rheumatoid arthritis  Moderate term, low dose corticosteroids for rheumatoid arthritis  Biologics for rheumatoid arthritis: an overview of Cochrane reviews  Low level laser therapy (Classes I, II and III) for treating rheumatoid arthritis  INJECTABLE GOLD FOR RHEUMATOID ARTHRITIS  Herbal therapy for treating rheumatoid arthritis  Folic acid and folinic acid for reducing side effects in patients receiving methotrexate for RHEUMATOID ARTHRITIS  WITHDRAWN: Dynamic exercise therapy for rheumatoid arthritis  Cyclosporine for treating rheumatoid arthritis  Cyclophosphamide for treating rheumatoid arthritis  Balneotherapy for rheumatoid arthritis  Azathioprine for treating rheumatoid arthritis.",RHEUMATOID ARTHRITIS,INJECTABLE GOLD FOR RHEUMATOID ARTHRITIS,RO-may_treat
502912492,7/14/2014 13:53:45,,1322859109,7/14/2014 13:53:25,zoombucks,0.7764,5919735,USA,PA,Doylestown,173.49.91.231,no_relation,327,307,,346,347,treats,0.993127066322841,907956-FS1-2,"Sulfasalazine for rheumatoid arthritis  Penicillamine for treating rheumatoid arthritis  Moderate term, low dose corticosteroids for rheumatoid arthritis  Biologics for rheumatoid arthritis: an overview of Cochrane reviews  Low level laser therapy (Classes I, II and III) for treating rheumatoid arthritis  INJECTABLE GOLD FOR RHEUMATOID ARTHRITIS  Herbal therapy for treating rheumatoid arthritis  Folic acid and folinic acid for reducing side effects in patients receiving methotrexate for RHEUMATOID ARTHRITIS  WITHDRAWN: Dynamic exercise therapy for rheumatoid arthritis  Cyclosporine for treating rheumatoid arthritis  Cyclophosphamide for treating rheumatoid arthritis  Balneotherapy for rheumatoid arthritis  Azathioprine for treating rheumatoid arthritis.",RHEUMATOID ARTHRITIS,INJECTABLE GOLD FOR RHEUMATOID ARTHRITIS,RO-may_treat
502912492,7/14/2014 15:01:21,,1322904333,7/14/2014 15:01:11,instagc,0.5536,18960682,GBR,"","",86.29.147.112,INJECTABLE GOLD FOR RHEUMATOID ARTHRITIS treats RHEUMATOID ARTHRITIS,327,307,,346,347,treats,0.993127066322841,907956-FS1-2,"Sulfasalazine for rheumatoid arthritis  Penicillamine for treating rheumatoid arthritis  Moderate term, low dose corticosteroids for rheumatoid arthritis  Biologics for rheumatoid arthritis: an overview of Cochrane reviews  Low level laser therapy (Classes I, II and III) for treating rheumatoid arthritis  INJECTABLE GOLD FOR RHEUMATOID ARTHRITIS  Herbal therapy for treating rheumatoid arthritis  Folic acid and folinic acid for reducing side effects in patients receiving methotrexate for RHEUMATOID ARTHRITIS  WITHDRAWN: Dynamic exercise therapy for rheumatoid arthritis  Cyclosporine for treating rheumatoid arthritis  Cyclophosphamide for treating rheumatoid arthritis  Balneotherapy for rheumatoid arthritis  Azathioprine for treating rheumatoid arthritis.",RHEUMATOID ARTHRITIS,INJECTABLE GOLD FOR RHEUMATOID ARTHRITIS,RO-may_treat
502912492,7/14/2014 15:05:02,,1322906496,7/14/2014 15:04:47,neodev,0.719,18755947,GBR,H2,Accrington,80.47.185.52,INJECTABLE GOLD FOR RHEUMATOID ARTHRITIS treats RHEUMATOID ARTHRITIS,327,307,,346,347,treats,0.993127066322841,907956-FS1-2,"Sulfasalazine for rheumatoid arthritis  Penicillamine for treating rheumatoid arthritis  Moderate term, low dose corticosteroids for rheumatoid arthritis  Biologics for rheumatoid arthritis: an overview of Cochrane reviews  Low level laser therapy (Classes I, II and III) for treating rheumatoid arthritis  INJECTABLE GOLD FOR RHEUMATOID ARTHRITIS  Herbal therapy for treating rheumatoid arthritis  Folic acid and folinic acid for reducing side effects in patients receiving methotrexate for RHEUMATOID ARTHRITIS  WITHDRAWN: Dynamic exercise therapy for rheumatoid arthritis  Cyclosporine for treating rheumatoid arthritis  Cyclophosphamide for treating rheumatoid arthritis  Balneotherapy for rheumatoid arthritis  Azathioprine for treating rheumatoid arthritis.",RHEUMATOID ARTHRITIS,INJECTABLE GOLD FOR RHEUMATOID ARTHRITIS,RO-may_treat
502912493,7/14/2014 12:33:53,,1322803834,7/14/2014 12:33:17,clixsense,0.9583,27871219,NLD,07,Amsterdam,87.210.207.223,no_relation,156,111,,164,137,causes,0.329292779969071,901581-FS1-4,"The high frequency of herpes simplex virus type 2 (HSV 2) antibodies in young women (21 years or younger) with CERVICAL CARCINOMA IN SITU and in women with DYSPLASIA or carcinoma in situ, matched for various sexual attributes to control women, provide support for a causal relation.",DYSPLASIA,CERVICAL CARCINOMA IN SITU,RO-disease_has_finding
502912493,7/14/2014 12:34:36,,1322804330,7/14/2014 12:34:29,neodev,0.9583,17610000,GBR,I2,Manchester,90.200.140.201,DYSPLASIA causes CERVICAL CARCINOMA IN SITU,156,111,,164,137,causes,0.329292779969071,901581-FS1-4,"The high frequency of herpes simplex virus type 2 (HSV 2) antibodies in young women (21 years or younger) with CERVICAL CARCINOMA IN SITU and in women with DYSPLASIA or carcinoma in situ, matched for various sexual attributes to control women, provide support for a causal relation.",DYSPLASIA,CERVICAL CARCINOMA IN SITU,RO-disease_has_finding
502912493,7/14/2014 12:36:18,,1322805377,7/14/2014 12:35:56,prodege,0.8889,27934334,GBR,Q2,Wokingham,86.166.73.21,no_relation,156,111,,164,137,causes,0.329292779969071,901581-FS1-4,"The high frequency of herpes simplex virus type 2 (HSV 2) antibodies in young women (21 years or younger) with CERVICAL CARCINOMA IN SITU and in women with DYSPLASIA or carcinoma in situ, matched for various sexual attributes to control women, provide support for a causal relation.",DYSPLASIA,CERVICAL CARCINOMA IN SITU,RO-disease_has_finding
502912493,7/14/2014 13:00:28,,1322821815,7/14/2014 12:59:57,prodege,0.7639,7664351,USA,NY,Cicero,74.111.0.21,no_relation,156,111,,164,137,causes,0.329292779969071,901581-FS1-4,"The high frequency of herpes simplex virus type 2 (HSV 2) antibodies in young women (21 years or younger) with CERVICAL CARCINOMA IN SITU and in women with DYSPLASIA or carcinoma in situ, matched for various sexual attributes to control women, provide support for a causal relation.",DYSPLASIA,CERVICAL CARCINOMA IN SITU,RO-disease_has_finding
502912493,7/14/2014 13:51:40,,1322857658,7/14/2014 13:51:13,clixsense,0.4042,25402344,CAN,ON,Wawa,24.109.124.45,DYSPLASIA causes CERVICAL CARCINOMA IN SITU,156,111,,164,137,causes,0.329292779969071,901581-FS1-4,"The high frequency of herpes simplex virus type 2 (HSV 2) antibodies in young women (21 years or younger) with CERVICAL CARCINOMA IN SITU and in women with DYSPLASIA or carcinoma in situ, matched for various sexual attributes to control women, provide support for a causal relation.",DYSPLASIA,CERVICAL CARCINOMA IN SITU,RO-disease_has_finding
502912493,7/14/2014 14:23:30,,1322879228,7/14/2014 14:23:24,neodev,0.3792,25224036,CAN,ON,Sudbury,67.204.218.187,CERVICAL CARCINOMA IN SITU causes DYSPLASIA,156,111,,164,137,causes,0.329292779969071,901581-FS1-4,"The high frequency of herpes simplex virus type 2 (HSV 2) antibodies in young women (21 years or younger) with CERVICAL CARCINOMA IN SITU and in women with DYSPLASIA or carcinoma in situ, matched for various sexual attributes to control women, provide support for a causal relation.",DYSPLASIA,CERVICAL CARCINOMA IN SITU,RO-disease_has_finding
502912493,7/14/2014 14:49:01,,1322896780,7/14/2014 14:48:50,clixsense,0.5125,7415230,GBR,A7,Birmingham,147.188.47.242,no_relation,156,111,,164,137,causes,0.329292779969071,901581-FS1-4,"The high frequency of herpes simplex virus type 2 (HSV 2) antibodies in young women (21 years or younger) with CERVICAL CARCINOMA IN SITU and in women with DYSPLASIA or carcinoma in situ, matched for various sexual attributes to control women, provide support for a causal relation.",DYSPLASIA,CERVICAL CARCINOMA IN SITU,RO-disease_has_finding
502912494,7/14/2014 12:36:46,,1322805656,7/14/2014 12:36:19,prodege,0.8889,27934334,GBR,Q2,Wokingham,86.166.73.21,FLUORIDE ION treats CARIES,95,26,,100,38,treats,0.993127066322841,907385-FS1-2,"The results show that the FLUORIDE ION concentration is sufficient (0.7 1.0 ppm F ) to prevent CARIES only in very few parts of Lower Austria, Upper Austria, Salzburg, Tirol, Carinthia, and Styria.",CARIES,FLUORIDE ION,RO-may_prevent
502912494,7/14/2014 13:04:30,,1322824381,7/14/2014 13:04:20,clixsense,0.7708,27793793,GBR,C5,Chester,151.230.27.155,no_relation,95,26,,100,38,treats,0.993127066322841,907385-FS1-2,"The results show that the FLUORIDE ION concentration is sufficient (0.7 1.0 ppm F ) to prevent CARIES only in very few parts of Lower Austria, Upper Austria, Salzburg, Tirol, Carinthia, and Styria.",CARIES,FLUORIDE ION,RO-may_prevent
502912494,7/14/2014 14:27:23,,1322882108,7/14/2014 14:26:52,neodev,0.4306,21515166,NLD,11,Nootdorp,83.86.58.179,FLUORIDE ION treats CARIES,95,26,,100,38,treats,0.993127066322841,907385-FS1-2,"The results show that the FLUORIDE ION concentration is sufficient (0.7 1.0 ppm F ) to prevent CARIES only in very few parts of Lower Austria, Upper Austria, Salzburg, Tirol, Carinthia, and Styria.",CARIES,FLUORIDE ION,RO-may_prevent
502912494,7/14/2014 15:05:02,,1322906504,7/14/2014 15:04:33,instagc,0.7125,28519532,USA,IA,Honey Creek,12.73.110.26,FLUORIDE ION treats CARIES,95,26,,100,38,treats,0.993127066322841,907385-FS1-2,"The results show that the FLUORIDE ION concentration is sufficient (0.7 1.0 ppm F ) to prevent CARIES only in very few parts of Lower Austria, Upper Austria, Salzburg, Tirol, Carinthia, and Styria.",CARIES,FLUORIDE ION,RO-may_prevent
502912494,7/14/2014 15:12:55,,1322910454,7/14/2014 15:12:11,elite,0.4429,28322695,GBR,A3,Barnsley,217.44.205.195,FLUORIDE ION treats CARIES,95,26,,100,38,treats,0.993127066322841,907385-FS1-2,"The results show that the FLUORIDE ION concentration is sufficient (0.7 1.0 ppm F ) to prevent CARIES only in very few parts of Lower Austria, Upper Austria, Salzburg, Tirol, Carinthia, and Styria.",CARIES,FLUORIDE ION,RO-may_prevent
502912494,7/14/2014 15:26:51,,1322918333,7/14/2014 15:26:17,clixsense,0.4244,26889820,GBR,C3,Shelford,92.18.120.203,no_relation,95,26,,100,38,treats,0.993127066322841,907385-FS1-2,"The results show that the FLUORIDE ION concentration is sufficient (0.7 1.0 ppm F ) to prevent CARIES only in very few parts of Lower Austria, Upper Austria, Salzburg, Tirol, Carinthia, and Styria.",CARIES,FLUORIDE ION,RO-may_prevent
502912494,7/14/2014 15:27:21,,1322918663,7/14/2014 15:27:02,instagc,0.3552,19004168,GBR,H2,Accrington,80.47.185.52,no_relation,95,26,,100,38,treats,0.993127066322841,907385-FS1-2,"The results show that the FLUORIDE ION concentration is sufficient (0.7 1.0 ppm F ) to prevent CARIES only in very few parts of Lower Austria, Upper Austria, Salzburg, Tirol, Carinthia, and Styria.",CARIES,FLUORIDE ION,RO-may_prevent
502912495,7/14/2014 12:34:42,,1322804404,7/14/2014 12:34:37,neodev,0.9583,17610000,GBR,I2,Manchester,90.200.140.201,DYSPLASIA diagnosed by INTRAEPITHELIAL LESION (HSIL),169,96,,177,125,diagnosed by,0.397359707119513,901923-FS1-13,Pap smears were reliable in screening for CIN; 75% of patients with CIN had high grade squamous INTRAEPITHELIAL LESION (HSIL) or LSIL in Pap smears taken at the time of DYSPLASIA,DYSPLASIA,INTRAEPITHELIAL LESION (HSIL),RO-disease_has_finding
502912495,7/14/2014 13:04:30,,1322824382,7/14/2014 13:04:20,clixsense,0.7708,27793793,GBR,C5,Chester,151.230.27.155,INTRAEPITHELIAL LESION (HSIL) diagnosed by DYSPLASIA,169,96,,177,125,diagnosed by,0.397359707119513,901923-FS1-13,Pap smears were reliable in screening for CIN; 75% of patients with CIN had high grade squamous INTRAEPITHELIAL LESION (HSIL) or LSIL in Pap smears taken at the time of DYSPLASIA,DYSPLASIA,INTRAEPITHELIAL LESION (HSIL),RO-disease_has_finding
502912495,7/14/2014 14:23:48,,1322879456,7/14/2014 14:23:41,neodev,0.3792,25224036,CAN,ON,Sudbury,67.204.218.187,INTRAEPITHELIAL LESION (HSIL) diagnosed by DYSPLASIA,169,96,,177,125,diagnosed by,0.397359707119513,901923-FS1-13,Pap smears were reliable in screening for CIN; 75% of patients with CIN had high grade squamous INTRAEPITHELIAL LESION (HSIL) or LSIL in Pap smears taken at the time of DYSPLASIA,DYSPLASIA,INTRAEPITHELIAL LESION (HSIL),RO-disease_has_finding
502912495,7/14/2014 14:56:25,,1322901236,7/14/2014 14:55:54,instagc,0.6593,13763729,USA,"","",75.182.89.225,DYSPLASIA diagnosed by INTRAEPITHELIAL LESION (HSIL),169,96,,177,125,diagnosed by,0.397359707119513,901923-FS1-13,Pap smears were reliable in screening for CIN; 75% of patients with CIN had high grade squamous INTRAEPITHELIAL LESION (HSIL) or LSIL in Pap smears taken at the time of DYSPLASIA,DYSPLASIA,INTRAEPITHELIAL LESION (HSIL),RO-disease_has_finding
502912495,7/14/2014 15:07:32,,1322907767,7/14/2014 15:06:52,instagc,0.7125,28519532,USA,IA,Honey Creek,12.73.110.26,DYSPLASIA diagnosed by INTRAEPITHELIAL LESION (HSIL),169,96,,177,125,diagnosed by,0.397359707119513,901923-FS1-13,Pap smears were reliable in screening for CIN; 75% of patients with CIN had high grade squamous INTRAEPITHELIAL LESION (HSIL) or LSIL in Pap smears taken at the time of DYSPLASIA,DYSPLASIA,INTRAEPITHELIAL LESION (HSIL),RO-disease_has_finding
502912495,7/14/2014 15:37:31,,1322924786,7/14/2014 15:36:54,clixsense,0.6484,19638651,USA,"","",173.23.121.63,DYSPLASIA diagnosed by INTRAEPITHELIAL LESION (HSIL),169,96,,177,125,diagnosed by,0.397359707119513,901923-FS1-13,Pap smears were reliable in screening for CIN; 75% of patients with CIN had high grade squamous INTRAEPITHELIAL LESION (HSIL) or LSIL in Pap smears taken at the time of DYSPLASIA,DYSPLASIA,INTRAEPITHELIAL LESION (HSIL),RO-disease_has_finding
502912495,7/14/2014 15:54:58,,1322934481,7/14/2014 15:54:16,clixsense,0.573,22177255,USA,CA,San Francisco,73.32.39.90,no_relation,169,96,,177,125,diagnosed by,0.397359707119513,901923-FS1-13,Pap smears were reliable in screening for CIN; 75% of patients with CIN had high grade squamous INTRAEPITHELIAL LESION (HSIL) or LSIL in Pap smears taken at the time of DYSPLASIA,DYSPLASIA,INTRAEPITHELIAL LESION (HSIL),RO-disease_has_finding
502912496,7/14/2014 12:34:48,,1322804460,7/14/2014 12:34:12,prodege,0.8889,27934334,GBR,Q2,Wokingham,86.166.73.21,SODIUM FLUORIDE treats DENTAL CARIES,181,69,,193,84,treats,0.565685424949238,907106-FS1-2,"A sample of 1,824 schoolchildren was randomly assigned to either the SODIUM FLUORIDE dentifrice or the stannous fluoride dentifrice and examined clinically and radiographically for DENTAL CARIES initially and after one, two, and three years of dentifrice usage.",DENTAL CARIES,SODIUM FLUORIDE,RO-may_prevent
502912496,7/14/2014 13:54:07,,1322859335,7/14/2014 13:53:46,zoombucks,0.7764,5919735,USA,PA,Doylestown,173.49.91.231,SODIUM FLUORIDE treats DENTAL CARIES,181,69,,193,84,treats,0.565685424949238,907106-FS1-2,"A sample of 1,824 schoolchildren was randomly assigned to either the SODIUM FLUORIDE dentifrice or the stannous fluoride dentifrice and examined clinically and radiographically for DENTAL CARIES initially and after one, two, and three years of dentifrice usage.",DENTAL CARIES,SODIUM FLUORIDE,RO-may_prevent
502912496,7/14/2014 14:09:54,,1322869870,7/14/2014 14:09:45,clixsense,0.7708,27793793,GBR,C5,Chester,151.230.27.155,SODIUM FLUORIDE treats DENTAL CARIES,181,69,,193,84,treats,0.565685424949238,907106-FS1-2,"A sample of 1,824 schoolchildren was randomly assigned to either the SODIUM FLUORIDE dentifrice or the stannous fluoride dentifrice and examined clinically and radiographically for DENTAL CARIES initially and after one, two, and three years of dentifrice usage.",DENTAL CARIES,SODIUM FLUORIDE,RO-may_prevent
502912496,7/14/2014 14:11:18,,1322870783,7/14/2014 14:10:55,clixsense,0.5125,7415230,GBR,A7,Birmingham,147.188.47.242,no_relation,181,69,,193,84,treats,0.565685424949238,907106-FS1-2,"A sample of 1,824 schoolchildren was randomly assigned to either the SODIUM FLUORIDE dentifrice or the stannous fluoride dentifrice and examined clinically and radiographically for DENTAL CARIES initially and after one, two, and three years of dentifrice usage.",DENTAL CARIES,SODIUM FLUORIDE,RO-may_prevent
502912496,7/14/2014 14:31:25,,1322885181,7/14/2014 14:31:13,instagc,0.644,15445601,USA,FL,Jacksonville,24.129.68.254,SODIUM FLUORIDE treats DENTAL CARIES,181,69,,193,84,treats,0.565685424949238,907106-FS1-2,"A sample of 1,824 schoolchildren was randomly assigned to either the SODIUM FLUORIDE dentifrice or the stannous fluoride dentifrice and examined clinically and radiographically for DENTAL CARIES initially and after one, two, and three years of dentifrice usage.",DENTAL CARIES,SODIUM FLUORIDE,RO-may_prevent
502912496,7/14/2014 14:35:20,,1322887833,7/14/2014 14:35:01,rewardsspot,0.57,17763704,USA,IL,Chicago,67.212.175.123,SODIUM FLUORIDE treats DENTAL CARIES,181,69,,193,84,treats,0.565685424949238,907106-FS1-2,"A sample of 1,824 schoolchildren was randomly assigned to either the SODIUM FLUORIDE dentifrice or the stannous fluoride dentifrice and examined clinically and radiographically for DENTAL CARIES initially and after one, two, and three years of dentifrice usage.",DENTAL CARIES,SODIUM FLUORIDE,RO-may_prevent
502912496,7/14/2014 15:02:22,,1322904878,7/14/2014 15:01:42,vivatic,0.5339,25451531,GBR,"","",83.67.28.193,no_relation,181,69,,193,84,treats,0.565685424949238,907106-FS1-2,"A sample of 1,824 schoolchildren was randomly assigned to either the SODIUM FLUORIDE dentifrice or the stannous fluoride dentifrice and examined clinically and radiographically for DENTAL CARIES initially and after one, two, and three years of dentifrice usage.",DENTAL CARIES,SODIUM FLUORIDE,RO-may_prevent
502912497,7/14/2014 13:02:06,,1322822850,7/14/2014 13:01:27,rewardsspot,0.7153,24482174,GBR,H9,London,46.23.68.180,no_relation,87,101,,112,113,causes,0.640512615220348,903953-FS1-4,Neither the impact of the HIV pandemic nor the occurrence of multiresistant strains of MYCOBACTERIUM TUBERCULOSIS has yet become a major problem in the care of TUBERCULOSIS patients in Sweden.,MYCOBACTERIUM TUBERCULOSIS,TUBERCULOSIS,RO-has_causative_agent
502912497,7/14/2014 13:08:23,,1322827105,7/14/2014 13:08:07,prodege,0.6278,11616695,GBR,P7,Wigan,92.29.199.166,MYCOBACTERIUM TUBERCULOSIS causes TUBERCULOSIS,87,101,,112,113,causes,0.640512615220348,903953-FS1-4,Neither the impact of the HIV pandemic nor the occurrence of multiresistant strains of MYCOBACTERIUM TUBERCULOSIS has yet become a major problem in the care of TUBERCULOSIS patients in Sweden.,MYCOBACTERIUM TUBERCULOSIS,TUBERCULOSIS,RO-has_causative_agent
502912497,7/14/2014 13:20:15,,1322835048,7/14/2014 13:19:14,clixsense,0.7,24896327,GBR,V2,Glasgow,94.2.231.4,no_relation,87,101,,112,113,causes,0.640512615220348,903953-FS1-4,Neither the impact of the HIV pandemic nor the occurrence of multiresistant strains of MYCOBACTERIUM TUBERCULOSIS has yet become a major problem in the care of TUBERCULOSIS patients in Sweden.,MYCOBACTERIUM TUBERCULOSIS,TUBERCULOSIS,RO-has_causative_agent
502912497,7/14/2014 13:41:10,,1322849856,7/14/2014 13:40:41,prodege,0.6181,17982533,GBR,H3,Leeds,90.193.39.185,no_relation,87,101,,112,113,causes,0.640512615220348,903953-FS1-4,Neither the impact of the HIV pandemic nor the occurrence of multiresistant strains of MYCOBACTERIUM TUBERCULOSIS has yet become a major problem in the care of TUBERCULOSIS patients in Sweden.,MYCOBACTERIUM TUBERCULOSIS,TUBERCULOSIS,RO-has_causative_agent
502912497,7/14/2014 14:27:23,,1322882110,7/14/2014 14:26:52,neodev,0.4306,21515166,NLD,11,Nootdorp,83.86.58.179,MYCOBACTERIUM TUBERCULOSIS causes TUBERCULOSIS,87,101,,112,113,causes,0.640512615220348,903953-FS1-4,Neither the impact of the HIV pandemic nor the occurrence of multiresistant strains of MYCOBACTERIUM TUBERCULOSIS has yet become a major problem in the care of TUBERCULOSIS patients in Sweden.,MYCOBACTERIUM TUBERCULOSIS,TUBERCULOSIS,RO-has_causative_agent
502912497,7/14/2014 14:31:12,,1322884965,7/14/2014 14:31:00,instagc,0.644,15445601,USA,FL,Jacksonville,24.129.68.254,no_relation,87,101,,112,113,causes,0.640512615220348,903953-FS1-4,Neither the impact of the HIV pandemic nor the occurrence of multiresistant strains of MYCOBACTERIUM TUBERCULOSIS has yet become a major problem in the care of TUBERCULOSIS patients in Sweden.,MYCOBACTERIUM TUBERCULOSIS,TUBERCULOSIS,RO-has_causative_agent
502912497,7/14/2014 14:34:41,,1322887343,7/14/2014 14:33:56,rewardsspot,0.57,17763704,USA,IL,Chicago,67.212.175.123,no_relation,87,101,,112,113,causes,0.640512615220348,903953-FS1-4,Neither the impact of the HIV pandemic nor the occurrence of multiresistant strains of MYCOBACTERIUM TUBERCULOSIS has yet become a major problem in the care of TUBERCULOSIS patients in Sweden.,MYCOBACTERIUM TUBERCULOSIS,TUBERCULOSIS,RO-has_causative_agent
502912498,7/14/2014 13:17:20,,1322833181,7/14/2014 13:16:47,clixsense,0.7,24896327,GBR,V2,Glasgow,94.2.231.4,HUMAN PAPILLOMA VIRUS causes WART,110,147,,130,151,causes,0.657595949221429,903914-FS1-4,These results support the hypothesis that stimulation of local cytokines by imiquimod leads to a reduction in HUMAN PAPILLOMA VIRUS (HPV) load; to WART regression and to the normalisation of keratinocyte proliferation without evidence of scarring.,HUMAN PAPILLOMA VIRUS,WART,RO-has_causative_agent
502912498,7/14/2014 14:10:31,,1322870258,7/14/2014 14:10:22,clixsense,0.7708,27793793,GBR,C5,Chester,151.230.27.155,WART causes HUMAN PAPILLOMA VIRUS,110,147,,130,151,causes,0.657595949221429,903914-FS1-4,These results support the hypothesis that stimulation of local cytokines by imiquimod leads to a reduction in HUMAN PAPILLOMA VIRUS (HPV) load; to WART regression and to the normalisation of keratinocyte proliferation without evidence of scarring.,HUMAN PAPILLOMA VIRUS,WART,RO-has_causative_agent
502912498,7/14/2014 14:25:17,,1322880602,7/14/2014 14:24:41,neodev,0.4306,21515166,NLD,11,Nootdorp,83.86.58.179,HUMAN PAPILLOMA VIRUS causes WART,110,147,,130,151,causes,0.657595949221429,903914-FS1-4,These results support the hypothesis that stimulation of local cytokines by imiquimod leads to a reduction in HUMAN PAPILLOMA VIRUS (HPV) load; to WART regression and to the normalisation of keratinocyte proliferation without evidence of scarring.,HUMAN PAPILLOMA VIRUS,WART,RO-has_causative_agent
502912498,7/14/2014 14:31:45,,1322885436,7/14/2014 14:31:32,instagc,0.644,15445601,USA,FL,Jacksonville,24.129.68.254,HUMAN PAPILLOMA VIRUS causes WART,110,147,,130,151,causes,0.657595949221429,903914-FS1-4,These results support the hypothesis that stimulation of local cytokines by imiquimod leads to a reduction in HUMAN PAPILLOMA VIRUS (HPV) load; to WART regression and to the normalisation of keratinocyte proliferation without evidence of scarring.,HUMAN PAPILLOMA VIRUS,WART,RO-has_causative_agent
502912498,7/14/2014 15:23:08,,1322916240,7/14/2014 15:22:34,clixsense,0.4244,26889820,GBR,C3,Shelford,92.18.120.203,no_relation,110,147,,130,151,causes,0.657595949221429,903914-FS1-4,These results support the hypothesis that stimulation of local cytokines by imiquimod leads to a reduction in HUMAN PAPILLOMA VIRUS (HPV) load; to WART regression and to the normalisation of keratinocyte proliferation without evidence of scarring.,HUMAN PAPILLOMA VIRUS,WART,RO-has_causative_agent
502912498,7/14/2014 15:33:11,,1322922299,7/14/2014 15:32:48,neodev,0.5101,21405167,USA,MD,Glen Burnie,69.137.237.73,HUMAN PAPILLOMA VIRUS causes WART,110,147,,130,151,causes,0.657595949221429,903914-FS1-4,These results support the hypothesis that stimulation of local cytokines by imiquimod leads to a reduction in HUMAN PAPILLOMA VIRUS (HPV) load; to WART regression and to the normalisation of keratinocyte proliferation without evidence of scarring.,HUMAN PAPILLOMA VIRUS,WART,RO-has_causative_agent
502912498,7/14/2014 15:53:19,,1322933559,7/14/2014 15:52:45,clixsense,0.573,22177255,USA,CA,San Francisco,73.32.39.90,HUMAN PAPILLOMA VIRUS causes WART,110,147,,130,151,causes,0.657595949221429,903914-FS1-4,These results support the hypothesis that stimulation of local cytokines by imiquimod leads to a reduction in HUMAN PAPILLOMA VIRUS (HPV) load; to WART regression and to the normalisation of keratinocyte proliferation without evidence of scarring.,HUMAN PAPILLOMA VIRUS,WART,RO-has_causative_agent
502912499,7/14/2014 12:43:53,,1322810637,7/14/2014 12:43:47,clixsense,0.875,25419319,GBR,H8,Liverpool,94.4.192.228,CADMIUM ION IN THE causes CADMIUM TOXICITY,104,159,,121,175,causes,0.686802819743445,903970-FS1-4,"The results suggest that cadmium thionein may play a paradoxical role, providing protection against the CADMIUM ION IN THE intracellular milieu, but promoting CADMIUM TOXICITY when it is present in sufficient amounts in the lumen of the intestine.",CADMIUM ION IN THE,CADMIUM TOXICITY,RO-has_causative_agent
502912499,7/14/2014 13:02:27,,1322823036,7/14/2014 13:02:02,prodege,0.7639,7664351,USA,NY,Cicero,74.111.0.21,no_relation,104,159,,121,175,causes,0.686802819743445,903970-FS1-4,"The results suggest that cadmium thionein may play a paradoxical role, providing protection against the CADMIUM ION IN THE intracellular milieu, but promoting CADMIUM TOXICITY when it is present in sufficient amounts in the lumen of the intestine.",CADMIUM ION IN THE,CADMIUM TOXICITY,RO-has_causative_agent
502912499,7/14/2014 13:02:43,,1322823256,7/14/2014 13:02:13,rewardsspot,0.7153,24482174,GBR,H9,London,46.23.68.180,no_relation,104,159,,121,175,causes,0.686802819743445,903970-FS1-4,"The results suggest that cadmium thionein may play a paradoxical role, providing protection against the CADMIUM ION IN THE intracellular milieu, but promoting CADMIUM TOXICITY when it is present in sufficient amounts in the lumen of the intestine.",CADMIUM ION IN THE,CADMIUM TOXICITY,RO-has_causative_agent
502912499,7/14/2014 14:30:59,,1322884845,7/14/2014 14:30:34,instagc,0.644,15445601,USA,FL,Jacksonville,24.129.68.254,no_relation,104,159,,121,175,causes,0.686802819743445,903970-FS1-4,"The results suggest that cadmium thionein may play a paradoxical role, providing protection against the CADMIUM ION IN THE intracellular milieu, but promoting CADMIUM TOXICITY when it is present in sufficient amounts in the lumen of the intestine.",CADMIUM ION IN THE,CADMIUM TOXICITY,RO-has_causative_agent
502912499,7/14/2014 14:45:33,,1322894784,7/14/2014 14:45:29,instagc,0.4611,27753923,GBR,"","",188.30.192.65,CADMIUM ION IN THE causes CADMIUM TOXICITY,104,159,,121,175,causes,0.686802819743445,903970-FS1-4,"The results suggest that cadmium thionein may play a paradoxical role, providing protection against the CADMIUM ION IN THE intracellular milieu, but promoting CADMIUM TOXICITY when it is present in sufficient amounts in the lumen of the intestine.",CADMIUM ION IN THE,CADMIUM TOXICITY,RO-has_causative_agent
502912499,7/14/2014 14:56:50,,1322901587,7/14/2014 14:56:27,elite,0.4302,28276268,USA,MI,Taylor,67.149.247.166,CADMIUM ION IN THE causes CADMIUM TOXICITY,104,159,,121,175,causes,0.686802819743445,903970-FS1-4,"The results suggest that cadmium thionein may play a paradoxical role, providing protection against the CADMIUM ION IN THE intracellular milieu, but promoting CADMIUM TOXICITY when it is present in sufficient amounts in the lumen of the intestine.",CADMIUM ION IN THE,CADMIUM TOXICITY,RO-has_causative_agent
502912499,7/14/2014 15:00:29,,1322903776,7/14/2014 14:59:32,vivatic,0.5339,25451531,GBR,"","",83.67.28.193,no_relation,104,159,,121,175,causes,0.686802819743445,903970-FS1-4,"The results suggest that cadmium thionein may play a paradoxical role, providing protection against the CADMIUM ION IN THE intracellular milieu, but promoting CADMIUM TOXICITY when it is present in sufficient amounts in the lumen of the intestine.",CADMIUM ION IN THE,CADMIUM TOXICITY,RO-has_causative_agent
502912500,7/14/2014 12:35:54,,1322805145,7/14/2014 12:35:20,prodege,0.8889,27934334,GBR,Q2,Wokingham,86.166.73.21,no_relation,191,133,,197,141,is location of,0.410997468263393,905412-FS1-9,Lacunes consist of small vascular lesions with a volume of between 2 and about 30 mm. These lacunar infarctions are determined by an ISCHEMIA caused by obstructive diseases of small terminal VESSELS in the deep areas of the brain.,VESSELS,ISCHEMIA,RO-has_finding_site
502912500,7/14/2014 12:49:09,,1322814086,7/14/2014 12:48:19,elite,0.75,27433978,AUS,05,Plympton,110.174.120.88,no_relation,191,133,,197,141,is location of,0.410997468263393,905412-FS1-9,Lacunes consist of small vascular lesions with a volume of between 2 and about 30 mm. These lacunar infarctions are determined by an ISCHEMIA caused by obstructive diseases of small terminal VESSELS in the deep areas of the brain.,VESSELS,ISCHEMIA,RO-has_finding_site
502912500,7/14/2014 13:54:46,,1322859811,7/14/2014 13:54:29,zoombucks,0.7764,5919735,USA,PA,Doylestown,173.49.91.231,no_relation,191,133,,197,141,is location of,0.410997468263393,905412-FS1-9,Lacunes consist of small vascular lesions with a volume of between 2 and about 30 mm. These lacunar infarctions are determined by an ISCHEMIA caused by obstructive diseases of small terminal VESSELS in the deep areas of the brain.,VESSELS,ISCHEMIA,RO-has_finding_site
502912500,7/14/2014 14:25:17,,1322880608,7/14/2014 14:24:41,neodev,0.4306,21515166,NLD,11,Nootdorp,83.86.58.179,VESSELS is location of ISCHEMIA,191,133,,197,141,is location of,0.410997468263393,905412-FS1-9,Lacunes consist of small vascular lesions with a volume of between 2 and about 30 mm. These lacunar infarctions are determined by an ISCHEMIA caused by obstructive diseases of small terminal VESSELS in the deep areas of the brain.,VESSELS,ISCHEMIA,RO-has_finding_site
502912500,7/14/2014 14:34:59,,1322887518,7/14/2014 14:34:43,rewardsspot,0.57,17763704,USA,IL,Chicago,67.212.175.123,VESSELS is location of ISCHEMIA,191,133,,197,141,is location of,0.410997468263393,905412-FS1-9,Lacunes consist of small vascular lesions with a volume of between 2 and about 30 mm. These lacunar infarctions are determined by an ISCHEMIA caused by obstructive diseases of small terminal VESSELS in the deep areas of the brain.,VESSELS,ISCHEMIA,RO-has_finding_site
502912500,7/14/2014 14:56:26,,1322901237,7/14/2014 14:56:11,elite,0.4302,28276268,USA,MI,Taylor,67.149.247.166,ISCHEMIA is location of VESSELS,191,133,,197,141,is location of,0.410997468263393,905412-FS1-9,Lacunes consist of small vascular lesions with a volume of between 2 and about 30 mm. These lacunar infarctions are determined by an ISCHEMIA caused by obstructive diseases of small terminal VESSELS in the deep areas of the brain.,VESSELS,ISCHEMIA,RO-has_finding_site
502912500,7/14/2014 15:03:11,,1322905352,7/14/2014 15:02:23,vivatic,0.5339,25451531,GBR,"","",83.67.28.193,VESSELS is location of ISCHEMIA,191,133,,197,141,is location of,0.410997468263393,905412-FS1-9,Lacunes consist of small vascular lesions with a volume of between 2 and about 30 mm. These lacunar infarctions are determined by an ISCHEMIA caused by obstructive diseases of small terminal VESSELS in the deep areas of the brain.,VESSELS,ISCHEMIA,RO-has_finding_site
502912501,7/14/2014 12:34:40,,1322804414,7/14/2014 12:34:15,clixsense,0.9583,27871219,NLD,07,Amsterdam,87.210.207.223,NEUROENDOCRINE DIFFERENTIATION causes SMALL CELL CARCINOMA,202,304,,231,324,causes,0.64699663922063,901816-FS1-4,"In investigation on carcinogenesis the first reports were published on the use of antisense oligonucleotides during inhibition of the development of tumours by a humoral mechanism and on the gene based NEUROENDOCRINE DIFFERENTIATION of the lungs, perhaps associated with the basis for the development of SMALL CELL CARCINOMA",NEUROENDOCRINE DIFFERENTIATION,SMALL CELL CARCINOMA,RO-disease_has_finding
502912501,7/14/2014 12:43:27,,1322810394,7/14/2014 12:43:20,clixsense,0.875,25419319,GBR,H8,Liverpool,94.4.192.228,NEUROENDOCRINE DIFFERENTIATION causes SMALL CELL CARCINOMA,202,304,,231,324,causes,0.64699663922063,901816-FS1-4,"In investigation on carcinogenesis the first reports were published on the use of antisense oligonucleotides during inhibition of the development of tumours by a humoral mechanism and on the gene based NEUROENDOCRINE DIFFERENTIATION of the lungs, perhaps associated with the basis for the development of SMALL CELL CARCINOMA",NEUROENDOCRINE DIFFERENTIATION,SMALL CELL CARCINOMA,RO-disease_has_finding
502912501,7/14/2014 13:21:16,,1322835777,7/14/2014 13:20:17,clixsense,0.7,24896327,GBR,V2,Glasgow,94.2.231.4,SMALL CELL CARCINOMA causes NEUROENDOCRINE DIFFERENTIATION,202,304,,231,324,causes,0.64699663922063,901816-FS1-4,"In investigation on carcinogenesis the first reports were published on the use of antisense oligonucleotides during inhibition of the development of tumours by a humoral mechanism and on the gene based NEUROENDOCRINE DIFFERENTIATION of the lungs, perhaps associated with the basis for the development of SMALL CELL CARCINOMA",NEUROENDOCRINE DIFFERENTIATION,SMALL CELL CARCINOMA,RO-disease_has_finding
502912501,7/14/2014 15:18:04,,1322913146,7/14/2014 15:17:54,clixsense,0.4823,19162475,GBR,M3,Frome,82.33.126.30,NEUROENDOCRINE DIFFERENTIATION causes SMALL CELL CARCINOMA,202,304,,231,324,causes,0.64699663922063,901816-FS1-4,"In investigation on carcinogenesis the first reports were published on the use of antisense oligonucleotides during inhibition of the development of tumours by a humoral mechanism and on the gene based NEUROENDOCRINE DIFFERENTIATION of the lungs, perhaps associated with the basis for the development of SMALL CELL CARCINOMA",NEUROENDOCRINE DIFFERENTIATION,SMALL CELL CARCINOMA,RO-disease_has_finding
502912501,7/14/2014 15:20:59,,1322914883,7/14/2014 15:20:05,prodege,0.639,27996604,CAN,QC,Boucherville,24.201.21.27,NEUROENDOCRINE DIFFERENTIATION causes SMALL CELL CARCINOMA,202,304,,231,324,causes,0.64699663922063,901816-FS1-4,"In investigation on carcinogenesis the first reports were published on the use of antisense oligonucleotides during inhibition of the development of tumours by a humoral mechanism and on the gene based NEUROENDOCRINE DIFFERENTIATION of the lungs, perhaps associated with the basis for the development of SMALL CELL CARCINOMA",NEUROENDOCRINE DIFFERENTIATION,SMALL CELL CARCINOMA,RO-disease_has_finding
502912501,7/14/2014 15:25:00,,1322917251,7/14/2014 15:23:41,clixsense,0.4244,26889820,GBR,C3,Shelford,92.18.120.203,NEUROENDOCRINE DIFFERENTIATION causes SMALL CELL CARCINOMA,202,304,,231,324,causes,0.64699663922063,901816-FS1-4,"In investigation on carcinogenesis the first reports were published on the use of antisense oligonucleotides during inhibition of the development of tumours by a humoral mechanism and on the gene based NEUROENDOCRINE DIFFERENTIATION of the lungs, perhaps associated with the basis for the development of SMALL CELL CARCINOMA",NEUROENDOCRINE DIFFERENTIATION,SMALL CELL CARCINOMA,RO-disease_has_finding
502912501,7/14/2014 15:30:27,,1322920536,7/14/2014 15:30:11,prodege,0.5494,2143114,CAN,BC,Vancouver,24.84.160.12,NEUROENDOCRINE DIFFERENTIATION causes SMALL CELL CARCINOMA,202,304,,231,324,causes,0.64699663922063,901816-FS1-4,"In investigation on carcinogenesis the first reports were published on the use of antisense oligonucleotides during inhibition of the development of tumours by a humoral mechanism and on the gene based NEUROENDOCRINE DIFFERENTIATION of the lungs, perhaps associated with the basis for the development of SMALL CELL CARCINOMA",NEUROENDOCRINE DIFFERENTIATION,SMALL CELL CARCINOMA,RO-disease_has_finding
502912502,7/14/2014 13:07:23,,1322826303,7/14/2014 13:06:58,prodege,0.6278,11616695,GBR,P7,Wigan,92.29.199.166,no_relation,196,183,,215,195,causes,0.741998516004452,903523-FS1-4,"Of the 5,442 ticks collected, 90% (4,893) were the winter tick, Dermacentor albipictus, and 10% (549) were the deer tick, Ixodes dammini, the primary vector of the causative agent of LYME DISEASE BORRELIA BURGDORFERI",BORRELIA BURGDORFERI,LYME DISEASE,RO-has_causative_agent
502912502,7/14/2014 14:23:09,,1322878963,7/14/2014 14:23:01,neodev,0.3792,25224036,CAN,ON,Sudbury,67.204.218.187,LYME DISEASE causes BORRELIA BURGDORFERI,196,183,,215,195,causes,0.741998516004452,903523-FS1-4,"Of the 5,442 ticks collected, 90% (4,893) were the winter tick, Dermacentor albipictus, and 10% (549) were the deer tick, Ixodes dammini, the primary vector of the causative agent of LYME DISEASE BORRELIA BURGDORFERI",BORRELIA BURGDORFERI,LYME DISEASE,RO-has_causative_agent
502912502,7/14/2014 14:36:01,,1322888242,7/14/2014 14:35:43,rewardsspot,0.57,17763704,USA,IL,Chicago,67.212.175.123,BORRELIA BURGDORFERI causes LYME DISEASE,196,183,,215,195,causes,0.741998516004452,903523-FS1-4,"Of the 5,442 ticks collected, 90% (4,893) were the winter tick, Dermacentor albipictus, and 10% (549) were the deer tick, Ixodes dammini, the primary vector of the causative agent of LYME DISEASE BORRELIA BURGDORFERI",BORRELIA BURGDORFERI,LYME DISEASE,RO-has_causative_agent
502912502,7/14/2014 14:45:45,,1322894854,7/14/2014 14:45:40,instagc,0.4611,27753923,GBR,"","",188.30.192.65,BORRELIA BURGDORFERI causes LYME DISEASE,196,183,,215,195,causes,0.741998516004452,903523-FS1-4,"Of the 5,442 ticks collected, 90% (4,893) were the winter tick, Dermacentor albipictus, and 10% (549) were the deer tick, Ixodes dammini, the primary vector of the causative agent of LYME DISEASE BORRELIA BURGDORFERI",BORRELIA BURGDORFERI,LYME DISEASE,RO-has_causative_agent
502912502,7/14/2014 15:11:43,,1322909938,7/14/2014 15:11:07,clixsense,0.5718,19803139,NLD,06,Veldhoven,212.61.84.196,no_relation,196,183,,215,195,causes,0.741998516004452,903523-FS1-4,"Of the 5,442 ticks collected, 90% (4,893) were the winter tick, Dermacentor albipictus, and 10% (549) were the deer tick, Ixodes dammini, the primary vector of the causative agent of LYME DISEASE BORRELIA BURGDORFERI",BORRELIA BURGDORFERI,LYME DISEASE,RO-has_causative_agent
502912502,7/14/2014 15:18:49,,1322913589,7/14/2014 15:18:43,clixsense,0.4823,19162475,GBR,M3,Frome,82.33.126.30,BORRELIA BURGDORFERI causes LYME DISEASE,196,183,,215,195,causes,0.741998516004452,903523-FS1-4,"Of the 5,442 ticks collected, 90% (4,893) were the winter tick, Dermacentor albipictus, and 10% (549) were the deer tick, Ixodes dammini, the primary vector of the causative agent of LYME DISEASE BORRELIA BURGDORFERI",BORRELIA BURGDORFERI,LYME DISEASE,RO-has_causative_agent
502912502,7/14/2014 15:23:40,,1322916529,7/14/2014 15:23:09,clixsense,0.4244,26889820,GBR,C3,Shelford,92.18.120.203,no_relation,196,183,,215,195,causes,0.741998516004452,903523-FS1-4,"Of the 5,442 ticks collected, 90% (4,893) were the winter tick, Dermacentor albipictus, and 10% (549) were the deer tick, Ixodes dammini, the primary vector of the causative agent of LYME DISEASE BORRELIA BURGDORFERI",BORRELIA BURGDORFERI,LYME DISEASE,RO-has_causative_agent
502912503,7/14/2014 12:35:54,,1322805142,7/14/2014 12:35:01,clixsense,0.9583,27871219,NLD,07,Amsterdam,87.210.207.223,ERECTILE DYSFUNCTION diagnosed by PAPAVERINE,84,121,,103,131,diagnosed by,0.755928946018454,906676-FS1-13,To evaluate the use of papaverine induced erection as a diagnostic test in men with ERECTILE DYSFUNCTION 24 patients had PAPAVERINE injected into the corpus cavernosum.,ERECTILE DYSFUNCTION,PAPAVERINE,RO-may_diagnose
502912503,7/14/2014 13:06:27,,1322825692,7/14/2014 13:05:49,prodege,0.6278,11616695,GBR,P7,Wigan,92.29.199.166,no_relation,84,121,,103,131,diagnosed by,0.755928946018454,906676-FS1-13,To evaluate the use of papaverine induced erection as a diagnostic test in men with ERECTILE DYSFUNCTION 24 patients had PAPAVERINE injected into the corpus cavernosum.,ERECTILE DYSFUNCTION,PAPAVERINE,RO-may_diagnose
502912503,7/14/2014 13:41:10,,1322849854,7/14/2014 13:40:41,prodege,0.6181,17982533,GBR,H3,Leeds,90.193.39.185,no_relation,84,121,,103,131,diagnosed by,0.755928946018454,906676-FS1-13,To evaluate the use of papaverine induced erection as a diagnostic test in men with ERECTILE DYSFUNCTION 24 patients had PAPAVERINE injected into the corpus cavernosum.,ERECTILE DYSFUNCTION,PAPAVERINE,RO-may_diagnose
502912503,7/14/2014 13:50:16,,1322856575,7/14/2014 13:49:47,clixsense,0.4042,25402344,CAN,ON,Wawa,24.109.124.45,PAPAVERINE diagnosed by ERECTILE DYSFUNCTION,84,121,,103,131,diagnosed by,0.755928946018454,906676-FS1-13,To evaluate the use of papaverine induced erection as a diagnostic test in men with ERECTILE DYSFUNCTION 24 patients had PAPAVERINE injected into the corpus cavernosum.,ERECTILE DYSFUNCTION,PAPAVERINE,RO-may_diagnose
502912503,7/14/2014 14:26:22,,1322881364,7/14/2014 14:25:55,neodev,0.4306,21515166,NLD,11,Nootdorp,83.86.58.179,no_relation,84,121,,103,131,diagnosed by,0.755928946018454,906676-FS1-13,To evaluate the use of papaverine induced erection as a diagnostic test in men with ERECTILE DYSFUNCTION 24 patients had PAPAVERINE injected into the corpus cavernosum.,ERECTILE DYSFUNCTION,PAPAVERINE,RO-may_diagnose
502912503,7/14/2014 15:05:58,,1322906900,7/14/2014 15:05:07,instagc,0.7125,28519532,USA,IA,Honey Creek,12.73.110.26,ERECTILE DYSFUNCTION diagnosed by PAPAVERINE,84,121,,103,131,diagnosed by,0.755928946018454,906676-FS1-13,To evaluate the use of papaverine induced erection as a diagnostic test in men with ERECTILE DYSFUNCTION 24 patients had PAPAVERINE injected into the corpus cavernosum.,ERECTILE DYSFUNCTION,PAPAVERINE,RO-may_diagnose
502912503,7/14/2014 15:12:55,,1322910455,7/14/2014 15:12:11,elite,0.4429,28322695,GBR,A3,Barnsley,217.44.205.195,no_relation,84,121,,103,131,diagnosed by,0.755928946018454,906676-FS1-13,To evaluate the use of papaverine induced erection as a diagnostic test in men with ERECTILE DYSFUNCTION 24 patients had PAPAVERINE injected into the corpus cavernosum.,ERECTILE DYSFUNCTION,PAPAVERINE,RO-may_diagnose
502912504,7/14/2014 13:03:35,,1322823826,7/14/2014 13:02:49,rewardsspot,0.7153,24482174,GBR,H9,London,46.23.68.180,ALLERGY causes VERNAL KERATOCONJUNCTIVITIS,222,337,,248,344,causes,0.842700971600384,900163-FS1-4,"Allergic eye diseases are characterized by IgE mast cell mediated, as seen in allergic conjunctivitis; chronic mast cell activation and eosinophil/T lymphocyte mediated response, as seen in giant papillary conjunctivitis, VERNAL KERATOCONJUNCTIVITIS and atopic keratoconjunctivitis; or a T lymphocyte mediated response in contact ocular ALLERGY",VERNAL KERATOCONJUNCTIVITIS,ALLERGY,RO-cause_of
502912504,7/14/2014 14:16:57,,1322874736,7/14/2014 14:16:48,clixsense,0.5125,7415230,GBR,A7,Birmingham,147.188.47.242,no_relation,222,337,,248,344,causes,0.842700971600384,900163-FS1-4,"Allergic eye diseases are characterized by IgE mast cell mediated, as seen in allergic conjunctivitis; chronic mast cell activation and eosinophil/T lymphocyte mediated response, as seen in giant papillary conjunctivitis, VERNAL KERATOCONJUNCTIVITIS and atopic keratoconjunctivitis; or a T lymphocyte mediated response in contact ocular ALLERGY",VERNAL KERATOCONJUNCTIVITIS,ALLERGY,RO-cause_of
502912504,7/14/2014 14:23:23,,1322879131,7/14/2014 14:23:18,neodev,0.3792,25224036,CAN,ON,Sudbury,67.204.218.187,VERNAL KERATOCONJUNCTIVITIS causes ALLERGY,222,337,,248,344,causes,0.842700971600384,900163-FS1-4,"Allergic eye diseases are characterized by IgE mast cell mediated, as seen in allergic conjunctivitis; chronic mast cell activation and eosinophil/T lymphocyte mediated response, as seen in giant papillary conjunctivitis, VERNAL KERATOCONJUNCTIVITIS and atopic keratoconjunctivitis; or a T lymphocyte mediated response in contact ocular ALLERGY",VERNAL KERATOCONJUNCTIVITIS,ALLERGY,RO-cause_of
502912504,7/14/2014 14:35:20,,1322887872,7/14/2014 14:35:01,rewardsspot,0.57,17763704,USA,IL,Chicago,67.212.175.123,ALLERGY causes VERNAL KERATOCONJUNCTIVITIS,222,337,,248,344,causes,0.842700971600384,900163-FS1-4,"Allergic eye diseases are characterized by IgE mast cell mediated, as seen in allergic conjunctivitis; chronic mast cell activation and eosinophil/T lymphocyte mediated response, as seen in giant papillary conjunctivitis, VERNAL KERATOCONJUNCTIVITIS and atopic keratoconjunctivitis; or a T lymphocyte mediated response in contact ocular ALLERGY",VERNAL KERATOCONJUNCTIVITIS,ALLERGY,RO-cause_of
502912504,7/14/2014 14:56:25,,1322901218,7/14/2014 14:55:54,instagc,0.6593,13763729,USA,"","",75.182.89.225,ALLERGY causes VERNAL KERATOCONJUNCTIVITIS,222,337,,248,344,causes,0.842700971600384,900163-FS1-4,"Allergic eye diseases are characterized by IgE mast cell mediated, as seen in allergic conjunctivitis; chronic mast cell activation and eosinophil/T lymphocyte mediated response, as seen in giant papillary conjunctivitis, VERNAL KERATOCONJUNCTIVITIS and atopic keratoconjunctivitis; or a T lymphocyte mediated response in contact ocular ALLERGY",VERNAL KERATOCONJUNCTIVITIS,ALLERGY,RO-cause_of
502912504,7/14/2014 15:18:31,,1322913427,7/14/2014 15:18:24,clixsense,0.4823,19162475,GBR,M3,Frome,82.33.126.30,VERNAL KERATOCONJUNCTIVITIS causes ALLERGY,222,337,,248,344,causes,0.842700971600384,900163-FS1-4,"Allergic eye diseases are characterized by IgE mast cell mediated, as seen in allergic conjunctivitis; chronic mast cell activation and eosinophil/T lymphocyte mediated response, as seen in giant papillary conjunctivitis, VERNAL KERATOCONJUNCTIVITIS and atopic keratoconjunctivitis; or a T lymphocyte mediated response in contact ocular ALLERGY",VERNAL KERATOCONJUNCTIVITIS,ALLERGY,RO-cause_of
502912504,7/14/2014 15:59:31,,1322937010,7/14/2014 15:58:56,prodege,0.5,28039757,GBR,L8,Southport,109.155.158.54,no_relation,222,337,,248,344,causes,0.842700971600384,900163-FS1-4,"Allergic eye diseases are characterized by IgE mast cell mediated, as seen in allergic conjunctivitis; chronic mast cell activation and eosinophil/T lymphocyte mediated response, as seen in giant papillary conjunctivitis, VERNAL KERATOCONJUNCTIVITIS and atopic keratoconjunctivitis; or a T lymphocyte mediated response in contact ocular ALLERGY",VERNAL KERATOCONJUNCTIVITIS,ALLERGY,RO-cause_of
502912505,7/14/2014 12:49:46,,1322814556,7/14/2014 12:49:11,elite,0.75,27433978,AUS,05,Plympton,110.174.120.88,no_relation,120,44,,143,56,treats,0.733016666137831,904726-FS1-2,The number of patients with well controlled HYPERTENSION is alarmingly low worldwide and new approaches to treatment of INCREASED BLOOD PRESSURE (BP) are being sought.,INCREASED BLOOD PRESSURE,HYPERTENSION,RO-has_definitional_manifestation
502912505,7/14/2014 12:57:06,,1322819539,7/14/2014 12:56:15,clixsense,0.8194,15189335,GBR,K3,Peterborough,81.156.166.189,no_relation,120,44,,143,56,treats,0.733016666137831,904726-FS1-2,The number of patients with well controlled HYPERTENSION is alarmingly low worldwide and new approaches to treatment of INCREASED BLOOD PRESSURE (BP) are being sought.,INCREASED BLOOD PRESSURE,HYPERTENSION,RO-has_definitional_manifestation
502912505,7/14/2014 13:50:45,,1322856910,7/14/2014 13:50:16,clixsense,0.4042,25402344,CAN,ON,Wawa,24.109.124.45,HYPERTENSION treats INCREASED BLOOD PRESSURE,120,44,,143,56,treats,0.733016666137831,904726-FS1-2,The number of patients with well controlled HYPERTENSION is alarmingly low worldwide and new approaches to treatment of INCREASED BLOOD PRESSURE (BP) are being sought.,INCREASED BLOOD PRESSURE,HYPERTENSION,RO-has_definitional_manifestation
502912505,7/14/2014 13:53:24,,1322858900,7/14/2014 13:53:01,zoombucks,0.7764,5919735,USA,PA,Doylestown,173.49.91.231,no_relation,120,44,,143,56,treats,0.733016666137831,904726-FS1-2,The number of patients with well controlled HYPERTENSION is alarmingly low worldwide and new approaches to treatment of INCREASED BLOOD PRESSURE (BP) are being sought.,INCREASED BLOOD PRESSURE,HYPERTENSION,RO-has_definitional_manifestation
502912505,7/14/2014 14:23:16,,1322879058,7/14/2014 14:23:10,neodev,0.3792,25224036,CAN,ON,Sudbury,67.204.218.187,INCREASED BLOOD PRESSURE treats HYPERTENSION,120,44,,143,56,treats,0.733016666137831,904726-FS1-2,The number of patients with well controlled HYPERTENSION is alarmingly low worldwide and new approaches to treatment of INCREASED BLOOD PRESSURE (BP) are being sought.,INCREASED BLOOD PRESSURE,HYPERTENSION,RO-has_definitional_manifestation
502912505,7/14/2014 14:57:27,,1322901969,7/14/2014 14:57:10,elite,0.4302,28276268,USA,MI,Taylor,67.149.247.166,HYPERTENSION treats INCREASED BLOOD PRESSURE,120,44,,143,56,treats,0.733016666137831,904726-FS1-2,The number of patients with well controlled HYPERTENSION is alarmingly low worldwide and new approaches to treatment of INCREASED BLOOD PRESSURE (BP) are being sought.,INCREASED BLOOD PRESSURE,HYPERTENSION,RO-has_definitional_manifestation
502912505,7/14/2014 15:01:41,,1322904539,7/14/2014 15:01:08,vivatic,0.5339,25451531,GBR,"","",83.67.28.193,no_relation,120,44,,143,56,treats,0.733016666137831,904726-FS1-2,The number of patients with well controlled HYPERTENSION is alarmingly low worldwide and new approaches to treatment of INCREASED BLOOD PRESSURE (BP) are being sought.,INCREASED BLOOD PRESSURE,HYPERTENSION,RO-has_definitional_manifestation
502912506,7/14/2014 12:43:46,,1322810605,7/14/2014 12:43:41,clixsense,0.875,25419319,GBR,H8,Liverpool,94.4.192.228,HEPATITIS A causes HEPATITIS A VIRUS,52,22,,68,33,causes,0.9,903786-FS1-4,Update: Prevention of HEPATITIS A after exposure to HEPATITIS A VIRUS and in international travelers.,HEPATITIS A VIRUS,HEPATITIS A,RO-has_causative_agent
502912506,7/14/2014 12:46:36,,1322812400,7/14/2014 12:45:53,elite,0.75,27433978,AUS,05,Plympton,110.174.120.88,HEPATITIS A VIRUS causes HEPATITIS A,52,22,,68,33,causes,0.9,903786-FS1-4,Update: Prevention of HEPATITIS A after exposure to HEPATITIS A VIRUS and in international travelers.,HEPATITIS A VIRUS,HEPATITIS A,RO-has_causative_agent
502912506,7/14/2014 13:06:57,,1322826000,7/14/2014 13:06:28,prodege,0.6278,11616695,GBR,P7,Wigan,92.29.199.166,HEPATITIS A VIRUS causes HEPATITIS A,52,22,,68,33,causes,0.9,903786-FS1-4,Update: Prevention of HEPATITIS A after exposure to HEPATITIS A VIRUS and in international travelers.,HEPATITIS A VIRUS,HEPATITIS A,RO-has_causative_agent
502912506,7/14/2014 14:10:21,,1322870120,7/14/2014 14:10:07,clixsense,0.7708,27793793,GBR,C5,Chester,151.230.27.155,HEPATITIS A VIRUS causes HEPATITIS A,52,22,,68,33,causes,0.9,903786-FS1-4,Update: Prevention of HEPATITIS A after exposure to HEPATITIS A VIRUS and in international travelers.,HEPATITIS A VIRUS,HEPATITIS A,RO-has_causative_agent
502912506,7/14/2014 15:18:32,,1322913413,7/14/2014 15:17:59,prodege,0.639,27996604,CAN,QC,Boucherville,24.201.21.27,HEPATITIS A VIRUS causes HEPATITIS A,52,22,,68,33,causes,0.9,903786-FS1-4,Update: Prevention of HEPATITIS A after exposure to HEPATITIS A VIRUS and in international travelers.,HEPATITIS A VIRUS,HEPATITIS A,RO-has_causative_agent
502912506,7/14/2014 15:31:44,,1322921309,7/14/2014 15:31:09,gifthulk,0.6484,21916793,GBR,"","",87.113.87.199,HEPATITIS A VIRUS causes HEPATITIS A,52,22,,68,33,causes,0.9,903786-FS1-4,Update: Prevention of HEPATITIS A after exposure to HEPATITIS A VIRUS and in international travelers.,HEPATITIS A VIRUS,HEPATITIS A,RO-has_causative_agent
502912506,7/14/2014 15:36:32,,1322924180,7/14/2014 15:36:03,clixsense,0.6484,19638651,USA,"","",173.23.121.63,HEPATITIS A VIRUS causes HEPATITIS A,52,22,,68,33,causes,0.9,903786-FS1-4,Update: Prevention of HEPATITIS A after exposure to HEPATITIS A VIRUS and in international travelers.,HEPATITIS A VIRUS,HEPATITIS A,RO-has_causative_agent
502912507,7/14/2014 13:06:57,,1322826001,7/14/2014 13:06:28,prodege,0.6278,11616695,GBR,P7,Wigan,92.29.199.166,DRASH SYNDROME contraindicates NEPHROPATHY,23,79,,33,93,contraindicates,0.474341649025257,906144-FS1-10,Gonadal dysgenesis and NEPHROPATHY are often indistinguishable from incomplete DRASH SYNDROME,NEPHROPATHY,DRASH SYNDROME,RO-has_manifestation
502912507,7/14/2014 13:22:18,,1322836567,7/14/2014 13:21:50,neodev,0.6667,19004420,GBR,M3,Bridgwater,86.160.70.204,no_relation,23,79,,33,93,contraindicates,0.474341649025257,906144-FS1-10,Gonadal dysgenesis and NEPHROPATHY are often indistinguishable from incomplete DRASH SYNDROME,NEPHROPATHY,DRASH SYNDROME,RO-has_manifestation
502912507,7/14/2014 15:01:10,,1322904215,7/14/2014 15:00:50,instagc,0.5536,18960682,GBR,"","",86.29.147.112,NEPHROPATHY contraindicates DRASH SYNDROME,23,79,,33,93,contraindicates,0.474341649025257,906144-FS1-10,Gonadal dysgenesis and NEPHROPATHY are often indistinguishable from incomplete DRASH SYNDROME,NEPHROPATHY,DRASH SYNDROME,RO-has_manifestation
502912507,7/14/2014 15:11:43,,1322909939,7/14/2014 15:11:07,clixsense,0.5718,19803139,NLD,06,Veldhoven,212.61.84.196,DRASH SYNDROME contraindicates NEPHROPATHY,23,79,,33,93,contraindicates,0.474341649025257,906144-FS1-10,Gonadal dysgenesis and NEPHROPATHY are often indistinguishable from incomplete DRASH SYNDROME,NEPHROPATHY,DRASH SYNDROME,RO-has_manifestation
502912507,7/14/2014 15:13:45,,1322910788,7/14/2014 15:12:55,elite,0.4429,28322695,GBR,A3,Barnsley,217.44.205.195,NEPHROPATHY contraindicates DRASH SYNDROME,23,79,,33,93,contraindicates,0.474341649025257,906144-FS1-10,Gonadal dysgenesis and NEPHROPATHY are often indistinguishable from incomplete DRASH SYNDROME,NEPHROPATHY,DRASH SYNDROME,RO-has_manifestation
502912507,7/14/2014 15:20:04,,1322914317,7/14/2014 15:19:31,prodege,0.639,27996604,CAN,QC,Boucherville,24.201.21.27,no_relation,23,79,,33,93,contraindicates,0.474341649025257,906144-FS1-10,Gonadal dysgenesis and NEPHROPATHY are often indistinguishable from incomplete DRASH SYNDROME,NEPHROPATHY,DRASH SYNDROME,RO-has_manifestation
502912507,7/14/2014 15:30:44,,1322920707,7/14/2014 15:30:38,prodege,0.5494,2143114,CAN,BC,Vancouver,24.84.160.12,NEPHROPATHY contraindicates DRASH SYNDROME,23,79,,33,93,contraindicates,0.474341649025257,906144-FS1-10,Gonadal dysgenesis and NEPHROPATHY are often indistinguishable from incomplete DRASH SYNDROME,NEPHROPATHY,DRASH SYNDROME,RO-has_manifestation
502912508,7/14/2014 12:34:21,,1322804218,7/14/2014 12:34:16,neodev,0.9583,17610000,GBR,I2,Manchester,90.200.140.201,ESOPHAGUS treats ESOPHAGEAL CANCER,122,32,,130,49,treats,0.477334370505438,902460-FS1-2,"Since 1982, three patients with ESOPHAGEAL CANCER complicated with pulmonary bullae have been treated by operation on the ESOPHAGUS and lung in one performance: In all the patients, the bullae were on the same side of the operation.",ESOPHAGUS,ESOPHAGEAL CANCER,RO-disease_has_primary_anatomic_site
502912508,7/14/2014 12:47:15,,1322812851,7/14/2014 12:46:37,elite,0.75,27433978,AUS,05,Plympton,110.174.120.88,no_relation,122,32,,130,49,treats,0.477334370505438,902460-FS1-2,"Since 1982, three patients with ESOPHAGEAL CANCER complicated with pulmonary bullae have been treated by operation on the ESOPHAGUS and lung in one performance: In all the patients, the bullae were on the same side of the operation.",ESOPHAGUS,ESOPHAGEAL CANCER,RO-disease_has_primary_anatomic_site
502912508,7/14/2014 12:57:06,,1322819528,7/14/2014 12:56:15,clixsense,0.8194,15189335,GBR,K3,Peterborough,81.156.166.189,no_relation,122,32,,130,49,treats,0.477334370505438,902460-FS1-2,"Since 1982, three patients with ESOPHAGEAL CANCER complicated with pulmonary bullae have been treated by operation on the ESOPHAGUS and lung in one performance: In all the patients, the bullae were on the same side of the operation.",ESOPHAGUS,ESOPHAGEAL CANCER,RO-disease_has_primary_anatomic_site
502912508,7/14/2014 13:18:19,,1322833773,7/14/2014 13:17:21,clixsense,0.7,24896327,GBR,V2,Glasgow,94.2.231.4,no_relation,122,32,,130,49,treats,0.477334370505438,902460-FS1-2,"Since 1982, three patients with ESOPHAGEAL CANCER complicated with pulmonary bullae have been treated by operation on the ESOPHAGUS and lung in one performance: In all the patients, the bullae were on the same side of the operation.",ESOPHAGUS,ESOPHAGEAL CANCER,RO-disease_has_primary_anatomic_site
502912508,7/14/2014 14:31:51,,1322885508,7/14/2014 14:31:46,instagc,0.644,15445601,USA,FL,Jacksonville,24.129.68.254,no_relation,122,32,,130,49,treats,0.477334370505438,902460-FS1-2,"Since 1982, three patients with ESOPHAGEAL CANCER complicated with pulmonary bullae have been treated by operation on the ESOPHAGUS and lung in one performance: In all the patients, the bullae were on the same side of the operation.",ESOPHAGUS,ESOPHAGEAL CANCER,RO-disease_has_primary_anatomic_site
502912508,7/14/2014 15:04:29,,1322906178,7/14/2014 15:03:54,instagc,0.7125,28519532,USA,IA,Honey Creek,12.73.110.26,no_relation,122,32,,130,49,treats,0.477334370505438,902460-FS1-2,"Since 1982, three patients with ESOPHAGEAL CANCER complicated with pulmonary bullae have been treated by operation on the ESOPHAGUS and lung in one performance: In all the patients, the bullae were on the same side of the operation.",ESOPHAGUS,ESOPHAGEAL CANCER,RO-disease_has_primary_anatomic_site
502912508,7/14/2014 15:19:29,,1322914008,7/14/2014 15:18:33,prodege,0.639,27996604,CAN,QC,Boucherville,24.201.21.27,no_relation,122,32,,130,49,treats,0.477334370505438,902460-FS1-2,"Since 1982, three patients with ESOPHAGEAL CANCER complicated with pulmonary bullae have been treated by operation on the ESOPHAGUS and lung in one performance: In all the patients, the bullae were on the same side of the operation.",ESOPHAGUS,ESOPHAGEAL CANCER,RO-disease_has_primary_anatomic_site
502912509,7/14/2014 13:39:49,,1322848951,7/14/2014 13:39:00,prodege,0.6181,17982533,GBR,H3,Leeds,90.193.39.185,PAPAVERINE treats ERECTILE DYSFUNCTION,84,121,,103,131,treats,0.629940788348712,906676-FS1-2,To evaluate the use of papaverine induced erection as a diagnostic test in men with ERECTILE DYSFUNCTION 24 patients had PAPAVERINE injected into the corpus cavernosum.,ERECTILE DYSFUNCTION,PAPAVERINE,RO-may_diagnose
502912509,7/14/2014 15:18:31,,1322913429,7/14/2014 15:18:24,clixsense,0.4823,19162475,GBR,M3,Frome,82.33.126.30,PAPAVERINE treats ERECTILE DYSFUNCTION,84,121,,103,131,treats,0.629940788348712,906676-FS1-2,To evaluate the use of papaverine induced erection as a diagnostic test in men with ERECTILE DYSFUNCTION 24 patients had PAPAVERINE injected into the corpus cavernosum.,ERECTILE DYSFUNCTION,PAPAVERINE,RO-may_diagnose
502912509,7/14/2014 15:30:09,,1322920427,7/14/2014 15:29:58,prodege,0.5494,2143114,CAN,BC,Vancouver,24.84.160.12,PAPAVERINE treats ERECTILE DYSFUNCTION,84,121,,103,131,treats,0.629940788348712,906676-FS1-2,To evaluate the use of papaverine induced erection as a diagnostic test in men with ERECTILE DYSFUNCTION 24 patients had PAPAVERINE injected into the corpus cavernosum.,ERECTILE DYSFUNCTION,PAPAVERINE,RO-may_diagnose
502912509,7/14/2014 15:31:44,,1322921308,7/14/2014 15:31:09,gifthulk,0.6484,21916793,GBR,"","",87.113.87.199,PAPAVERINE treats ERECTILE DYSFUNCTION,84,121,,103,131,treats,0.629940788348712,906676-FS1-2,To evaluate the use of papaverine induced erection as a diagnostic test in men with ERECTILE DYSFUNCTION 24 patients had PAPAVERINE injected into the corpus cavernosum.,ERECTILE DYSFUNCTION,PAPAVERINE,RO-may_diagnose
502912509,7/14/2014 15:36:32,,1322924182,7/14/2014 15:36:03,clixsense,0.6484,19638651,USA,"","",173.23.121.63,PAPAVERINE treats ERECTILE DYSFUNCTION,84,121,,103,131,treats,0.629940788348712,906676-FS1-2,To evaluate the use of papaverine induced erection as a diagnostic test in men with ERECTILE DYSFUNCTION 24 patients had PAPAVERINE injected into the corpus cavernosum.,ERECTILE DYSFUNCTION,PAPAVERINE,RO-may_diagnose
502912509,7/14/2014 15:53:42,,1322933718,7/14/2014 15:53:19,clixsense,0.573,22177255,USA,CA,San Francisco,73.32.39.90,PAPAVERINE treats ERECTILE DYSFUNCTION,84,121,,103,131,treats,0.629940788348712,906676-FS1-2,To evaluate the use of papaverine induced erection as a diagnostic test in men with ERECTILE DYSFUNCTION 24 patients had PAPAVERINE injected into the corpus cavernosum.,ERECTILE DYSFUNCTION,PAPAVERINE,RO-may_diagnose
502912509,7/14/2014 15:57:52,,1322936089,7/14/2014 15:57:15,prodege,0.5,28039757,GBR,L8,Southport,109.155.158.54,no_relation,84,121,,103,131,treats,0.629940788348712,906676-FS1-2,To evaluate the use of papaverine induced erection as a diagnostic test in men with ERECTILE DYSFUNCTION 24 patients had PAPAVERINE injected into the corpus cavernosum.,ERECTILE DYSFUNCTION,PAPAVERINE,RO-may_diagnose
502912510,7/14/2014 12:43:53,,1322810634,7/14/2014 12:43:47,clixsense,0.875,25419319,GBR,H8,Liverpool,94.4.192.228,WHIPPLE'S DISEASE causes BACTERIUM,65,124,,73,141,causes,0.64699663922063,903809-FS1-4,This is in accordance with the phylogenetic relationship of this BACTERIUM as well as with known epidemiological aspects of WHIPPLE'S DISEASE,BACTERIUM,WHIPPLE'S DISEASE,RO-has_causative_agent
502912510,7/14/2014 12:44:23,,1322810937,7/14/2014 12:43:21,elite,0.75,27433978,AUS,05,Plympton,110.174.120.88,BACTERIUM causes WHIPPLE'S DISEASE,65,124,,73,141,causes,0.64699663922063,903809-FS1-4,This is in accordance with the phylogenetic relationship of this BACTERIUM as well as with known epidemiological aspects of WHIPPLE'S DISEASE,BACTERIUM,WHIPPLE'S DISEASE,RO-has_causative_agent
502912510,7/14/2014 13:42:11,,1322850606,7/14/2014 13:41:40,prodege,0.6181,17982533,GBR,H3,Leeds,90.193.39.185,no_relation,65,124,,73,141,causes,0.64699663922063,903809-FS1-4,This is in accordance with the phylogenetic relationship of this BACTERIUM as well as with known epidemiological aspects of WHIPPLE'S DISEASE,BACTERIUM,WHIPPLE'S DISEASE,RO-has_causative_agent
502912510,7/14/2014 14:55:53,,1322900870,7/14/2014 14:55:31,instagc,0.6593,13763729,USA,"","",75.182.89.225,no_relation,65,124,,73,141,causes,0.64699663922063,903809-FS1-4,This is in accordance with the phylogenetic relationship of this BACTERIUM as well as with known epidemiological aspects of WHIPPLE'S DISEASE,BACTERIUM,WHIPPLE'S DISEASE,RO-has_causative_agent
502912510,7/14/2014 15:04:27,,1322906156,7/14/2014 15:03:58,neodev,0.719,18755947,GBR,H2,Accrington,80.47.185.52,no_relation,65,124,,73,141,causes,0.64699663922063,903809-FS1-4,This is in accordance with the phylogenetic relationship of this BACTERIUM as well as with known epidemiological aspects of WHIPPLE'S DISEASE,BACTERIUM,WHIPPLE'S DISEASE,RO-has_causative_agent
502912510,7/14/2014 15:27:14,,1322918598,7/14/2014 15:26:53,clixsense,0.4244,26889820,GBR,C3,Shelford,92.18.120.203,no_relation,65,124,,73,141,causes,0.64699663922063,903809-FS1-4,This is in accordance with the phylogenetic relationship of this BACTERIUM as well as with known epidemiological aspects of WHIPPLE'S DISEASE,BACTERIUM,WHIPPLE'S DISEASE,RO-has_causative_agent
502912510,7/14/2014 15:30:52,,1322920759,7/14/2014 15:30:20,gifthulk,0.6484,21916793,GBR,"","",87.113.87.199,no_relation,65,124,,73,141,causes,0.64699663922063,903809-FS1-4,This is in accordance with the phylogenetic relationship of this BACTERIUM as well as with known epidemiological aspects of WHIPPLE'S DISEASE,BACTERIUM,WHIPPLE'S DISEASE,RO-has_causative_agent
502912511,7/14/2014 12:43:46,,1322810601,7/14/2014 12:43:41,clixsense,0.875,25419319,GBR,H8,Liverpool,94.4.192.228,NEPHROPATHY diagnosed by DRASH SYNDROME,23,79,,33,93,diagnosed by,0.316227766016838,906144-FS1-13,Gonadal dysgenesis and NEPHROPATHY are often indistinguishable from incomplete DRASH SYNDROME,NEPHROPATHY,DRASH SYNDROME,RO-has_manifestation
502912511,7/14/2014 14:56:26,,1322901221,7/14/2014 14:56:11,elite,0.4302,28276268,USA,MI,Taylor,67.149.247.166,NEPHROPATHY diagnosed by DRASH SYNDROME,23,79,,33,93,diagnosed by,0.316227766016838,906144-FS1-13,Gonadal dysgenesis and NEPHROPATHY are often indistinguishable from incomplete DRASH SYNDROME,NEPHROPATHY,DRASH SYNDROME,RO-has_manifestation
502912511,7/14/2014 15:27:14,,1322918617,7/14/2014 15:26:53,clixsense,0.4244,26889820,GBR,C3,Shelford,92.18.120.203,no_relation,23,79,,33,93,diagnosed by,0.316227766016838,906144-FS1-13,Gonadal dysgenesis and NEPHROPATHY are often indistinguishable from incomplete DRASH SYNDROME,NEPHROPATHY,DRASH SYNDROME,RO-has_manifestation
502912511,7/14/2014 15:30:27,,1322920537,7/14/2014 15:30:11,prodege,0.5494,2143114,CAN,BC,Vancouver,24.84.160.12,NEPHROPATHY diagnosed by DRASH SYNDROME,23,79,,33,93,diagnosed by,0.316227766016838,906144-FS1-13,Gonadal dysgenesis and NEPHROPATHY are often indistinguishable from incomplete DRASH SYNDROME,NEPHROPATHY,DRASH SYNDROME,RO-has_manifestation
502912511,7/14/2014 15:55:52,,1322934950,7/14/2014 15:55:16,instagc,0.3429,18985376,GBR,D2,Derby,86.5.192.8,no_relation,23,79,,33,93,diagnosed by,0.316227766016838,906144-FS1-13,Gonadal dysgenesis and NEPHROPATHY are often indistinguishable from incomplete DRASH SYNDROME,NEPHROPATHY,DRASH SYNDROME,RO-has_manifestation
502912511,7/14/2014 15:58:24,,1322936378,7/14/2014 15:57:53,prodege,0.5,28039757,GBR,L8,Southport,109.155.158.54,no_relation,23,79,,33,93,diagnosed by,0.316227766016838,906144-FS1-13,Gonadal dysgenesis and NEPHROPATHY are often indistinguishable from incomplete DRASH SYNDROME,NEPHROPATHY,DRASH SYNDROME,RO-has_manifestation
502912511,7/14/2014 16:06:11,,1322940865,7/14/2014 16:05:22,prodege,0.5,22360212,GBR,I1,Luton,82.6.41.191,no_relation,23,79,,33,93,diagnosed by,0.316227766016838,906144-FS1-13,Gonadal dysgenesis and NEPHROPATHY are often indistinguishable from incomplete DRASH SYNDROME,NEPHROPATHY,DRASH SYNDROME,RO-has_manifestation
502912512,7/14/2014 12:43:27,,1322810393,7/14/2014 12:43:20,clixsense,0.875,25419319,GBR,H8,Liverpool,94.4.192.228,ALLERGIC REACTION causes CHRONIC ALLERGIC STATE,52,90,,68,112,causes,0.989743318610787,900317-FS1-4,This results in the amplification of any subsequent ALLERGIC REACTION contributing to the CHRONIC ALLERGIC STATE,ALLERGIC REACTION,CHRONIC ALLERGIC STATE,RO-cause_of
502912512,7/14/2014 13:01:34,,1322822524,7/14/2014 13:00:59,prodege,0.7639,7664351,USA,NY,Cicero,74.111.0.21,ALLERGIC REACTION causes CHRONIC ALLERGIC STATE,52,90,,68,112,causes,0.989743318610787,900317-FS1-4,This results in the amplification of any subsequent ALLERGIC REACTION contributing to the CHRONIC ALLERGIC STATE,ALLERGIC REACTION,CHRONIC ALLERGIC STATE,RO-cause_of
502912512,7/14/2014 13:08:06,,1322826853,7/14/2014 13:07:40,prodege,0.6278,11616695,GBR,P7,Wigan,92.29.199.166,ALLERGIC REACTION causes CHRONIC ALLERGIC STATE,52,90,,68,112,causes,0.989743318610787,900317-FS1-4,This results in the amplification of any subsequent ALLERGIC REACTION contributing to the CHRONIC ALLERGIC STATE,ALLERGIC REACTION,CHRONIC ALLERGIC STATE,RO-cause_of
502912512,7/14/2014 14:17:14,,1322874893,7/14/2014 14:16:59,clixsense,0.5125,7415230,GBR,A7,Birmingham,147.188.47.242,ALLERGIC REACTION causes CHRONIC ALLERGIC STATE,52,90,,68,112,causes,0.989743318610787,900317-FS1-4,This results in the amplification of any subsequent ALLERGIC REACTION contributing to the CHRONIC ALLERGIC STATE,ALLERGIC REACTION,CHRONIC ALLERGIC STATE,RO-cause_of
502912512,7/14/2014 14:31:25,,1322885179,7/14/2014 14:31:13,instagc,0.644,15445601,USA,FL,Jacksonville,24.129.68.254,ALLERGIC REACTION causes CHRONIC ALLERGIC STATE,52,90,,68,112,causes,0.989743318610787,900317-FS1-4,This results in the amplification of any subsequent ALLERGIC REACTION contributing to the CHRONIC ALLERGIC STATE,ALLERGIC REACTION,CHRONIC ALLERGIC STATE,RO-cause_of
502912512,7/14/2014 14:35:40,,1322888027,7/14/2014 14:35:22,rewardsspot,0.57,17763704,USA,IL,Chicago,67.212.175.123,ALLERGIC REACTION causes CHRONIC ALLERGIC STATE,52,90,,68,112,causes,0.989743318610787,900317-FS1-4,This results in the amplification of any subsequent ALLERGIC REACTION contributing to the CHRONIC ALLERGIC STATE,ALLERGIC REACTION,CHRONIC ALLERGIC STATE,RO-cause_of
502912512,7/14/2014 14:45:50,,1322894888,7/14/2014 14:45:46,instagc,0.4611,27753923,GBR,"","",188.30.192.65,ALLERGIC REACTION causes CHRONIC ALLERGIC STATE,52,90,,68,112,causes,0.989743318610787,900317-FS1-4,This results in the amplification of any subsequent ALLERGIC REACTION contributing to the CHRONIC ALLERGIC STATE,ALLERGIC REACTION,CHRONIC ALLERGIC STATE,RO-cause_of
502912513,7/14/2014 12:34:40,,1322804385,7/14/2014 12:34:15,clixsense,0.9583,27871219,NLD,07,Amsterdam,87.210.207.223,BONE is location of PSEUDARTHROSIS,15,90,,18,104,is location of,0.309529293013655,905494-FS1-9,Instability of BONE fragments is regarded as the most important factor in pathogenesis of PSEUDARTHROSIS,BONE,PSEUDARTHROSIS,RO-has_finding_site
502912513,7/14/2014 14:31:45,,1322885437,7/14/2014 14:31:32,instagc,0.644,15445601,USA,FL,Jacksonville,24.129.68.254,no_relation,15,90,,18,104,is location of,0.309529293013655,905494-FS1-9,Instability of BONE fragments is regarded as the most important factor in pathogenesis of PSEUDARTHROSIS,BONE,PSEUDARTHROSIS,RO-has_finding_site
502912513,7/14/2014 14:34:59,,1322887519,7/14/2014 14:34:43,rewardsspot,0.57,17763704,USA,IL,Chicago,67.212.175.123,BONE is location of PSEUDARTHROSIS,15,90,,18,104,is location of,0.309529293013655,905494-FS1-9,Instability of BONE fragments is regarded as the most important factor in pathogenesis of PSEUDARTHROSIS,BONE,PSEUDARTHROSIS,RO-has_finding_site
502912513,7/14/2014 14:55:30,,1322900622,7/14/2014 14:55:09,instagc,0.6593,13763729,USA,"","",75.182.89.225,BONE is location of PSEUDARTHROSIS,15,90,,18,104,is location of,0.309529293013655,905494-FS1-9,Instability of BONE fragments is regarded as the most important factor in pathogenesis of PSEUDARTHROSIS,BONE,PSEUDARTHROSIS,RO-has_finding_site
502912513,7/14/2014 15:03:11,,1322905358,7/14/2014 15:02:23,vivatic,0.5339,25451531,GBR,"","",83.67.28.193,BONE is location of PSEUDARTHROSIS,15,90,,18,104,is location of,0.309529293013655,905494-FS1-9,Instability of BONE fragments is regarded as the most important factor in pathogenesis of PSEUDARTHROSIS,BONE,PSEUDARTHROSIS,RO-has_finding_site
502912513,7/14/2014 15:09:44,,1322909030,7/14/2014 15:09:17,clixsense,0.5718,19803139,NLD,06,Veldhoven,212.61.84.196,BONE is location of PSEUDARTHROSIS,15,90,,18,104,is location of,0.309529293013655,905494-FS1-9,Instability of BONE fragments is regarded as the most important factor in pathogenesis of PSEUDARTHROSIS,BONE,PSEUDARTHROSIS,RO-has_finding_site
502912513,7/14/2014 15:23:08,,1322916243,7/14/2014 15:22:34,clixsense,0.4244,26889820,GBR,C3,Shelford,92.18.120.203,no_relation,15,90,,18,104,is location of,0.309529293013655,905494-FS1-9,Instability of BONE fragments is regarded as the most important factor in pathogenesis of PSEUDARTHROSIS,BONE,PSEUDARTHROSIS,RO-has_finding_site
502912514,7/14/2014 12:36:19,,1322805382,7/14/2014 12:35:56,clixsense,0.9583,27871219,NLD,07,Amsterdam,87.210.207.223,INSENSITIVITY SYNDROME (TESTICULAR FEMINIZATION SYNDROME) causes ESTROGEN SECRETING MALIGNANT SEX CORD STROMAL TUMOR,127,58,,177,115,causes,0.933256525257383,906067-FS1-4,We report on a 68 year old patient with complete androgen INSENSITIVITY SYNDROME (TESTICULAR FEMINIZATION SYNDROME) in whom an ESTROGEN SECRETING MALIGNANT SEX CORD STROMAL TUMOR developed in an intraabdominal testis.,ESTROGEN SECRETING MALIGNANT SEX CORD STROMAL TUMOR,INSENSITIVITY SYNDROME (TESTICULAR FEMINIZATION SYNDROME),RO-has_manifestation
502912514,7/14/2014 13:02:06,,1322822854,7/14/2014 13:01:27,rewardsspot,0.7153,24482174,GBR,H9,London,46.23.68.180,no_relation,127,58,,177,115,causes,0.933256525257383,906067-FS1-4,We report on a 68 year old patient with complete androgen INSENSITIVITY SYNDROME (TESTICULAR FEMINIZATION SYNDROME) in whom an ESTROGEN SECRETING MALIGNANT SEX CORD STROMAL TUMOR developed in an intraabdominal testis.,ESTROGEN SECRETING MALIGNANT SEX CORD STROMAL TUMOR,INSENSITIVITY SYNDROME (TESTICULAR FEMINIZATION SYNDROME),RO-has_manifestation
502912514,7/14/2014 13:42:47,,1322851013,7/14/2014 13:42:12,prodege,0.6181,17982533,GBR,H3,Leeds,90.193.39.185,no_relation,127,58,,177,115,causes,0.933256525257383,906067-FS1-4,We report on a 68 year old patient with complete androgen INSENSITIVITY SYNDROME (TESTICULAR FEMINIZATION SYNDROME) in whom an ESTROGEN SECRETING MALIGNANT SEX CORD STROMAL TUMOR developed in an intraabdominal testis.,ESTROGEN SECRETING MALIGNANT SEX CORD STROMAL TUMOR,INSENSITIVITY SYNDROME (TESTICULAR FEMINIZATION SYNDROME),RO-has_manifestation
502912514,7/14/2014 13:49:47,,1322856232,7/14/2014 13:49:22,clixsense,0.4042,25402344,CAN,ON,Wawa,24.109.124.45,ESTROGEN SECRETING MALIGNANT SEX CORD STROMAL TUMOR causes INSENSITIVITY SYNDROME (TESTICULAR FEMINIZATION SYNDROME),127,58,,177,115,causes,0.933256525257383,906067-FS1-4,We report on a 68 year old patient with complete androgen INSENSITIVITY SYNDROME (TESTICULAR FEMINIZATION SYNDROME) in whom an ESTROGEN SECRETING MALIGNANT SEX CORD STROMAL TUMOR developed in an intraabdominal testis.,ESTROGEN SECRETING MALIGNANT SEX CORD STROMAL TUMOR,INSENSITIVITY SYNDROME (TESTICULAR FEMINIZATION SYNDROME),RO-has_manifestation
502912514,7/14/2014 14:23:16,,1322879071,7/14/2014 14:23:10,neodev,0.3792,25224036,CAN,ON,Sudbury,67.204.218.187,ESTROGEN SECRETING MALIGNANT SEX CORD STROMAL TUMOR causes INSENSITIVITY SYNDROME (TESTICULAR FEMINIZATION SYNDROME),127,58,,177,115,causes,0.933256525257383,906067-FS1-4,We report on a 68 year old patient with complete androgen INSENSITIVITY SYNDROME (TESTICULAR FEMINIZATION SYNDROME) in whom an ESTROGEN SECRETING MALIGNANT SEX CORD STROMAL TUMOR developed in an intraabdominal testis.,ESTROGEN SECRETING MALIGNANT SEX CORD STROMAL TUMOR,INSENSITIVITY SYNDROME (TESTICULAR FEMINIZATION SYNDROME),RO-has_manifestation
502912514,7/14/2014 14:24:40,,1322880129,7/14/2014 14:24:06,neodev,0.4306,21515166,NLD,11,Nootdorp,83.86.58.179,INSENSITIVITY SYNDROME (TESTICULAR FEMINIZATION SYNDROME) causes ESTROGEN SECRETING MALIGNANT SEX CORD STROMAL TUMOR,127,58,,177,115,causes,0.933256525257383,906067-FS1-4,We report on a 68 year old patient with complete androgen INSENSITIVITY SYNDROME (TESTICULAR FEMINIZATION SYNDROME) in whom an ESTROGEN SECRETING MALIGNANT SEX CORD STROMAL TUMOR developed in an intraabdominal testis.,ESTROGEN SECRETING MALIGNANT SEX CORD STROMAL TUMOR,INSENSITIVITY SYNDROME (TESTICULAR FEMINIZATION SYNDROME),RO-has_manifestation
502912514,7/14/2014 14:36:32,,1322888628,7/14/2014 14:36:03,rewardsspot,0.57,17763704,USA,IL,Chicago,67.212.175.123,INSENSITIVITY SYNDROME (TESTICULAR FEMINIZATION SYNDROME) causes ESTROGEN SECRETING MALIGNANT SEX CORD STROMAL TUMOR,127,58,,177,115,causes,0.933256525257383,906067-FS1-4,We report on a 68 year old patient with complete androgen INSENSITIVITY SYNDROME (TESTICULAR FEMINIZATION SYNDROME) in whom an ESTROGEN SECRETING MALIGNANT SEX CORD STROMAL TUMOR developed in an intraabdominal testis.,ESTROGEN SECRETING MALIGNANT SEX CORD STROMAL TUMOR,INSENSITIVITY SYNDROME (TESTICULAR FEMINIZATION SYNDROME),RO-has_manifestation
502912515,7/14/2014 12:34:21,,1322804220,7/14/2014 12:34:16,neodev,0.9583,17610000,GBR,I2,Manchester,90.200.140.201,MPNSTS causes NEUROFIBROMATOSIS TYPE 1,222,167,,227,191,causes,0.301511344577764,906234-FS1-4,"PDGFRA, PDGFRB, and EGFR were immunohistochemically, biochemically, cytogenetically, and mutationally analyzed along with the detection of their cognate ligands in 16 NEUROFIBROMATOSIS TYPE 1 (NF1) related and 11 sporadic MPNSTS",MPNSTS,NEUROFIBROMATOSIS TYPE 1,RO-has_manifestation
502912515,7/14/2014 13:00:59,,1322822146,7/14/2014 13:00:28,prodege,0.7639,7664351,USA,NY,Cicero,74.111.0.21,no_relation,222,167,,227,191,causes,0.301511344577764,906234-FS1-4,"PDGFRA, PDGFRB, and EGFR were immunohistochemically, biochemically, cytogenetically, and mutationally analyzed along with the detection of their cognate ligands in 16 NEUROFIBROMATOSIS TYPE 1 (NF1) related and 11 sporadic MPNSTS",MPNSTS,NEUROFIBROMATOSIS TYPE 1,RO-has_manifestation
502912515,7/14/2014 13:06:27,,1322825643,7/14/2014 13:05:49,prodege,0.6278,11616695,GBR,P7,Wigan,92.29.199.166,no_relation,222,167,,227,191,causes,0.301511344577764,906234-FS1-4,"PDGFRA, PDGFRB, and EGFR were immunohistochemically, biochemically, cytogenetically, and mutationally analyzed along with the detection of their cognate ligands in 16 NEUROFIBROMATOSIS TYPE 1 (NF1) related and 11 sporadic MPNSTS",MPNSTS,NEUROFIBROMATOSIS TYPE 1,RO-has_manifestation
502912515,7/14/2014 13:23:13,,1322837378,7/14/2014 13:22:19,neodev,0.6667,19004420,GBR,M3,Bridgwater,86.160.70.204,no_relation,222,167,,227,191,causes,0.301511344577764,906234-FS1-4,"PDGFRA, PDGFRB, and EGFR were immunohistochemically, biochemically, cytogenetically, and mutationally analyzed along with the detection of their cognate ligands in 16 NEUROFIBROMATOSIS TYPE 1 (NF1) related and 11 sporadic MPNSTS",MPNSTS,NEUROFIBROMATOSIS TYPE 1,RO-has_manifestation
502912515,7/14/2014 13:51:11,,1322857339,7/14/2014 13:50:46,clixsense,0.4042,25402344,CAN,ON,Wawa,24.109.124.45,NEUROFIBROMATOSIS TYPE 1 causes MPNSTS,222,167,,227,191,causes,0.301511344577764,906234-FS1-4,"PDGFRA, PDGFRB, and EGFR were immunohistochemically, biochemically, cytogenetically, and mutationally analyzed along with the detection of their cognate ligands in 16 NEUROFIBROMATOSIS TYPE 1 (NF1) related and 11 sporadic MPNSTS",MPNSTS,NEUROFIBROMATOSIS TYPE 1,RO-has_manifestation
502912515,7/14/2014 14:57:55,,1322902284,7/14/2014 14:57:28,elite,0.4302,28276268,USA,MI,Taylor,67.149.247.166,NEUROFIBROMATOSIS TYPE 1 causes MPNSTS,222,167,,227,191,causes,0.301511344577764,906234-FS1-4,"PDGFRA, PDGFRB, and EGFR were immunohistochemically, biochemically, cytogenetically, and mutationally analyzed along with the detection of their cognate ligands in 16 NEUROFIBROMATOSIS TYPE 1 (NF1) related and 11 sporadic MPNSTS",MPNSTS,NEUROFIBROMATOSIS TYPE 1,RO-has_manifestation
502912515,7/14/2014 15:20:59,,1322914881,7/14/2014 15:20:05,prodege,0.639,27996604,CAN,QC,Boucherville,24.201.21.27,no_relation,222,167,,227,191,causes,0.301511344577764,906234-FS1-4,"PDGFRA, PDGFRB, and EGFR were immunohistochemically, biochemically, cytogenetically, and mutationally analyzed along with the detection of their cognate ligands in 16 NEUROFIBROMATOSIS TYPE 1 (NF1) related and 11 sporadic MPNSTS",MPNSTS,NEUROFIBROMATOSIS TYPE 1,RO-has_manifestation
502912516,7/14/2014 12:37:18,,1322806012,7/14/2014 12:36:47,prodege,0.8889,27934334,GBR,Q2,Wokingham,86.166.73.21,no_relation,184,240,,203,250,diagnosed by,0.333333333333333,900016-FS1-13,"Visual evoked potentials (VEPs) produced by pattern reversal were compared with those elicited by onset of motion in 37 amblyopic children (20 with anisometropic amblyopia, seven with STRABISMIC AMBLYOPIA and 10 with both anisometropia and STRABISMUS",STRABISMIC AMBLYOPIA,STRABISMUS,RO-cause_of
502912516,7/14/2014 13:00:03,,1322821492,7/14/2014 12:59:23,rewardsspot,0.7153,24482174,GBR,H9,London,46.23.68.180,STRABISMIC AMBLYOPIA diagnosed by STRABISMUS,184,240,,203,250,diagnosed by,0.333333333333333,900016-FS1-13,"Visual evoked potentials (VEPs) produced by pattern reversal were compared with those elicited by onset of motion in 37 amblyopic children (20 with anisometropic amblyopia, seven with STRABISMIC AMBLYOPIA and 10 with both anisometropia and STRABISMUS",STRABISMIC AMBLYOPIA,STRABISMUS,RO-cause_of
502912516,7/14/2014 15:18:42,,1322913536,7/14/2014 15:18:32,clixsense,0.4823,19162475,GBR,M3,Frome,82.33.126.30,STRABISMUS diagnosed by STRABISMIC AMBLYOPIA,184,240,,203,250,diagnosed by,0.333333333333333,900016-FS1-13,"Visual evoked potentials (VEPs) produced by pattern reversal were compared with those elicited by onset of motion in 37 amblyopic children (20 with anisometropic amblyopia, seven with STRABISMIC AMBLYOPIA and 10 with both anisometropia and STRABISMUS",STRABISMIC AMBLYOPIA,STRABISMUS,RO-cause_of
502912516,7/14/2014 15:30:53,,1322920775,7/14/2014 15:30:45,prodege,0.5494,2143114,CAN,BC,Vancouver,24.84.160.12,STRABISMUS diagnosed by STRABISMIC AMBLYOPIA,184,240,,203,250,diagnosed by,0.333333333333333,900016-FS1-13,"Visual evoked potentials (VEPs) produced by pattern reversal were compared with those elicited by onset of motion in 37 amblyopic children (20 with anisometropic amblyopia, seven with STRABISMIC AMBLYOPIA and 10 with both anisometropia and STRABISMUS",STRABISMIC AMBLYOPIA,STRABISMUS,RO-cause_of
502912516,7/14/2014 15:52:44,,1322933201,7/14/2014 15:51:56,clixsense,0.573,22177255,USA,CA,San Francisco,73.32.39.90,no_relation,184,240,,203,250,diagnosed by,0.333333333333333,900016-FS1-13,"Visual evoked potentials (VEPs) produced by pattern reversal were compared with those elicited by onset of motion in 37 amblyopic children (20 with anisometropic amblyopia, seven with STRABISMIC AMBLYOPIA and 10 with both anisometropia and STRABISMUS",STRABISMIC AMBLYOPIA,STRABISMUS,RO-cause_of
502912516,7/14/2014 15:56:36,,1322935374,7/14/2014 15:55:53,instagc,0.3429,18985376,GBR,D2,Derby,86.5.192.8,no_relation,184,240,,203,250,diagnosed by,0.333333333333333,900016-FS1-13,"Visual evoked potentials (VEPs) produced by pattern reversal were compared with those elicited by onset of motion in 37 amblyopic children (20 with anisometropic amblyopia, seven with STRABISMIC AMBLYOPIA and 10 with both anisometropia and STRABISMUS",STRABISMIC AMBLYOPIA,STRABISMUS,RO-cause_of
502912516,7/14/2014 15:57:52,,1322936088,7/14/2014 15:57:15,prodege,0.5,28039757,GBR,L8,Southport,109.155.158.54,no_relation,184,240,,203,250,diagnosed by,0.333333333333333,900016-FS1-13,"Visual evoked potentials (VEPs) produced by pattern reversal were compared with those elicited by onset of motion in 37 amblyopic children (20 with anisometropic amblyopia, seven with STRABISMIC AMBLYOPIA and 10 with both anisometropia and STRABISMUS",STRABISMIC AMBLYOPIA,STRABISMUS,RO-cause_of
502912517,7/14/2014 13:07:39,,1322826519,7/14/2014 13:07:25,prodege,0.6278,11616695,GBR,P7,Wigan,92.29.199.166,no_relation,52,22,,68,33,treats,0.3,903786-FS1-2,Update: Prevention of HEPATITIS A after exposure to HEPATITIS A VIRUS and in international travelers.,HEPATITIS A VIRUS,HEPATITIS A,RO-has_causative_agent
502912517,7/14/2014 14:10:05,,1322869969,7/14/2014 14:09:56,clixsense,0.7708,27793793,GBR,C5,Chester,151.230.27.155,no_relation,52,22,,68,33,treats,0.3,903786-FS1-2,Update: Prevention of HEPATITIS A after exposure to HEPATITIS A VIRUS and in international travelers.,HEPATITIS A VIRUS,HEPATITIS A,RO-has_causative_agent
502912517,7/14/2014 14:25:52,,1322881043,7/14/2014 14:25:18,neodev,0.4306,21515166,NLD,11,Nootdorp,83.86.58.179,HEPATITIS A VIRUS treats HEPATITIS A,52,22,,68,33,treats,0.3,903786-FS1-2,Update: Prevention of HEPATITIS A after exposure to HEPATITIS A VIRUS and in international travelers.,HEPATITIS A VIRUS,HEPATITIS A,RO-has_causative_agent
502912517,7/14/2014 14:56:50,,1322901588,7/14/2014 14:56:27,elite,0.4302,28276268,USA,MI,Taylor,67.149.247.166,HEPATITIS A treats HEPATITIS A VIRUS,52,22,,68,33,treats,0.3,903786-FS1-2,Update: Prevention of HEPATITIS A after exposure to HEPATITIS A VIRUS and in international travelers.,HEPATITIS A VIRUS,HEPATITIS A,RO-has_causative_agent
502912517,7/14/2014 14:57:16,,1322901864,7/14/2014 14:57:00,instagc,0.6593,13763729,USA,"","",75.182.89.225,no_relation,52,22,,68,33,treats,0.3,903786-FS1-2,Update: Prevention of HEPATITIS A after exposure to HEPATITIS A VIRUS and in international travelers.,HEPATITIS A VIRUS,HEPATITIS A,RO-has_causative_agent
502912517,7/14/2014 15:04:04,,1322905947,7/14/2014 15:03:13,vivatic,0.5339,25451531,GBR,"","",83.67.28.193,HEPATITIS A VIRUS treats HEPATITIS A,52,22,,68,33,treats,0.3,903786-FS1-2,Update: Prevention of HEPATITIS A after exposure to HEPATITIS A VIRUS and in international travelers.,HEPATITIS A VIRUS,HEPATITIS A,RO-has_causative_agent
502912517,7/14/2014 15:27:02,,1322918430,7/14/2014 15:26:47,instagc,0.3552,19004168,GBR,H2,Accrington,80.47.185.52,no_relation,52,22,,68,33,treats,0.3,903786-FS1-2,Update: Prevention of HEPATITIS A after exposure to HEPATITIS A VIRUS and in international travelers.,HEPATITIS A VIRUS,HEPATITIS A,RO-has_causative_agent
